LEWIS_FORMATTED (DO NOT DELETE)

12/29/2020 8:27 PM

Is Germline Gene Editing Exceptional?
Myrisha S. Lewis*
Advances in gene editing have recently received significant scientific
and media attention. Gene editing, especially CRISPR-Cas9, has revived
multiple longstanding ethical debates, including debates related to
parental autonomy, health disparities, disability perspectives, and racial
and economic inequalities. Germline, or heritable, gene editing generates
several newer, neglected bioethical debates, including those about the
shared human germline and whether there is a “line” that humans should
not cross.
This Article addresses several interrelated ethical and legal questions
related to germline gene editing. Those questions address why, if at all,
germline gene editing needs to be regulated and, if germline gene editing
needs to be regulated, whether it can be regulated under existing law.
Ultimately, this Article finds that germline gene editing should and can be
regulated under existing law; however, the current federal-centric regime
is not the optimal way to regulate this subset of gene editing.
Instead, this Article argues that germline gene editing should be
regulated like traditional assisted reproductive technology, such as in
vitro fertilization, instead of as an exceptional, federally-regulated
medical product. Doing so would reduce regulatory barriers in access to
innovation, and the technique would be subject to a significantly less
burdensome and less federally dominated regime than it is today.
Additionally, this Article’s proposed regulatory treatment of germline
gene editing would increase access to the technique and remove the
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federal government, which is prone to regulate based on social and
political views, from the practice of medicine, in order to allow access to a
procedure that could improve or save many lives.
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I. INTRODUCTION
Every year, women give birth to children with incurable diseases
or diseases with devastating symptoms and extensive suffering.1
Further, many of those diseases have genetic causes, which means that
subsequent generations may also suffer from those diseases and could
be burdened with the knowledge that they could pass on these
conditions to their children and future generations.2 Beyond the
burdens on those who are directly impacted by these diseases, the
healthcare system must cope with the financial and logistical impacts of
these diseases.3 For example, recent debates have focused on the high
price of American healthcare, especially for pharmaceuticals.4 Most
recently, as politicians and the public focused on the high price of drugs,
this debate intensified when the U.S. Food and Drug Administration
(FDA) approved a drug to treat spinal muscular atrophy in children with
a one-time cost of $2.1 million.5 What if we could avoid the health and
financial burdens of genetically-caused diseases?
Germline gene editing, which is the target of unique regulatory
treatment in the United States, offers that possibility. Germline gene
editing consists of two medical techniques: one that yields a heritable
genetic modification, which could be passed on to future generations,
1 See Carolyn Jacobs Chachkin, What Potent Blood: Non-Invasive Prenatal Genetic
Diagnosis and the Transformation of Modern Prenatal Care, 33 AM. J.L. & MED. 9, 47–48
(2007); Birth Defects Research, MARCH OF DIMES https://www.marchofdimes.org/
research/birth-defects-research.aspx (last visited Oct. 19, 2019).
2 See Lori B. Andrews, A Conceptual Framework for Genetic Policy: Comparing the
Medical, Public Health, and Fundamental Rights Models, 79 WASH. U. L.Q. 221, 247–48
(2001); Angela Liang, The Argument Against a Physician’s Duty to Warn for Genetic
Diseases: The Conflicts Created by Safer v. Estate of Pack, 1 J. HEALTH CARE L. & POL’Y 437,
443–44 (1998); ARNOLD CHRISTIANSON ET AL., MARCH OF DIMES, GLOBAL REPORT ON BIRTH
DEFECTS, (2006), https://www.marchofdimes.org/global-report-on-birth-defects-thehidden-toll-of-dying-and-disabled-children-full-report.pdf.
3 See, e.g., Nina Gonzaludo et al., Estimating the Burden and Economic Impact of
Pediatric Genetic Disease, 21 GENETICS IN MED. 1781, 1787 (Dec. 20, 2018),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6752475/pdf/41436_2018_Article_
398.pdf. But see CHRISTIANSON ET AL., supra note 2 at 10–11.
4 Ezekiel J. Emanuel, Big Pharma’s Go-To Defense of Soaring Drug Prices Doesn’t Add
Up, ATLANTIC, (Mar. 23, 2019), https://www.theatlantic.com/health/archive/2019/
03/drug-prices-high-cost-research-and-development/585253; Austin Frakt, Something
Happened to U.S. Drug Costs in the 1990s, N.Y. TIMES, (Nov. 12, 2018),
https://www.nytimes.com/2018/11/12/upshot/why-prescription-drug-spendinghigher-in-the-us.html; Ben Hirschler, How the U.S. Pays 3 Times More for Drugs, SCI. AM.
(Oct. 13, 2015), https://www.scientificamerican.com/article/how-the-u-s-pays-3times-more-for-drugs.
5 Linda Carroll & Lauren Dunn, $2.1 Million Drug to Treat Rare Genetic Disease
Approved by FDA, NBC NEWS (May 24, 2019), https://www.nbcnews.com/health/healthnews/2-1-million-drug-treat-rare-genetic-disease-approved-fda-n1009956.
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and another that uses “traditional” assisted reproductive technology
(“ART”), which does not involve genetic modification, namely, in vitro
fertilization (“IVF”).6
In terms of accessing heritable genetic
modification, however, options are severely limited, unlike the
availability of traditional ART.7
The regulatory regime is especially hostile toward treatments with
therapeutic uses that could prevent disease inheritance or correct
defective genes by using genetic modification, such as germline gene
editing.8 Thus, even though some trials related to gene editing in adults,
as opposed to embryos, are going forward, access to preventive or
germline gene editing remains limited.9 This access is limited because
gene editing of embryos, like other techniques involving genetic
modification, has been subjected to a federal-centric regime that
hinders innovation.10
Some prospective parents, such as those who both carry recessive
traits, cannot simultaneously naturally reproduce and have a genetically
related child without risking passing the disease on to their children.11
Germline gene editing is a solution to this problem. Current United
6 See infra Part II; Henry T. Greely, CRISPR’d Babies: Human Germline Genome
Editing in the ‘He Jiankui Affair,’ 6 J. OF L. & BIOSCIENCES 111, 113 (2019) (“In short:
germline editing creates changes that a person’s descendants can inherit, as opposed to
changes that could not be passed on to future generations.”).
7 See Susan Winterberg et al., Technology Factsheet Series: Genome Editing, HARV.
KENNEDY SCH. BELFER CTR. FOR SCI. & INT’L AFF. & CRCS CTR. FOR RES. ON COMPUTATION & SOC’Y
(2019), https://www.belfercenter.org/sites/default/files/2019-06/TechFactSheet/
genomeediting%20-%206.pdf; see also infra note 8.
8 See discussion infra Section II.B. of FDA treatment of forms of ART involving
genetic modification. For more detailed accounts, see Myrisha S. Lewis, The American
Democratic Deficit in Assisted Reproductive Technology Innovation, 45 AM. J.L. & MED. 130,
131–32, 149–55 (2019) [hereinafter Lewis, The American Democratic Deficit]; Myrisha
S. Lewis, How Subterranean Regulation Hinders Innovation in Assisted Reproductive
Technology, 39 CARDOZO L. REV. 1239, 1273–74 (2018) [hereinafter Lewis, How
Subterranean].
9 See, e.g., Michael Nedelman & Minali Nigam, Trial Underway in US Uses Geneediting in People with Severe Sickle Cell Disease, CNN (July 30, 2019),
https://www.cnn.com/2019/07/30/health/crispr-trial-sickle-cell; Rob Stein, In A 1st,
Doctors in U.S. Use CRISPR Tool To Treat Patient with Genetic Disorder, NPR (July 29,
2019), https://www.npr.org/sections/health-shots/2019/07/29/744826505/sicklecell-patient-reveals-why-she-is-volunteering-for-landmark-gene-editing-st.
10 See supra note 8.
11 See Eric Rakowski, Who Should Pay for Bad Genes?, 90 CAL. L. REV. 1345, 1349
(2002); see also Tay-Sachs, U.S NAT’L LIBR. OF MED. (Feb. 11, 2020),
https://ghr.nlm.nih.gov/condition/tay-sachs-disease#inheritance; Tay-Sachs Disease,
NAT’L CTR. FOR ADVANCING TRANSLATIONAL SCIS., https://rarediseases.info.nih.gov/diseases/
7737/tay-sachs-disease/cases/50741 (last visited Nov. 20, 2020). Tay-Sachs is a disease
where if both parents carried the recessive gene, they could pass on the trait to their
children if they reproduced naturally.
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States regulation, however, severely curtails a technique that could
permit parents who are carriers of various inheritable diseases, such as
Tay-Sachs, sickle cell anemia, Alzheimer’s disease, Huntington’s disease,
inheritable forms of blindness, and cystic fibrosis, to prevent their
children from inheriting or being carriers for those diseases.12 This
severely curtailed access to the technology is striking not only because
of the possible delay in access to promising medical treatment but also
because parents can make so many other decisions for their children
(and future children), including use of IVF (which would be required for
the gene editing of embryos); selection of embryos to implant using IVF;
prenatal testing; enrollment of children in clinical trials; and many other
decisions about the upbringing of their children, including their
children’s medical care.13
Often, new technologies with potential for uses that society views
as harmful, such as germline gene editing, artificial intelligence,
genomically modified organisms, robotics, and cloning, face requests for
regulation.14 A November 2018 Vanity Fair article asked, “Is Gene
Editing More Dangerous than Nuclear Weapons?” thus emphasizing the
fear and concern surrounding potential uses of gene editing.15 ART,
12 See Genetic Disorders, U.S. NAT’L LIBR. OF MED., https://medlineplus.gov/genetic
disorders.html (last visited Oct. 26, 2020); see, e.g., Sharon Begley, Scientists Unveil The
‘Most Clever CRISPR Gadget’ So Far, STAT News (Apr. 20, 2016), https://www.stat
news.com/2016/04/20/clever-crispr-advance-unveiled/; Berly McCoy, CRISPR Geneediting ‘Eliminates’ HIV in Some Mice. What Does It Mean for Humans?, PBS NEWS HOUR
(July 2, 2019, 5:40 PM), https://www.pbs.org/newshour/science/crispr-gene-editingeliminates-hiv-in-some-mice-what-does-it-mean-for-humans. But see Eric S. Lander,
What We Don’t Know, in 24 NAS INTERNATIONAL SUMMIT ON HUMAN GENE EDITING,
COMMISSIONED PAPERS 24 (2015), https://www.nap.edu/resource/21913/
gene_papers.pdf (noting that in terms of the genetic treatment of disease “if we really
care about helping parents avoid cases of genetic disease, germline editing is not the
first, second, third, or fourth thing that we should be thinking about”).
13 See U.S. Food and Drug Admin., HHS, Additional Safeguards for Children in Clinical
Investigations of Food and Drug Administration-Regulated Products, 78 Fed. Reg. 12937,
12944 (Feb. 26, 2013); Troxel v. Granville, 530 U.S. 57, 66–70, 72–73 (2000); Prince v.
Massachusetts, 321 U.S. 158, 166 (1944); Sonia M. Suter, A Brave New World of Designer
Babies?, 22 BERKELEY TECH. L.J. 897, 923 (2007). For more on parental autonomy and
child welfare, see Section III.A.
14 For discussions of technologies that have generated scholarly and public calls for
more (or basic) regulation, see Jane R. Bambauer, Dr. Robot, 51 U.C. DAVIS L. REV. 383,
384 (2017); Ryan Calo, Robotics and the Lessons of Cyberlaw, 103 CAL. L. REV. 513, 551–53
(2015); Mark Fenwick et. al., Regulation Tomorrow: What Happens When Technology Is
Faster Than the Law?, 6 AM. U. BUS. L. REV. 561, 563 (2017); Henry T. Greely, Neuroscience,
Artificial Intelligence, Crispr—and Dogs and Cats, 51 U.C. DAVIS L. REV. 2303, 2328 (2018);
John O. McGinnis, Accelerating AI, 104 NW. U. L. REV. 366, 366–67 (2010).
15 See Nick Bilton, The “Black Ball” Hypothesis: Is Gene Editing More Dangerous than
Nuclear Weapons?, VANITY FAIR (Nov. 28, 2018), https://www.vanityfair.com/news/
2018/11/is-gene-editing-more-dangerous-than-nuclear-weapons; see also Eli Y.
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specifically IVF, was similarly compared to the “atom bomb” when it was
a new technique.16 Further, before IVF was a reality, observers noted
that “the ‘brave new world’ of Aldous Huxley may be nearer
realization.”17 Discussing gene editing and similar techniques in
apocalyptic terms tends to lead to requests for overregulation and
reduced access to medical innovation. Instead, this Article draws
parallels between germline gene editing and most new and existing
technologies or treatments, which come with advantages and
disadvantages, including gene therapy and IVF, which were previously
discussed in apocalyptic terms but are now widely available and subject
to a substantially less burdensome regulatory regime.18
This Article argues that germline gene editing should be treated
similarly to IVF, which is subject to physician self-regulation and state
laws addressing the practice of medicine, instead of like a federallyregulated medical product.19 More specifically, this Article emphasizes
a risk-based approach where regulatory regimes exist to manage risks
or to compensate those who are harmed, as evidenced by the regulatory
regimes created by environmental law, medical malpractice,
pharmaceutical regulation, consumer protection, and tort law.20
Adashi, Fifty Years After Huxley: The Roadmap of Reproductive Medicine Revisited and
Updated: The 2015 SRI-Pardi Distinguished Scientist Plenary Lecture of the Society for
Reproductive Investigation, 22 REPROD. SCI. 1330, 1330 (2015); see also infra note 77 and
accompanying text (noting calls for moratoria or periods of time in which human
germline gene editing not be attempted).
16 Jason Pontin, Science is Getting Us Closer to the End of Fertility, WIRED (Mar. 27,
2018), https://www.wired.com/story/reverse-infertility.
17 MARGARET MARSH & WANDA RONNER, THE PURSUIT OF PARENTHOOD: REPRODUCTIVE
TECHNOLOGY FROM TEST-TUBE BABIES TO UTERUS TRANSPLANTS 20 (2019).
18 See infra Section II.B. (discussing the characterization of the regulatory regime
surrounding IVF and other traditional ART techniques as “minimally regulated” or
“unregulated” and the state regulation of ART). The term “gene therapy” generally
applies to non-somatic or non-heritable genetic modification.
19 For more on state regulation of the practice of medicine and IVF see infra Section
II.B. For more on self-regulation in the field of ART, see, for example, Jennifer L. Rosato,
The Children of ART (Assisted Reproductive Technology): Should the Law Protect Them
from Harm?, 2004 UTAH L. REV. 57, 66 (2004) (“The American Society for Reproductive
Medicine (‘ASRM’) is the primary professional organization that oversees the field of
reproductive medicine, and the Society of Assisted Reproductive Technology (‘SART’),
an affiliated organization, specifically covers IVF programs, in addition to other types of
ART programs.” (citations omitted)).
20 See William Green, The FDA, Contraceptive Marketing Approval and Products
Liability Litigation: Depo-Provera and the Risk of Osteoporosis, 68 FOOD & DRUG L.J. 115,
116–17 (2013); Anna B. Laakmann, When Should Physicians Be Liable for Innovation, 36
CARDOZO L. REV. 913, 916 (2015); Jonathan Remy Nash, The Supreme Court and the
Regulation of Risk in Criminal Law Enforcement, 92 B.U. L. REV. 171, 192–97 (2012)
(exploring the “paradigmatic risk regulation as undertaken by agencies in the context of
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Scientific advances that potentially impact the gene pool elicit
political, legal, and scientific controversy.21 Germline gene editing
provides the promise of eventually eradicating certain diseases instead
of just treating a disease after it has been inherited.22 Gene editing has
been characterized as “an ideal method to correct inherited
disorders.”23 Many bodies of literature apply to the regulation of gene
editing, including those that examine innovation, risk-regulation,
bioethics, health law with an emphasis on food and drug law,
administrative law, and intellectual property law.24
This Article builds on my prior scholarship regarding the role of
ethical and social considerations in scientific decision-making and uses
those considerations to structure a system for regulating germline gene
editing techniques.25 This Article makes several contributions to the
bioethics, food and drug law, and health law literatures. With respect to
bioethics literature, this Article outlines the various reasons why
individuals are opposed to gene editing technologies. This Article shows
that many of those reasons are the same reasons that lead to opposition
environmental regulation”). See generally Mark Geistfeld, Negligence, Compensation,
and the Coherence of Tort Law, 91 GEO. L.J. 585 (2003); Michele Goodwin, A View from the
Cradle: Tort Law and the Private Regulation of Assisted Reproduction, 59 EMORY L.J. 1039,
1089–1100 (2010).
21 For a definition of the gene pool, see, for example, The Collective Set of Alleles in a
Population Is Its Gene Pool, SCITABLE BY NATURE EDUC. (2014), https://www.nature.com/
scitable/topicpage/the-collective-set-of-alleles-in-a-6385985 (“The collection of all the
genes and the various alternate or allelic forms of those genes within a population is
called its gene pool.”).
22 The Science and Ethics of Genetically Engineered Human DNA: Hearing Before the
Subcommittee on Research and Technology of the H. Comm. on Sci., Space, and Technology,
114th Cong. 1, 23 (2015), (statement of Dr. Elizabeth McNally), https://www.gov
info.gov/content/pkg/CHRG-114hhrg97564/pdf/CHRG-114hhrg97564.pdf
[hereinafter The Science and Ethics of Genetically Engineered Human DNA].
23 Donald B. Kohn et al., Ethical and Regulatory Aspects of Genome Editing, 127
BLOOD 2553, 2553 (2016). This characterization applies to both somatic and germline
gene editing.
24 See, e.g., Stuart Minor Benjamin & Arti K. Rai, Fixing Innovation Policy: A Structural
Perspective, 77 GEO. WASH. L. REV. 1, 19 (2008) (citing Rebecca S. Eisenberg, The Role of
the FDA in Innovation Policy, 13 MICH. TELECOMM. & TECH. L. REV. 345, 347 (2007)); Stuart
Minor Benjamin & Arti K. Rai, Who’s Afraid of the APA? What the Patent System Can Learn
from Administrative Law, 95 GEO. L.J. 269, 275 (2007). For more on gene editing from a
patent perspective, see Green, supra note 20, at 115–17; Laakmann, supra note 20, at
916; Nash, supra note 20, at 192–97; Arti K. Rai, Building A Better Innovation System:
Combining Facially Neutral Patent Standards with Therapeutics Regulation, 45 HOUS. L.
REV. 1037, 1040 (2008); Jacob S. Sherkow, Patent Protection for CRISPR: An ELSI Review,
4 J.L. & BIOSCIENCES 565 (2017). See generally Mark Geistfeld, Negligence, Compensation,
and the Coherence of Tort Law, 91 GEO. L.J. 585 (2003) (discussing “the . . . long-held belief
that the tort system is designed to compensate physical injuries”).
25 See Lewis, The American Democratic Deficit, supra note 8.
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to IVF. With respect to the food and drug law literature, this Article
examines the role that the FDA has taken in the regulation of gene
modifying ARTs, before explaining why the FDA should not regulate
gene modifying ARTs. As to the broader health law field, this Article
analyzes the regulatory treatment of a controversial medical technique.
This Article recommends a regime for regulating germline gene
editing that embodies values that are beneficial to researchers, the
public, and governmental bodies. Science often outpaces the law, but in
the time required for germline gene editing to be commercially ready,
there is adequate time to improve the regulatory regime to actually
accommodate that form of gene editing.26 This would differ from the
regulatory treatment of other techniques such as ART, for which the law
has lagged behind science.
Part II of this Article provides background on traditional ART and
innovative genetic technologies and ARTs before providing an overview
of the American regulatory system that currently applies to gene editing
and traditional ART. Part III explores bioethical debates that have
arisen in the context of the technologies discussed in Part II, in addition
to providing an overview of bioethical debates that are unique to
germline gene editing technologies, in support of the argument that
those morality-based objections are insufficient to support the federal
treatment of germline gene editing. Part IV advocates for a regulatory
treatment of germline gene editing technologies that is similar to that of
traditional ART, namely IVF, by drawing on the regulatory and scientific
challenges that accompany techniques involving genetic modification
and ART.

26 See infra Section II.B. (discussing self-regulation in the medical profession); see
also NUFFIELD COUNCIL ON BIOETHICS, GENOME EDITING AND HUMAN REPRODUCTION: SOCIAL AND
ETHICAL ISSUES 31 (2018) [hereinafter NUFFIELD COUNCIL ON BIOETHICS, GENOME EDITING AND
HUMAN REPRODUCTION: SOCIAL AND ETHICAL ISSUES]; Lyria Bennett Moses, Understanding
Legal Responses to Technological Change: The Example of In Vitro Fertilization, 6 MINN.
J.L. SCI. & TECH. 505, 515–17 (2005); Anna Funk, Human Gene Editing is Controversial.
Shoukhrat Mitalipov Isn’t Deterred, DISCOVER MAG., (April 15, 2019), http://discover
magazine.com/2019/may/repairing-the-future (“Mitalipov estimates the gene editing
technology [for use on embryos] won’t be ready for clinical trials—meaning tests in real
pregnancies—for another five to 10 years.”); Rob Stein, First U.S. Patients Treated With
CRISPR As Human Gene-Editing Trials Get Underway, NPR (Apr. 16, 2019, 11:01 AM),
https://www.npr.org/sections/health-shots/2019/04/16/712402435/first-u-spatients-treated-with-crispr-as-gene-editing-human-trials-get-underway (“[I]t will be
many years before any CRISPR treatment could become widely available.”).
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II. EMERGING TECHNOLOGIES IN GENE EDITING AND “TRADITIONAL” ART
As evidenced by the number of Nobel Prizes awarded concerning
genetic innovation and the sums generated by patents on DNA-related
technology, genetic advances are significant.27 Germline gene editing,
which would occur before a child is born and result in heritable changes,
requires the use of ART, namely IVF, which is legal in the United States.28
ART, unlike gene editing, is not subject to patent restrictions.29
This Part provides relevant scientific and legal background,
including the history of the regulation of traditional ART and the FDA’s
unexpected assertions of jurisdiction over techniques involving the
combination of ART and genetic modification. In prior works, I have
outlined the FDA’s gradual assertion of jurisdiction over techniques that
combine ART and genetic modification (what I have referred to as
“AARTs”) and germline genetic modification before arguing that these
techniques, involving genetic modification like cytoplasmic and
mitochondrial transfer, should be treated similarly to IVF, which falls
within state-regulated practice of medicine, as opposed to within the
federal regulation of medical products.30 This Article takes a similar
position related to germline gene editing.

27 See, e.g., 1972: First Recombinant DNA, NAT’L INSTS. OF HEALTH, NAT’L HUM. GENOME
RES. INST. (Apr. 26, 2013), https://www.genome.gov/25520302/online-education-kit1972-first-recombinant-dna; The Birth of Biotech, MIT TECH. REV. (July 1, 2000),
https://www.technologyreview.com/s/400767/the-birth-of-biotech/; The Nobel Prize
in Chemistry 1980, NOBEL PRIZE, https://www.nobelprize.org/prizes/chemistry/
1980/summary (last visited May 4, 2019); The Nobel Prize in Physiology or Medicine
1962, NOBEL PRIZE, https://www.nobelprize.org/prizes/medicine/1962/summary (last
visited May 4, 2019).
28 See, e.g., Eli Adashi & I. Glenn Cohen, Heritable Genome Editing: Edited Eggs and
Sperm to the Rescue?, 322 JAMA (2019); Heritable Genome Editing: Action Needed To
Secure Responsible Way Forward, NUFFIELD COUNCIL ON BIOETHICS (July 17, 2018),
http://nuffieldbioethics.org/news/2018/heritable-genome-editing-action-neededsecure-responsible; Yanting Zeng et al., Correction of the Marfan Syndrome Pathogenic
FBN1 Mutation by Base Editing in Human Cells and Heterozygous Embryos, 26 MOLECULAR
THERAPY 2631, 2631 (2018), https://www.cell.com/molecular-therapy-family/
molecular-therapy/fulltext/S1525-0016%2818%2930378-2#%20 (discussing the
potential combination of gene editing and PGD).
29 See, e.g., Jon Cohen, CRISPR Patent Fight Revived, 365 SCI. 15–16 (July 5, 2019),
https://science.sciencemag.org/content/365/6448/15.2/tab-pdf.
30 See discussion infra Section II.B.
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A. Scientific Background
1. Genes
There are a number of terms related to genetics, ART, and the
regulation of medical products that are important for discussing the
regulatory treatment of gene editing. As a foundational matter, genes
are the source of hereditary traits in humans and other living
organisms.31 Genes are a part of the human genome.32 Within the
human genome, 23 pairs of chromosomes contain “approximately
22,000 genes.”33 Each of these approximately 22,000 genes is “encoded
as DNA” contained in the nucleus of the cell.34 But genes are not static.
The term “mutation” refers to a change in the genetic sequence.35 While
“[s]ome mutations are harmless . . . others can cause disease or increase
the risk of disease. As a result, the study of genetics can lead to valuable
medical breakthroughs.”36

31

Assoc. for Molecular Pathology v. Myriad Genetics, 569 U.S. 576, 580 (2013).
NUFFIELD COUNCIL ON BIOETHICS, GENOME EDITING AND HUMAN REPRODUCTION: SOCIAL AND
ETHICAL ISSUES, supra note 26, at 7 (noting that the “genome is the complete set of genes”);
see also Greely, supra note 6, at 115 (explaining why the author uses the term “genome
editing” instead of “gene editing”);
33 Myriad, 569 U.S. at 580. But see Human Genome Project Information Archive
1990–2003, About the Human Genome Project (Mar. 26, 2019), https://web.ornl.gov/
sci/techresources/Human_Genome/project/index.shtml (noting that there are
“approximately 20,000-25,000 genes in human DNA”). See also Cassandra Willyard,
New Human Gene Tally Reignites Debate, NATURE (Jun. 19, 2018),
https://www.nature.com/articles/d41586-018-05462-w.
34 Myriad, 569 U.S. at 580; John A. Robertson, Procreative Liberty in the Era of
Genomics, 29 AM. J.L. & MED. 439, 439 (2003). See generally J.D. Watson & F.H.C. Crick,
Molecular Structure of Nucleic Acids: A Structure for
Deoxyribose Nucleic Acid, 171 NATURE 737 (1953).
35 Myriad, 569 U.S. at 582.
36 Id. See also Genetic Disorders, MEDLINEPLUS, U.S. NAT’L LIBR. OF MED. (Apr. 17, 2018),
https://medlineplus.gov/geneticdisorders.html.
You can inherit a gene mutation from one or both parents. A
mutation can also happen during your lifetime. There are three types
of genetic disorders:
•
Single-gene disorders, where a mutation affects one gene [like]
[s]ickle cell anemia . . . .
•
Chromosomal disorders, [like Down syndrome] where
chromosomes (or parts of chromosomes) are missing or
changed. Chromosomes are the structures that hold our genes
....
•
Complex disorders, [like colon cancer] where there are
mutations in two or more genes. Often your lifestyle and
environment also play a role.
Id.
32
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2. Somatic Gene Therapy
In recent years, media coverage has frequently addressed germline
gene editing and gene therapy.37 Genetic engineering has existed since
1972 when researchers published articles in the Proceedings of the
National Academies of Sciences on their use of recombinant DNA
technology.38 The first human clinical trials involving gene therapy took
place in 1990.39 Germline gene editing of embryos implicates
reproductive cells such as egg or sperm as opposed to somatic cells, the
other types of cells in the body.40 While it is expected that somatic cell
gene therapy only changes an individual patient’s genes (and is
therefore not heritable), genome editing introduces heritable genetic
modifications.41 Gene therapy, or gene transfer, which only affects an
individual’s somatic cells, does not engender the same opposition as
germline gene editing.42

37

at 3.

See The Science and Ethics of Genetically Engineered Human DNA, supra note 22,

38 There were a number of publications related to recombinant DNA in 1972 and
1973. See Russell Spivak et al., Germ-line Gene Editing and Congressional Reaction in
Context: Learning from Almost 50 Years of Congressional Reactions to Biomedical
Breakthroughs, 30 J. L. & HEALTH 20, 23 n.9 and accompanying text (2017). For more on
recombinant DNA technologies, see Stanley Cohen et al., Construction of Biologically
Functional Bacterial Plasmids In Vitro (R factor/restriction enzyme/transformation/
endonuclease/antibiotic resistance), 70 PROC. NAT’L ACAD. OF SCI. 3240, 3244 (1973),
https://www.pnas.org/content/pnas/70/11/3240.full.pdf; Eileen M. Kane, Human
Genome Editing: An Evolving Regulatory Climate, 57 JURIMETRICS J. 301, 301–02 (2017);
Jennifer Khan, The CRISPR Quandary, N.Y. TIMES MAG. (Nov. 9, 2015),
https://www.nytimes.com/2015/11/15/magazine/the-crispr-quandary.html; 1972:
First Recombinant DNA, NAT’L INSTS. OF HEALTH (Apr. 26, 2013),
https://www.genome.gov/25520302/online-education-kit-1972-first-recombinantdna.
39 How Does Gene Therapy Work?, SCI. AM. (May 13, 2008), https://www.scientific
american.com/article/experts-gene-therapy; see also How Does Gene Therapy Work?,
MEDLINEPLUS, U.S. NAT’L LIBR. OF MED. (Apr. 30, 2019), https://ghr.nlm.nih.gov/primer/
therapy/procedures.
40 Somatic Cells, NAT’L HUM. GENOME RES. INST., https://www.genome.gov/geneticsglossary/Somatic-Cells (last visited June 3, 2019).
41 See Katrine S. Bosley et al., CRISPR Germline Engineering—The Community Speaks,
33 NATURE BIOTECHNOLOGY 478, 485 (2015).
42 Id.; see also Marcy Darnovsky & Katie Hasson, CRISPR’s Twisted Tales: clarifying
misconceptions about heritable genome editing, 63 PERSPS. IN BIO. & MED. 155, 158 (2020);
Sarah Polcz & Anna Lewis, CRISPR-CAS9 and the Non-Germline Non-Controversy, 3 J.L. &
BIOSCIENCES 413, 413–14 (2016); Nicholas Wade, Scientists Seek Ban on Method of Editing
the Human Genome, N.Y. TIMES (Mar. 20, 2015), https://www.nytimes.com/2015/03/
20/science/biologists-call-for-halt-to-gene-editing-technique-in-humans.html.
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3. Germline Gene Editing
Germline gene editing technology like CRISPR-Cas9 modifies DNA
contained in the nucleus of the cell (“nuclear DNA”) as opposed to DNA
outside of the nucleus such as mitochondrial DNA, which has been the
target of other forms of ART that arguably do not implicate the human
germline.43 As noted in the Introduction, germline gene editing offers
the ability to prevent a future child from contracting a disease altogether
by removing the genetic mutation that would result in disease.44
Germline gene editing could also reduce the likelihood that individuals
will be affected by diseases with genetic risk factors, such as breast
cancer.45 The definition of the term “germline” is disputed: some think
that it incorporates only changes to nuclear DNA, while others argue
that it includes changes to non-nuclear DNA, such as mitochondrial
43 See What is DNA?, NAT’L INSTS. OF HEALTH, U.S. NAT’L LIBR. OF MED., https://ghr.nlm.
nih.gov/primer/basics/dna (“DNA, or deoxyribonucleic acid, is the hereditary material
in humans and almost all other organisms. Nearly every cell in a person’s body has the
same DNA. Most DNA is . . . nuclear DNA[], but a small amount of DNA can also be found
in the mitochondria . . . .”) (last visited Oct. 18, 2020). Compare Lucía Gómez-Tatay, José
M. Hernández-Andreu & Justo Aznar, Mitochondrial Modification Techniques and Ethical
Issues, 6 J. CLINICAL MED. 1, 3 (2017) (noting that gene editing could be adapted to act on
mitochondrial DNA, but “to prevent the transgenerational transmission of
mitochondrial diseases, it needs to act on the germline[,]” and that the technology does
not yet work well with mitochondrial DNA), with Rosamund Scott & Stephen Wilkinson,
Germline Genetic Modification and Identity: the Mitochondrial and Nuclear Genomes, 37
OXFORD J. LEGAL STUD. 886, 887 (2017) (stating that, in 2016, the US Institute of Medicine
“held that [Mitochondrial Replacement Therapy] . . . constitute[s] genetic modification
and that, since mitochondria are maternally inherited, . . . [it] amount[s] to germline
modification if female offspring are born”). For more information on the many uses and
advances in CRISPR, see Sharon Begley, CRISPR Advances Are Coming Fast. Here’s Your
Guide, STAT PLUS, https://www.statnews.com/feature/crispr/tracker. For a brief
history of the development of CRISPR, including competing claims as to who first created
the technology, see Greely, supra note 6, at 2326–29. For more on the disputes related
to the meaning of the term “germline,” see David Baltimore et al., A Prudent Path
Forward for Genomic Engineering and Germline Gene Modification, 348 SCI. 36, 37 (2015).
44 See supra Part I.
45 See GERMAN ETHICS COUNCIL, INTERVENING IN THE HUMAN GERMLINE: OPINION: EXECUTIVE
SUMMARY & RECOMMENDATIONS 12 (Aileen Sharpe trans., 2019), https://www.ethi
krat.org/fileadmin/Publikationen/Stellungnahmen/englisch/opinion-intervening-inthe-human-germline-summary.pdf (“The correction of a germline mutation in the
Breast Cancer 1 (BRCA1) gene could, for example, reduce the breast cancer risk of a
woman affected by this form of familial breast cancer from about 75 percent to the level
of the general female population of about 12 percent.”). But see Sharon Begley, You Had
Questions for David Liu About CRISPR, Prime Editing, and Advice to Young Scientists. He
Has Answers, STAT NEWS (Nov. 6, 2019), https://www.statnews.com/2019/11/06/
questions-david-liu-crispr-prime-editing-answers (“BRCA1 and BRCA2 variants that
predispose individuals to cancer, and many other genetic variants like these, could in
principle be addressed by genetic therapies. However, there are a number of challenges
associated with using gene editing for this purpose.”).
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DNA.46 In this Article, the term germline genetic modification refers to
the use of technology that modifies nuclear DNA.
While human gene therapy has been possible since 1980, gene
editing technology has existed since at least 2003.47 Gene editing
technology allows genes to be “deleted, inserted or replaced by a
different piece of DNA.”48 The gene editing technology, CRISPR-Cas9,
which is the focus of most gene editing-related media coverage, first
appeared in scientific literature in 2012.49
Germline gene editing, like many innovations (including somatic
gene therapy), is accompanied by safety concerns.50 These concerns
include those related to mosaicism and off-target effects.51 Mosaicism
exists when an organism includes both edited and unedited cells; this is
significant because the goal of gene editing is to edit all of the cells such
that the genetic modification is uniform.52 “Off-target effects” are also
46 Ainsley J. Newson & Anthony Wrigley, Is Mitochondrial Donation Germ-Line Gene
Therapy? Classifications and Ethical Implications, 31 BIOETHICS 55, 57–58 (2017).
47 Kane, supra note 38, at 303, 307.
48 See The Science and Ethics of Genetically Engineered Human DNA, supra note 22, at
3 (citing Andrew Pollack, A Powerful New Way to Edit DNA, N.Y. TIMES (Mar. 3, 2014),
https://www.nytimes.com/2014/03/04/health/a-powerful-new-way-to-editdna.html).
49 See George Q. Daley et al., After the Storm—A Responsible Path for Genome Editing,
380 NEW ENG. J. MED. 897, 897 (2019). For an explanation of how the CRISPR-Cas9
technology operates, see Andrew Pollack, A Powerful New Way to Edit DNA, N.Y. TIMES
(Mar. 3, 2014), https://www.nytimes.com/2014/03/04/health/a-powerful-new-wayto-edit-dna.html?searchResultPosition=16. CRISPR-Cas9 is a gene editing method; it is
not, however, the only method of editing genes. See, e.g., What Are Genome Editing and
CRISPR-Cas9?, NAT’L INSTS. OF HEALTH, U.S. NAT’L LIBR. OF MED., https://ghr.nlm.nih.gov/
primer/genomicresearch/genomeediting (last visited Oct. 18, 2020).
Several approaches to genome editing have been developed. A recent
one is known as CRISPR-Cas9, which is short for clustered regularly
interspaced short palindromic repeats and CRISPR-associated
protein 9. The CRISPR-Cas9 system has generated a lot of excitement
in the scientific community because it is faster, cheaper, more
accurate, and more efficient than other existing genome editing
methods.
Id.
50 See, e.g., Francoise Baylis, Human Germline Genome Editing and Broad Societal
Consensus, 1 NATURE HUM. BEHAVIOR 1, 1 (2017); NAT’L ACAD. SCIS., ENG., & MED., HUM.
GENOME EDITING 237, 302 (2017) [hereinafter NAT’L ACADS. SCIS., ENG’G & MED., HUMAN
GENOME EDITING: SCI., ETHICS, AND GOVERNANCE].
51 See, e.g., Baylis, supra note 50, at 1; NAT’L ACADS. SCIS., ENG’G & MED., HUMAN GENOME
EDITING: SCI., ETHICS, AND GOVERNANCE, supra note 50, at 116.
52 See Hong Ma et. al, Correction of a Pathogenic Gene Mutation in Human Embryos,
548 NATURE 413, 415 (2017) (discussing efforts to avoid mosaicism in embryos); see also
Bosley et al., supra note 41, at 480 (statement of Dr. Jennifer Doudna) (“[I]f the ‘edited’
individual is chimeric for the intended correction, they may still have diseased cells in
critical tissues.”). For more information on mosaicism, see NAT’L ACAD. OF SCIS., HERITABLE
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referred to as “unintended consequences.”53 It is possible that the gene
editing will not do exactly what the editor intended, as seen with twins
who were born as a result of an experiment by Dr. He Jiankui, a nowdisgraced Chinese scientist who announced the birth of the first “CRISPR
babies”; neither of the twins born after the germline gene editing had
the exact modified gene that the doctor intended.54 According to Dr. He,
the first CRISPR babies, who were edited to prevent HIV transmission,
suffered from mosaicism, with one baby having cells that were both
edited and unedited.55 Additionally, the gene that Dr. He Jiankui
targeted did not necessarily confer automatic protection against HIV1.56 Further, the targeted mutation, CCR5, corresponds to increased
susceptibility to West Nile virus, influenza, enhanced memory, and
possibly a shortened life span.57 Other research indicates that the CCR5
gene could be connected to improved stroke recovery outcomes.58
Many articles related to gene editing also focus on off-target
effects.59 Off-target effects occur when scientists target one gene for
editing and inadvertently impact other non-targeted genes.60 Over time,
scientists have minimized the off-target effects of gene editing, but offtarget effects remain a cause for concern among both scientists and
ethicists.61
HUMAN GENOME EDITING 68–69 (2020) [hereinafter NAT’L ACADS. SCIS., HERITABLE HUMAN
GENOME EDITING].
53 NAT’L ACADS. SCI., ENG’G & MED., HUMAN GENOME EDITING: SCIENCE, ETHICS, AND
GOVERNANCE, supra note 50, at 122; see also NAT’L ACADS. SCIS., HERITABLE HUMAN GENOME
EDITING, supra note 52, at 67–68.
54 See Henry T. Greely, He Jiankui, Embryo Editing, CCR5, The London Patient, and
Jumping to Conclusions, STAT NEWS (Apr. 15, 2019), https://www.statnews.com/2019/
04/15/jiankui-embryo-editing-ccr5.
55 See Gina Kolata & Pam Belluck, Why Are Scientists So Upset About the First Crispr
Babies?, N.Y. TIMES (Dec. 5, 2018), https://www.nytimes.com/2018/12/05/health/
crispr-gene-editing-embryos.html.
56 See id.
57 See Darnovsky & Hasson, supra note 42, at 156; Sara Reardon, Gene Edits to
‘CRISPR babies’ Might Have Shortened Their Life Expectancy, NATURE (June 4, 2019),
https://www.nature.com/articles/d41586-019-01739-w.
58 See Greely, supra note 6, at 159–60 (discussing the connection between CCR5 and
stroke recovery and noting that “[t]he evidence of benefit in stroke recovery, if any,
applies only to Nana,” who is one of the so-called CRISPR babies).
59 See, e.g., Ma et. al, supra note 52, at 416.
60 Id.
61 See, e.g., Letter from Burt Adelman, M.D., Special Advisor, Novo Ventures, et al. to
Alex Azar II, Secretary, U.S. Dep’t of Health & Human Services (Apr. 24, 2019),
https://www.asgct.org/global/documents/clinical-germline-gene-editing-letter.aspx
(calling for a moratorium on germline gene editing but not somatic gene editing). But
see Yanting Zeng et al., Correction of the Marfan Syndrome Pathogenic FBN1 Mutation by
Base Editing in Human Cells and Heterozygous Embryos, 26 MOLECULAR THERAPY 2631,
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When considering the risks and benefits of germline gene editing
as opposed to other treatment options, there are a limited number of
diseases that germline gene editing would address better than other
methods of treatment.62 Nevertheless, germline and somatic gene
editing offer the possibility of great medical promise.63
4. Assisted Reproductive Technology
ART has incited religious, ethical, and political controversy since
1978 when the first baby was born as a result of IVF.64 Controversy has
also accompanied other forms of ART and medical screening techniques
related to reproduction, including the use of preimplantation genetic
diagnosis (“PGD”), amniocentesis, and sperm banks.65 Most recently,
mitochondrial transfer, a form of ART involving genetic modification to
prevent maternal mitochondrial disease transmission, has similarly led
to intense debate and opposition, with clinical trials going forward in
the United Kingdom but not in the United States.66 ART safety concerns
include those related to the drugs used to stimulate egg production;
continued correlations between ART and adverse maternal-fetal
outcomes; and some often-dismissed concerns about ART’s long-term
effects.67
Germline gene editing could improve the efficacy of traditional
68
ART. For example, PGD is used in combination with forms of ART such
as IVF.69 PGD can screen embryos created using IVF for genetic
2631, 2634 (2018) (discussing the results of an experiment in which base editing was
used to eliminate off-target effects).
62 The Science and Ethics of Genetically Engineered Human DNA, supra note 22, at 64
(providing the answers to post-hearing questions of Dr. Elizabeth McNally, which
observed that “[t]echnology and its medical application are judged based on the riskbenefit ratio”).
63 See supra Part I.
64 In IVF, an egg is fertilized by sperm in a laboratory. Adam Eley, How Has IVF
Developed Since the First ‘Test-tube Baby’?, BBC NEWS (Jul. 23, 2015),
https://www.bbc.com/news/health-33599353; see also June Carbone & Jody Lyneé
Madeira, Buyers in the Baby Market: Toward a Transparent Consumerism, 91 WASH. L.
REV. 71, 102 (2016); Moses, supra note 26, at 522–26, 536–45.
65 R. Alta Charo, Who’s Afraid of the Big Bad (Germline Editing) Wolf?, 63 PERSPS. IN
BIOLOGY & MED. 93, 93 (2020).
66 See Lewis, The American Democratic Deficit, supra note 8, at 146–49 (discussing
debate and opposition to mitochondrial transfer).
67 See infra note 391 and accompanying text; see also Martha Field, Compensated
Surrogacy, 89 WASH. L. REV. 1155, 1159 (2014).
68 NAT’L ACADS. SCIS., HERITABLE HUMAN GENOME EDITING, supra note 52, at 120.
69 See, e.g., Jeani Chang et al., Outcomes of In Vitro Fertilization with Preimplantation
Genetic Diagnosis: An Analysis of the United States Assisted Reproductive Technology
Surveillance Data, 2011–2012, 105 FERTIL. & STERIL. 394 (2016); NUFFIELD COUNCIL ON
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abnormalities, with the goal of allowing individuals to select embryos
that do not contain those abnormalities.70 PGD cannot address all
genetic abnormalities or diseases but can detect “single- gene defects or
chromosomal abnormalities” such as Down Syndrome or Tay-Sachs.71
PGD can also be used for sex selection and to affirmatively select for
certain traits, such as a genetic match for a sibling in need of a tissue
transplant.72 Embryos that meet the requested constraints are then
implanted for pregnancy.73 In certain instances, PGD reveals that
“[m]any embryos are unsuitable for transfer because they are affected
by . . . genetic disease or are of poor quality.”74 This concern is
exacerbated when there are fewer embryos to choose from due to
limitations like compromised fertility.75
It is expected that there are very limited circumstances in which
germline gene editing is the only option; however, parents still might
prefer germline gene editing to PGD for the potential positive health
outcomes of their future children.76 Combining germline gene editing
with PGD “could rescue otherwise viable embryos that were carrying
the abnormal allele and theoretically double the probability of the birth

BIOETHICS, GENOME EDITING AND HUMAN REPRODUCTION: SOCIAL AND ETHICAL ISSUES, supra note
26, at 1. PGD is also referred to as “preimplantation genetic testing.” Chang et al., supra
note 69, at 394–95.
70 See Jaime S. King, Predicting Probability: Regulating the Future of Preimplantation
Genetic Screening, 8 YALE J. HEALTH POL’Y, L. & ETHICS, 283, 285 (2008); Preimplantation
Genetic Diagnosis: PGD, AMER. PREGNANCY ASSOC., https://americanpregnancy.org/
infertility/preimplantation-genetic-diagnosis (last visited Jul. 27, 2019). PGD is also
used to create children with certain genetic characteristics so that they can be “matches”
for older siblings. These children are sometimes referred to as savior siblings. See, e.g.,
Susannah Baruch, Preimplantation Genetic Diagnosis and Parental Preferences: Beyond
Deadly Disease, 8 HOUS. J. HEALTH L. & POL’Y 245, 256 (2008); Ferris Jabr, Are We Too Close
to Making Gattaca a Reality?, SCI. AM.: BRAINWAVES (Oct. 28, 2013), https://blogs.scientific
american.com/brainwaves/are-we-too-close-to-making-gattaca-a-reality.
71 PGD Q&A, CTR. FOR ADVANCED REPRODUCTIVE SERV., https://www.uconnfertility.com/
specialized-programs/pre-implant-genetic-diagnosis-program/pgd-qa (last visited
Sept. 14, 2020); see also PGD Detected Diseases, CTR. FOR ADVANCED REPRODUCTIVE SERV.,
https://www.uconnfertility.com/specialized-programs/pre-implant-geneticdiagnosis-program/pgd-detected-diseases (last visited Sept. 14, 2020).
72 See supra note 71. See also S. Sheldon & S. Wilkinson, Should Selecting Saviour
Siblings Be Banned?, 30 J. MED. ETHICS 533, 533 (2004).
73 Sheldon & Wilkinson, supra note 72, at 533.
74 Daley et al., supra note 49, at 899.
75 Id.; see also Eli Y. Adashi & I. Glenn Cohen, The Case for Remedial Germline
Editing—The Long-term View, 323 J. MED. ETHICS 1762, 1762–63 (2020) (discussing the
limitations of PGD as compared to germline gene editing).
76 NAT’L ACADS. SCIS., ENG’G & MED., HUMAN GENOME EDITING: SCI., ETHICS, AND GOVERNANCE,
supra note 50, at 115, 120.
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of the healthy baby.”77 Thus, ART’s effectiveness could improve due to
a higher probability that embryos that would usually be discarded in
traditional ART could instead result in a healthy pregnancy and
childbirth. Combining gene editing with PGD could also create “savior
siblings” for families seeking tissue matches for existing children who
need stem cell transplants, a use that some would likely consider
controversial.78 Yet scholars have also noted that, in some instances,
germline gene editing and PGD will be mutually exclusive.79
Nevertheless, from both practical and bioethical perspectives, for those
who are opposed to ART based on the destruction of embryos (or its
contribution to the number of leftover embryos), combining PGD with
germline gene editing or using germline gene editing alone might
eventually reduce the number of discarded embryos in ART, although
further innovation will destroy embryos in the research process.80

77

Daley et al., supra note 49, at 899.
See Andrew Joseph, Could Editing the DNA of Embryos with CRISPR Help Save
People Who Are Already Alive?, STAT NEWS (Sept. 16, 2019), https://www.statnews.com/
2019/09/16/could-editing-the-dna-of-embryos-with-crispr-help-save-people-whoare-already-alive.
79 See Adashi & Cohen, supra note 75, at 1763.
The [two international] panels [considering remedial germline
editing (RGE)] would do well to recognize the potential substantial
advantages of RGE over PGD, and that the 2 techniques are mutually
exclusive. They cannot be sequentially applied to maximize the
number of transferable embryos because RGE is applied at the time
of fertilization and it is ill-suited to correct genetic defects identified
by PGD in day 5 blastocysts. Given PGD’s unavoidable limitations,
future efforts at curtailing heritable monogenic disorders would do
well to prioritize safe and effective RGE.
Id.
80 See Sharon Begley, U.S. Scientists Edit Genome of Human Embryo, But Cast Doubt
on Possibility of ‘Designer Babies’, STAT NEWS (Aug. 2, 2017), https://www.stat
news.com/2017/08/02/crispr-designer-babies/; Pam Belluck, In Breakthrough,
Scientists Edit a Dangerous Mutation from Genes in Human Embryos, N.Y. TIMES (Aug. 2,
2017), https://www.nytimes.com/2017/08/02/science/gene-editing-humanembryos.html. But see Giulia Cavaliere, Background Paper: The Ethics of Human Genome
Editing, WHO EXPERT ADVISORY COMM. ON DEVELOPING GLOBAL STANDARDS FOR GOVERNANCE AND
OVERSIGHT OF HUMAN GENOME EDITING 5, https://www.who.int/ethics/topics/humangenome-editing/WHO-Commissioned-Ethics-paper-March19.pdf (noting that germline
gene-editing research involves the destruction of human embryos). For more
information on the controversy that accompanies research on human embryos, see
NAT’L ACADS. SCIS., ENG’G & MED., HUMAN GENOME EDITING: SCI., ETHICS, AND GOVERNANCE, supra
note 50, at 80–81.
78
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B. Legal Background
Subjecting germline gene editing in the U.S. to administrative
hurdles is part of a longstanding federal regulatory hostility to gene
modifying techniques in the United States. Despite the practiceproducts divide in which the federal government regulates medical
products and states regulate the practice of medicine, there is little
federal regulation of traditional ART, and most regulation comes from
states.81 Most commentators characterize traditional ART as “minimally
regulated,” “unregulated,” or non-uniformly regulated.82
This
characterization stems from the general inapplicability of federal
statutes to traditional ART, with most regulation coming from state
regulation of the practice of medicine, although a few federal regulations
do apply to laboratory conditions.83 States have also responded to
81 For more on the practice-products distinction, which corresponds to state
jurisdiction over the practice of medicine through mechanisms such as the licensing of
health professionals and state tort law regimes and federal jurisdiction over the premarketing approval of products, such as drugs, devices, and biologics, see Barbara J.
Evans, Distinguishing Product and Practice Regulation in Personalized Medicine, 81
CLINICAL PHARMACOLOGY & THERAPEUTICS 288, 288 (2007); Patricia J. Zettler,
Pharmaceutical Federalism, 92 IND. L.J. 845, 892 (2017); Patricia J. Zettler, Toward
Coherent Federal Oversight of Medicine, 52 SAN DIEGO L. REV. 427, 434–54, 460–64 (2015).
For more on the practice-products divide in the regulation of innovative therapies
including gene editing and gene therapy, see Myrisha S. Lewis, Innovating Federalism in
the Life Sciences, 92 TEMPLE L. REV. 383, 402–10 (2020).
82 See Lewis, How Subterranean, supra note 8 at 1241 n.1, 1251–53 (providing a
summary of prevailing views on the regulation of traditional ART).
83 Federal regulations do apply to ART and PGD; however, those regulations tend to
focus on compliance-related issues such as “donor material safety, transparency, and
reporting requirements, as is the case with IVF, or on quality control of the laboratories
(though not necessarily the actual diagnostics) used for PGD” as opposed to restricting
access to the techniques or the method of technique used. NAT’L ACADS. SCIS., ENG’G & MED.,
HUMAN GENOME EDITING: SCI., ETHICS, AND GOVERNANCE, supra note 50, at 131. For examples
of federal regulation that applies to ART, see 42 U.S.C. § 264 (2012); 21 C.F.R. § 1271.3(d)
(2016); U.S. FOOD & DRUG ADMIN., ELIGIBILITY DETERMINATION FOR DONORS OF HUMAN CELLS,
TISSUES, AND CELLULAR AND TISSUE-BASED PRODUCTS (2007); Final Rule and Notice, 69 Fed.
Reg. 29,786, 29,787 (May 25, 2004); Human Cells, Tissues, and Cellular and TissueBased Products; Establishment Registration and Listing, 66 Fed. Reg. 5447 (Jan. 19,
2001). But see Seema Mohapatra, Global Legal Responses to Prenatal Gender
Identification and Sex Selection, 13 NEV. L.J. 690, 701 (2013) (discussing the FDA’s
jurisdiction over MicroSort, a sperm-sorting device that was in the process of obtaining
FDA approval until 2011 when “the FDA informed [the Genetics and IVF institute where
clinical trials related to MicroSort were occurring] that it would no longer be allowed to
enroll any more families in the FDA clinical trial for family-balancing purposes”).
Medical devices are also regulated by the FDA. See, e.g., U.S. FOOD AND DRUG ADMIN.,
OVERVIEW OF DEVICE REGULATION (2020), https://www.fda.gov/medical-devices/deviceadvice-comprehensive-regulatory-assistance/overview-device-regulation. Medical
devices are not discussed in this Article as the FDA treats somatic and germline gene
editing as drugs and/or biologics, not devices.
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certain technologies that could lead to the creation of children, namely
by enacting statutes banning human cloning.84
In previous articles, I have noted that this characterization of ART
as “minimally regulated” or “unregulated” is accurate only insofar as it
relates to traditional ART, which is ART not involving genetic
modification. ART involving genetic modification is unexpectedly
subject to the federal government’s burdensome regime that applies to
regulated products.85 This Article is part of that thread of scholarship
and explores another form of genetic modification in ART, namely, the
combination of IVF with genome modification, over which the FDA
surprisingly declared jurisdiction, as discussed below.86 Like my other
articles, this Article, when deciding between two potential regulators for
forms of ART involving genetic modification, selects states (and their
accompanying hands-off regime) over the federal government.87 That
selection stems not only from a jurisdictional objection to treating a
medical technique like a drug but also from a normative perspective
about which regulator is the most transparent and may further parental
autonomy and innovation in a way that will lead to a diversity of
outcomes.88 In other words, the regulation of germline gene editing
would be better carried out by physicians (who are regulated by states)
than the federal government.
Most of the commentary related to the regulation of germline gene
editing has focused on the relevance of moratoria and guidelines in the
applicable scientific community, as well as the role of the FDA in the
regulation of somatic and germline gene editing in the United States.89
This FDA-centric view is surprising because states have jurisdiction
over the practice of medicine, and the federal government has
jurisdiction over the tools used in the practice of medicine, such as
84 The Article differentiates cloning technology from reproductive technology
because cloning involves copying one individual as opposed to reproduction which
focuses on two individuals. For more on state statutes banning reproductive cloning,
see Judith F. Daar, The Prospect of Human Cloning: Improving Nature or Dooming the
Species?, 33 SETON HALL L. REV. 511, 515 (2003); Charles Thomas, Novel Assisted
Reproductive Technologies and Procreative Liberty: Examining in Vitro Gametogenesis
Relative to Currently Practiced Assisted Reproductive Procedures and Reproductive
Cloning, 26 S. CAL. INTERDISC. L.J. 623, 636 n.98 (2017).
85 See infra pp. 760–61.
86 See Id.
87 See Id.
88 See Lewis, The American Democratic Deficit, supra note 8, at 157–63
89 See, e.g., Eric S. Lander et al., Adopt a Moratorium on Heritable Genome Editing, 567
NATURE 165, 165 (2019); Carrie D. Wolinetz & Francis S. Collins, NIH Supports Call for
Moratorium on Clinical Uses of Germline Gene Editing, NATURE (Mar. 13, 2019),
https://www.nature.com/articles/d41586-019-00814-6.
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medical devices and fertility drugs.90 Thus, for the regulation of
traditional ART, the only federal statute specifically enacted to address
ART is the Fertility Clinic Success Rate Act, which implements a
reporting regime administered by the Centers for Disease Control (not
the FDA) but lacks an enforcement mechanism.91
The FDA has proclaimed jurisdiction over somatic and germline
gene editing, even though the practice of medicine does not fall within
federal jurisdiction.92 As a practical matter, this means that the FDA
does not approve surgical techniques or traditional ART techniques like
IVF, for example.93 While courts resolved the FDA’s questioned
jurisdiction over innovative new therapies, such as regenerative
medicine techniques and stem cell treatments, in the FDA’s favor, the
FDA’s asserted jurisdiction over reproductive techniques involving
genetic modification has yet to be litigated.94
Medicine, innovation, and reproduction are all accompanied by
risk. The FDA does not punish physicians for medical malpractice, as
state tort law provides remedies for harms incurred as a result of
medical treatment (medical malpractice), and states license physicians
through licensing regimes.95 Thus, those harmed by gene editing could

90 See supra note 81 (discussing the practice-products divide between the stateregulated practice of medicine and federally-regulated medical products).
91 See 42 U.S.C. §§ 263a-1-7 (2012) (codifying the Fertility Clinic Success Rate Act).
92 Information About Self-Administration of Gene Therapy, U.S. FOOD & DRUG ADMIN.
(Nov. 21, 2017), https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapyproducts/information-about-self-administration-gene-therapy (“FDA considers any
use of CRISPR/Cas9 gene editing in humans to be gene therapy. . . . Clinical studies of
gene therapy in humans require the submission of an investigational new drug
application (IND) prior to their initiation in the United States, and marketing of a gene
therapy product requires submission and approval of a biologics license application
(BLA).”); see also Lars Noah, State Affronts to Federal Primacy in the Licensure of
Pharmaceutical Products, 2016 MICH. ST. L. REV. 1, 15 (noting “Congress[‘s] repeated[] . . .
assurances that the FDA’s authority to license therapeutic products would not interfere
with the practice of medicine”); The FDA’s New Policy Steps and Enforcement Efforts To
Ensure Proper Oversight of Stem Cell Therapies and Regenerative Medicine, U.S. FOOD &
DRUG ADMIN., (Aug. 28, 2017) (Statement from FDA Commissioner Scott Gottlieb, M.D.),
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm573443.htm
(noting the “close calls” between state and federal jurisdiction posed by new treatments
and medical fields)
93 See, e.g., Nancy M.P. King, The Line Between Clinical Innovation and Human
Experimentation, 32 SETON HALL L. REV. 573, 575 (2002).
94 See, e.g., United States v. Regenerative Scis., 741 F.3d 1314, 1317–21 (D.C. Cir.
2014); United States v. US Stem Cell Clinic, 403 F. Supp. 3d 1279, 1285–1301 (S.D. Fla.
2019).
95 See, e.g., BARRY R. FURROW ET AL., HEALTH LAW: CASES, MATERIALS, AND PROBLEMS 87 (7th
ed. 2013); Lori B. Andrews, The Shadow Health Care System: Regulation of Alternative
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avail themselves of remedies under state tort law like other patients.96
While this ex post approach does not prevent risk, risk-free medicine
and innovation are not required in other areas (and cannot co-exist with
these areas), including ART and PGD.97 Even though germline gene
editing could lead to intergenerational risk, as germline gene editing
would affect a future child and that future child’s children, the
regulatory system has addressed transgenerational harms before, such
as in the case of the multigenerational harms of diethylstilbestrol (DES)
exposure.98 Some state statutes focus on the availability of insurance
coverage for ART, but states do not regulate the actual techniques used
in ART; although states do regulate physicians through licensing
regimes and criminal law.99 States also recognize the impacts of ART
within the framework of family law.100 Further, ethical norms have
evolved in ART, including those discussed and promulgated by
organizations such as the Society for Assisted Reproductive Technology
and the American Society for Reproductive Medicine.101 In this way,
traditional ART is regulated similarly to surgical techniques, which are
subject to little regulatory oversight, whereas techniques involving the

Health Care Providers, 32 HOUS. L. REV. 1273, 1298–1308 (1996); David M. Studdert et al.,
Medical Malpractice, 350 NEW. ENG. J. MED. 283, 283 (2004).
96 See, e.g., Michele Goodwin, A View from the Cradle: Tort Law and the Private
Regulation of Assisted Reproduction, 59 EMORY L.J. 1039, 1089–1100 (2010) (discussing
current and potential applications of tort law to ART); Gary E. Marchant, Legal Risks and
Liabilities of Human Gene Editing, 13 SCITECH LAW. 26, 27–29 (2016) (discussing the
prospective causes of action available to those injured through germline gene editing
research or clinical use).
97 See, e.g., Bratislav Stankovic, “It’s a Designer Baby!”—Opinions on Regulation of
Preimplantation Genetic Diagnosis, 2005 UCLA J.L. & TECH. 3, 20 (noting the inaccuracy
of genetic tests).
98 See NUFFIELD COUNCIL ON BIOETHICS, GENOME EDITING AND HUMAN REPRODUCTION: SOCIAL
AND ETHICAL ISSUES, supra note 26, at 88 (discussing transgenerational changes in the
context of germline gene editing); Marianthi-Anna Kioumourtzoglou et al., Association
of Exposure to Diethylstilbestrol During Pregnancy with Multigenerational
Neurodevelopmental Deficits, 172 JAMA PEDIATRIC 670, 675 (2018); Suryanarayana V.
Vulimiri & Ofelia Olivero, Introduction: Special Issue on Transplacental/
Transgenerational Mutagenesis and Carcinogenesis, 60 ENVTL. & MOLECULAR MUTAGENESIS
392, 392–93 (2019); Ctrs. for Disease Control and Prevention, About DES,
https://www.cdc.gov/des/consumers/about/index.html (last visited Dec. 21, 2020).
See infra notes 322–23 (discussing DES exposure and the regulatory regime’s response).
99 Lewis, The American Democratic Deficit, supra note 8, at 155.
100 Id.
101 For a discussion of each of these organizations, see MARSH & RONNER, supra note
17, at 186–87.
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combination of ART and genetic modification are subject to
substantially more burdensome regimes.102
This Part provides an overview of the various legal provisions that
apply to aspects of germline gene editing, including the minimally
regulated IVF, which is combined with the highly regulated genetic
modification. This Article advocates for extending the current regime
for the state-based regulation of traditional, or non-gene modifying, ART
to germline gene editing and other forms of ART involving genetic
modification. The remainder of this Part provides background on how
the federal regulatory regime has been applied to germline gene editing.
This analysis indicates how the federal government has acted in a
hostile manner toward gene editing by regulating it to the point of
effective preclusion. This hostility has surfaced through (1) federal
funding restrictions, (2) barriers imposed through administrative law,
and (3) Congressional restrictions on administrative agencies. Part IV
will build on this overview by showing how the application of federal
regulation to ART involving genetic modification is not only misplaced
but also involves the federal regulatory system’s hostility to germline
genetic modification, which manifests similar risks to ART and
approved gene therapy products.
1. Federal Funding Restrictions
Federal funding restrictions have had a significant impact on
medical innovation requiring embryonic research as germline gene
editing requires. For example, various conservatives have “opposed
federal funding of embryo research because they believed that life
begins at the moment when the sperm and egg unite.”103 This same
opposition also limited funding for IVF research, which led to private
funding and private innovation in IVF.104 Eventually, these informal
failures to provide funding to IVF research became codified in the
Dickey-Wicker Amendment, a federal budget rider that has been
renewed every year since 1996 and limits funding of research involving
the (controversial) creation or destruction of embryos.105

102 See generally King, supra note 93 (discussing the limited oversight over clinical
innovation).
103 MARSH & RONNER, supra note 17, at 72, 108.
104 Id. at 73.
105 Id. at 144, 176; see also NAT’L ACADS. SCIS., ENG’G & MED., HUMAN GENOME EDITING: SCI.,
ETHICS, AND GOVERNANCE, supra note 50, at 80–81. For more on the controversy related to
the destruction of embryos and research on embryos, see infra Section II.A.4.
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The National Institutes of Health (NIH) have influenced scientific
innovation and the federal drug approval process.106 The NIH is an
operating division of the U.S. Department of Health and Human Services
that “invests about $41.7[] billion annually in medical research.”107 The
NIH has its own research campus, employs over 6,000 scientists, and
disburses funding for medical innovation through a system of
competitive grants.108 NIH funding recipients are subject to a number
of provisions, including mandatory federal regulations and oversight by
various bodies.109 Historically, one of those bodies, the Recombinant
DNA Advisory Committee, commonly referred to as the “RAC,” was a
federal advisory committee whose guidelines applied to recipients of
federal funding.110 The RAC reviewed “human gene transfer protocols
subject to the NIH Guidelines”;111 the Guidelines “were applicable to all
experiments performed at, or sponsored by, any institutions receiving
NIH funding.”112
The FDA asserted jurisdiction over gene therapy in 1986, and
“required the submission of a protocol for approval to the [NIH’s
Recombinant DNA Advisory Committee] RAC” in addition to the
submission of an investigational new drug (IND) application to the FDA
for human gene therapy trials.113 At the same time, the RAC has long
106 See MARCY E. GALLO ET AL., CONG. RES. SERV., R44824, ADVANCED GENE EDITING: CRISPRCAS9, 17–18 (2018).
107 NAT’L INSTS. OF HEALTH, BUDGET (Jan. 24, 2019), https://www.nih.gov/aboutnih/what-we-do/budget.
108 Id. See Grants Compliance & Oversight, NAT’L INST. OF HEALTH, https://grants.nih.
gov/policy/compliance.htm (last visited Jan. 10, 2020).
109 See id. (discussing federal regulations and oversight applicable to parties with NIH
grants). See generally NAT’L INSTS. OF HEALTH, NIH GRANTS POLICY STATEMENT (2019),
https://grants.nih.gov/grants/policy/nihgps/nihgps.pdf (discussing the policies
applicable to grant recipients).
110 See Jordan Paradise, U.S. Regulatory Challenges for Gene Editing, 13 SCI. TECH. LAW.
10, 12 (2016). (“Technically, private institutions are not subject to the RAC-IRB-FDA
framework, yet adherence is the norm; market entry of any commercial drug, device, or
biologic product always requires affirmative FDA review and approval or clearance.”);
see also Recombinant DNA Advisory Committee, NAT’L INSTS. OF HEALTH,
https://osp.od.nih.gov/biotechnology/recombinant-dna-advisory-committee (last
visited Sept. 25, 2018) (“The Recombinant DNA Advisory Committee (RAC) was
established by NIH in 1974 to provide recommendations to the NIH Director and a
public forum for discussion of the scientific, safety, and ethical issues related to basic
and clinical research involving recombinant or synthetic nucleic acid molecules.”).
111 See also The NIH Review Process for Human Gene Transfer Trials, NAT’L INSTS. OF
HEALTH, https://osp.od.nih.gov/biotechnology/faq-onthe-nih-review-process-forhuman-gene-transfer-trials/ (last visited Sept. 25, 2018).
112 Kane, Human Genome Editing, supra note 38, at 306.
113 Id. at 307; Application of Current Statutory Authorities to Human Somatic Cell
Therapy Products and Gene Therapy Products, 58 Fed. Reg. 53248, 53251, (U.S. Food &

LEWIS_FORMATTED (DO NOT DELETE)

758

SETON HALL LAW REVIEW

12/29/2020 8:27 PM

[Vol. 51:735

held the institutional view that it would not “entertain proposals to
modify the human germline.”114 Thus, individuals seeking to research
human germline gene editing face significant financial restrictions. 115
While these financial restrictions do not automatically equate to
marketing or regulatory restrictions, as detailed in the next subsection,
the FDA has exhibited a similar hostility to germline genetic
modification.
2. Administrative Legal Barriers
The FDA administers a regulatory regime intended to ensure that
a number of medical products marketed for approval in the United
States, including drugs, biologics, and medical devices, are safe and
effective.116 Since 1993, the FDA has asserted responsibility for the
regulation of gene therapy.117 The FDA has stated that it would regulate
gene therapy as a biologic and/or drug.118 The FDA has proclaimed that
it will treat germline gene editing in the same manner as gene

Drug Admin. Oct. 14, 1993), https://www.fda.gov/downloads/BiologicsBloodVaccines/
SafetyAvailability/UCM148113.pdf; see also U.S. FOOD & DRUG ADMIN., Statement of Policy
for Regulating Biotechnology Products, 51 Fed. Reg. 23,310, 23,311, (U.S. Food & Drug
Admin. Jun. 26, 1986) https://www.govinfo.gov/content/pkg/FR-1986-06-26/pdf/FR1986-06-26.pdf (“Nucleic acids or viruses used for human gene therapy will be subject
to the same requirements as other biological drugs. It is possible that scientific reviews
of these products will also be performed by the National Institutes of Health.”)
114 Statement on NIH Funding of Research Using Gene-editing Technologies in Human
Embryos, NAT’L INSTS. OF HEALTH, (Apr. 28, 2015), https://www.nih.gov/about-nih/whowe-are/nih-director/statements/statement-nih-funding-research-using-gene-editingtechnologies-human-embryos. For more on the RAC, see Francis S. Collins & Scott
Gottlieb, The Next Phase of Human Gene-Therapy Oversight, 379 NEW ENG. J. MED. 1393,
1393–95 (2018) [hereinafter Collins & Gottlieb, The Next Phase of Human Gene-Therapy
Oversight]; NAT’L ACADS. SCIS., ENG’G & MED., HUMAN GENOME EDITING: SCI., ETHICS, AND
GOVERNANCE, supra note 50, at 56–57.
115 See Paradise, supra note 110 (noting the influence of NIH-funding restrictions on
those who are not even individual funding recipients); see also Collins & Gottlieb, supra
note 114 , at 1393–95 (detailing the current roles of the FDA and the NIH in the
regulation of gene therapy products).
116 See, e.g., U.S. FOOD & DRUG ADMIN., What Does FDA Regulate? (Aug. 22, 2018),
https://www.fda.gov/aboutfda/transparency/basics/ucm194879.htm. For more on
the difference between drugs and biologics, see W. Nicholson Price II & Arti K. Rai,
Manufacturing Barriers to Biologics Competition and Innovation, 101 IOWA L. REV. 1023,
1026, 1032–33 (2016).
117 See Application of Current Statutory Authorities to Human Somatic Cell Therapy
Products and Gene Therapy Products, 58 Fed. Reg. 53248, 53251 (U.S. Food & Drug
Admin. Oct. 14, 1993), https://www.fda.gov/downloads/BiologicsBloodVaccines/
SafetyAvailability/UCM148113.pdf.
118 Collins & Gottlieb, supra note 114, at 1393–95.
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therapy.119 As a matter of “ethical controversy,” the National Academy
of Sciences (NAS) has noted that there is a “broad international
consensus” that not only permits but encourages somatic cell gene
therapy as long as it is proven “safe and effective.”120 In 2017, the FDA
approved the first gene therapy product for use in the United States, in
addition to two other gene therapy products for marketing in the United
States.121
In previous works, I have traced the FDA’s unexpected regulation
of forms of ART involving genetic modifications of various degrees.122
The regulation of reproductive technology is unexpected due to the
aforementioned practice-products divide, and the FDA’s regulatory
assertion essentially means that reproductive techniques (or the
children created as a result) are drugs and/or biologics.123 Despite the
dearth of federal statutes that apply to traditional ART, the FDA has
asserted jurisdiction over forms of ART requiring genetic modification,
119 U.S. Food and Drug Admin., Information About Self-Administration of Gene Therapy
(Nov. 21, 2017), https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapyproducts/information-about-self-administration-gene-therapy.
FDA considers any use of CRISPR/Cas9 gene editing in humans to be
gene therapy. . . . Clinical studies of gene therapy in humans require
the submission of an investigational new drug application (IND)
prior to their initiation in the United States, and marketing of a gene
therapy product requires submission and approval of a biologics
license application (BLA).
Id. When this Article uses the term “gene therapy,” it is referring to somatic or nonheritable genetic modification.
120 NAT’L ACADS. SCIS., ENG’G & MED., HUMAN GENOME EDITING: SCI., ETHICS, AND GOVERNANCE,
supra note 50, at 147; see also NAT’L ACADS. OF SCI., HERITABLE HUMAN GENOME EDITING, supra
note 52, at 126–29 (discussing effectiveness in the context of germline gene editing).
121 Collins & Gottlieb, supra note 114, at 1393–95; Information About SelfAdministration of Gene Therapy, U.S. FOOD & DRUG ADMIN. (Nov. 21, 2017),
https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/
information-about-self-administration-gene-therapy; Application of Current Statutory
Authorities to Human Somatic Cell Therapy Products and Gene Therapy Products, 58
Fed. Reg. 53248, 53251 (U.S. Food & Drug Admin. Oct. 14, 1993), https://www.fda.gov/
downloads/BiologicsBloodVaccines/SafetyAvailability/UCM148113.pdf (defining gene
therapy).
122 See generally Myrisha S. Lewis, Halted Innovation: The Expansion of Federal
Jurisdiction over Medicine and the Human Body, 2018 UTAH L. REV. 1073 (2018)
[hereinafter Lewis, Halted Innovation]; Lewis, How Subterranean, supra note 8.
123 Id. For more on the difficulty of applying the FDA’s statutory requirements to
controversial procedures related to reproduction, see Richard A. Merrill & Bryan J. Rose,
FDA Regulation of Human Cloning: Usurpation or Statesmanship?, 15 HARV. J.L. & TECH. 85,
123–24 (2001); Gail H. Javitt & Kathy Hudson, Regulating (for the Benefit of) Future
Persons: A Different Perspective on the FDA’s Jurisdiction to Regulate Human Reproductive
Cloning, 2003 UTAH L. REV. 1201, 1227–28 (2003); Lewis, How Subterranean, supra
note 8, at 1264.
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including cytoplasmic transfer, mitochondrial transfer, and more
recently, germline gene editing.124 These jurisdictional assertions have
come in the form of letters sent by the FDA to physician-researchers
asserting that their work requires an IND application, despite the states
regulating the practice of medicine.125 FDA jurisdictional assertions
have also come in the form of agency declarations on its website, which
include not only cytoplasmic transfer and mitochondrial transfer, two
techniques that arguably do not involve heritable genetic modification,
but also germline genetic modification.126 These FDA actions have
deterred innovation even though the FDA regulates medical products
and not techniques or the practice of medicine.127
124 See, e.g., Lewis, How Subterranean, supra note 8, at 1243–47; infra notes 113, 119
(providing the FDA’s declarations of jurisdiction over gene therapy and germline gene
editing). The FDA has also asserted jurisdiction over cloning which is not a form of ART.
125 Lewis, How Subterranean, supra note 8, at 1250, 1254–56.
126 See Advisory on Legal Restrictions on the Use of Mitochondrial Replacement
Techniques to Introduce Donor Mitochondria into Reproductive Cells Intended for Transfer
into a Human Recipient, U.S. FOOD & DRUG ADMIN. (Mar. 16, 2018) https://www.fda.gov/
vaccines-blood-biologics/cellular-gene-therapy-products/advisory-legal-restrictionsuse-mitochondrial-replacement-techniques-introduce-donor-mitochondria; FDA
Regulation of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P’s)
Product List, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/vaccines-blood-biologics/
tissue-tissue-products/fda-regulation-human-cells-tissues-and-cellular-and-tissuebased-products-hctps-product-list (last updated Feb. 1, 2018).. For more on the dispute
over the definition of germline, see NAT’L ACADS. SCI., ENG’G & MED., MITOCHONDRIAL
REPLACEMENT TECHNIQUES: ETHICAL, SOCIAL, AND POLICY CONSIDERATIONS 88–89 (2016);
Radhika Viswanathan, 3 Biological Parents, 1 Child, and an International Controversy, VOX
(July 28, 2018, 10:00 AM), https://www.vox.com/2018/7/24/17596354/
mitochondrial-replacement-therapy-three-parent-baby-controversy; NUFFIELD COUNCIL
ON BIOETHICS, NOVEL TECHNIQUES FOR THE PREVENTION OF MITOCHONDRIAL DNA DISORDERS: AN
ETHICAL REVIEW 58 (2012) (“In spite of the separability of alterations to nuclear and
mitochondrial genes which some commentators argue for, the Working Group will
however refer to the techniques of PNT and MST as ‘germline therapies’ because they
introduce a change that is incorporated into the (mitochondrial) genes of the resulting
people, and so will be incorporated into the germline that they will go on to develop.
This terminology seems appropriate because before the cell reconstruction procedure
was performed and the relevant parts of the mother’s and donor’s egg or embryo
combined, the person that would have originally resulted from their mother’s egg or
embryo had it been left unchanged would have had a different genetic makeup (and
thus, a different germline). We refer to the techniques of PNT and MST as ‘germline
therapies’ while acknowledging that some changes to the mitochondrial genes have
germline effects that are different from the germline effects of changes to nuclear
genes.”); Mitochondrial Replacement Therapy, UNITED MITOCHONDRIAL DISEASE FOUND.,
https://www.umdf.org/mitochondrial-replacement-therapy/ (last visited Aug. 5,
2020) (“[Mitochondrial replacement therapy] is NOT genetic manipulation, but rather a
technological innovation and an expansion of in vitro fertilization, a clinically-approved
technique used for four decades.”).
127 See supra note 81 and accompanying text (discussing the practice-products
divide).
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3. Budget Riders
Since 2015, the Consolidated Appropriations Act has prohibited
the FDA from using any of its funds to consider IND applications that
involve human germline editing.128 Specifically, the budget rider refers
to a “heritable genetic modification,” a term that is not defined and has
resulted in some scholarly debate.129 This budget rider came after
decades of FDA regulatory actions, such as Untitled Letters, which
targeted researchers providing techniques involving genetic
modification but fell short of direct enforcement action.130 While some
members of Congress have expressed disagreement with the budget
rider, Congress has renewed the budget rider every year since 2015.
That renewal has been accompanied by laudatory statements related to
its preservation of “the sanctity of life.”131 These life-based arguments

128 See Katherine Drabiak, Emerging Governance of Mitochondrial Replacement
Therapy: Assessing Coherence Between Scientific Evidence and Policy Outcomes, 20
DEPAUL J. HEALTH CARE L. 1, 27 (2018) (citing NAT’L ACADS. SCI., ENG’G & MED., MITOCHONDRIAL
REPLACEMENT TECHNIQUES: ETHICAL, SOCIAL, AND POLICY CONSIDERATIONS 2 (2016)) (observing
that “the [NAS] report recently questioned whether [mitochondrial replacement
therapy] constitutes heritable germline modification, asserting it would require
additional legal analysis which makes the application of the spending prohibition
uncertain”); Russell Spivak et al., Germ-line Gene Editing and Congressional Reaction in
Context: Learning from Almost 50 Years of Congressional Reactions to Biomedical
Breakthroughs, 30 J.L. & HEALTH 20, 22–23 (2017).
129 NAT’L ACADS. SCIS., ENG’G & MED., HUMAN GENOME EDITING: SCI., ETHICS, AND GOVERNANCE,
supra note 50, at 191 (citing Consolidated Appropriations Act of 2016, H.R. 2029, 114th
Cong., 1st Sess. (2015), https://www.congress.gov/114/bills/hr2029/BILLS-114hr20
29enr.pdf) (last visited January 4, 2017). For more on the potential applicability (or
inapplicability) of the budget rider to techniques such as mitochondrial transfer, see
Glenn Cohen, Circumvention Medical Tourism and Cutting Edge Medicine: The Case of
Mitochondrial Replacement Therapy, 25 IND. J. GLOBAL LEGAL STUD. 439, 442 (2018);
Katherine Drabiak, Emerging Governance of Mitochondrial Replacement Therapy:
Assessing Coherence Between Scientific Evidence and Policy Outcomes, 20 DEPAUL J.
HEALTH CARE L. 1, 27 (2018) (citing to NAT’L ACADS. OF SCIS., ENG’G & MED, MITOCHONDRIAL
REPLACEMENT TECHNIQUES: ETHICAL, SOCIAL, AND POLICY CONSIDERATIONS 2 (2016)); Joshua D.
Seitz, Striking A Balance: Policy Considerations for Human Germline Modification, 16
SANTA CLARA J. INT’L L. 60, 95 (2018).
130 See Lewis, How Subterranean, supra note 8 and accompanying text; see also supra
notes 126–27 (noting the debate over the germline and what is “heritable” genetic
modification).
131 Eli Adashi & I. Glenn Cohen, Heritable Genome Editing: Edited Eggs and Sperm to
the Rescue?, JAMA F. (Oct. 3, 2019) (providing the following comments of two members
of Congress on the “Consolidated Appropriation Act of 2016, the moratorium prohibits
the US Food and Drug Administration from addressing research ‘in which a human
embryo is intentionally created or modified to include heritable genetic modification.’
Expounding on the bill in question, Rep Harold D. Rogers (R, Kentucky) noted that it
‘preserves the sanctity of life,’ adding ‘new provisions prohibiting genetic editing of
human embryos.’ Rep Robert B. Aderholt (R, Alabama) said the “prohibition on gene
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connect to bioethical concerns regarding the proper role of humans on
earth and to previous debates on the morality and legality of abortion
discussed in Part III.132 Ultimately, due to the budget rider, private,
domestic clinical trials would still be restricted because, according to
the FDA, FDA acceptance of a new drug or biologic application would be
required for systemic trials related to these techniques according to the
FDA.133
At the same time, federal bans do not prohibit innovation, but they
can reduce access to innovation domestically and/or drive it abroad.
For example, New York-based physicians who work on mitochondrial
transfer in the U.S. have traveled to Mexico to provide techniques to
U.S.- based patients (with the aim of leading to a human birth) in
contravention of federal law, which prohibits the use of the technique in
the U.S. without an IND application.134 Similarly, a researcher working
on mitochondrial transfer, a technique involving inheritable genetic
modification, entered into a partnership to conduct research in Korea
instead of in the United States, where federal funding is limited due to
restrictions.135 In the context of germline gene editing, some have
expressed concern that such a moratorium could eventually lead to
“genome editing tourism” where scientists move to countries with lax
rules on germline gene editing to continue researching and ultimately
providing the technique to patients.136 Such tourism would mean that
editing of human embryos . . . is a tremendous victory for those who are concerned about
life.”).
132 Id. (“Given that the prospect of editing of the human embryo genome is caught up
in the debate over abortion, proponents of gene editing will be hard-pressed to secure
the broad political support required for its actualization.”).
133 See, e.g., U.S. FOOD & DRUG ADMIN., GUIDANCE FOR CLINICAL INVESTIGATORS, SPONSORS, AND
IRBS: INVESTIGATIONAL NEW DRUG APPLICATIONS (INDS)—DETERMINING WHETHER HUMAN
RESEARCH STUDIES CAN BE CONDUCTED WITHOUT AN IND 5–7 (Sept. 2013),
https://www.fda.gov/downloads/drugs/guidances/ucm229175.pdf.
134 See Michelle Roberts, First ‘Three Person Baby’ Born Using New Method, BBC NEWS
(Sept. 27, 2016) https://www.bbc.com/news/health-37485263; see also John Zhang et
al., Live Birth Derived From Oocyte Spindle Transfer to Prevent Mitochondrial Disease, 34
REPROD. BIOMEDICINE ONLINE 36, 361–68 (2017).
135 David Cyranoski & Boer Deng, Stem-Cell Star Lands in Same Venture as Disgraced
Cloner, NATURE (Feb. 11, 2015), https://www.nature.com/news/stem-cell-star-landsin-same-venture-as-disgraced-cloner-1.16907. Some states, like California, have
created regimes that provide funding for activities like stem cell research that have faced
political opposition at the federal level in the United States. See June Carbone, Negating
the Genetic Tie: Does the Law Encourage Unnecessary Risks?, 79 UMKC L. REV. 333, 360
(2010).
136 See Bosley et al., supra note 41, at 483 (statement of Anthony Perry, Department
of Biology and Biochemistry at the University of Bath); see also Letter to Honorable Alex
Azar II, Secretary of the U.S. Dept. of Health and Human Services (Apr. 24, 2019)
https://www.asgct.org/global/documents/clinical-germline-gene-editing-letter.aspx.
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germline gene editing would be limited to patients who can afford to
travel abroad and require physicians and researchers to travel abroad
in order to conduct research and patient care.137 Potential genome
editing tourism also leads to a concern that those providing these
techniques to patients may be unscrupulous researchers who may not
properly inform patients or work in furtherance of patient health.138
III. SOCIAL, POLITICAL, AND ETHICAL DEBATES THAT CAN INFLUENCE
REGULATION
Germline gene editing not only raises previous bioethical debates
related to ART but also generates new debates related to the regulation
of new medical products and technologies.139 It is important to address
the bioethical debates that arise due to germline gene editing and also
make clear which of the ethical concerns that accompany gene editing
also stem from reproduction or assisted reproduction in general.
Gene editing technologies (both somatic and reproductive) have
led to much scientific, legal, and ethical discussion.140 Both scientists
and regulators are concerned about the safety and effectiveness of gene
editing technologies.141 Due to inheritable changes and lack of longterm research, regulators, scientists, and ethicists generally treat
germline gene editing as legally, ethically, and scientifically distinct from
gene therapy and traditional ART.142
137 NAT’L ACADS. SCIS., ENG’G & MED., HUMAN GENOME EDITING: SCI., ETHICS, AND GOVERNANCE,
supra note 50, at 190 (referring to “regulatory havens” with “lenient or nonexisting
regulations”).
138 See Francis S. Collins, Statement on Claim of First Gene-Edited Babies by Chinese
Researcher (Nov. 28, 2018), https://www.nih.gov/about-nih/who-we-are/nihdirector/statements/statement-claim-first-gene-edited-babies-chinese-researcher
(statement by Francis S. Collins, National Institutes of Health Director).
139 See also NUFFIELD COUNCIL ON BIOETHICS, GENOME EDITING AND HUMAN REPRODUCTION:
SOCIAL AND ETHICAL ISSUES, supra note 26, at 2–3 (discussing the role of language in
discussions of genome editing and the meanings and use of the concepts of “moral”
“ethical” and “activity [of] bioethics”).
140 See, e.g., Paradise, supra note 110, at 11.
141 See discussion infra Parts III and IV (discussing safety and effectiveness concerns
in FDA regulation); see also Yanting Zeng et al., Correction of the Marfan Syndrome
Pathogenic FBN1 Mutation by Base Editing in Human Cells and Heterozygous Embryos, 26
MOLECULAR THERAPY 2631, 2635 (2018), https://www.cell.com/molecular-therapyfamily/molecular-therapy/fulltext/S1525-0016%2818%2930378-2#%20 (referring
to “safety and efficiency” of gene editing and stating “[b]esides efficiency, a successful
gene therapy needs perfect precision and specificity.”).
142 See Kane, supra note 38, at 302–03. But see Julia D. Mahoney & Gil Siegal, Beyond
Nature? Genomic Modification and the Future of Humanity, 81 LAW & CONTEMP. PROBS. 195,
212 (2018) (arguing that “drawing a [regulatory] bright line between somatic and
heritable genome editing is not persuasive on either moral or practical grounds”).
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There are many bases for these anti-genetic modification views,
including science-fiction movies and classic literature that highlight the
perils of human hubris, and the general thought that such a change is
simply “not something we should do.”143 Evidence of these anti-genetic
modification perspectives appears not only in statements of certain
members of the public but also in many politicians’ statements,
including members of both the Democratic and Republican parties.144
These anti-genetic modification perspectives also motivate federal
regulation.145 There are three significant categories of opposition to
genome editing: safety concerns, efficacy concerns, and morality
concerns. Nonetheless, many discussions of gene editing, especially
germline gene editing, group all of these concerns together and refer to
them collectively.146 Addressing these concerns together often leads to
a blending of the standard in FDA product approval for “safety and
effectiveness,” with concerns related to political, social, and moral
issues.147
Yet when some commentators discuss “safety and
143 See, e.g., Steven Pinker, The Moral Imperative for Bioethics, BOSTON GLOBE (Aug. 1,
2015), https://www.bostonglobe.com/opinion/2015/07/31/the-moral-imperativefor-bioethics/JmEkoyzlTAu9oQV76JrK9N/story.html; see also Bosley et al., supra
note 41, at 481.
144 See, e.g., John P. Holdren, A Note on Genome Editing, OBAMA WHITE HOUSE ARCHIVE:
WHITE HOUSE BLOG (May 26, 2015, 10:40 AM), https://obamawhitehouse.archives.gov/
blog/2015/05/26/note-genome-editing; Sarah Karlin, Gene Editing: The Next Frontier
in America’s Abortion Wars, POLITICO (Feb. 16, 2016), https://www.politico.com/story/
2016/02/gene-editing-abortion-wars-219230.
145 See Lewis, How Subterranean, supra note 8; Lewis, The American Democratic
Deficit, supra note 8; Javitt & Hudson, supra note 123, at 1216–17; see also NIH Guidelines
for Research Involving Recombinant or Synthetic Nucleic Acid Molecules, NAT’L INSTS. OF
HEALTH (Apr. 2016), https://osp.od.nih.gov/biotechnology/nih-guidelines; Francis S.
Collins, Statement on NIH Funding of Research Using Gene-Editing Technologies in Human
Embryos, NAT’L INSTS. OF HEALTH (Apr. 28, 2015), https://www.nih.gov/about-nih/whowe-are/nih-director/statements/statement-nih-funding-research-using-gene-editingtechnologies-human-embryos; Carrie D. Wolinetz & Francis S. Collins, NIH Supports Call
for Moratorium on Clinical Uses of Germline Gene Editing, NATURE (Mar. 13, 2019),
https://www.nature.com/articles/d41586-019-00814-6.
146 See, e.g., The Science and Ethics of Genetically Engineered Human DNA, supra
note 22, at 20 (statement of Dr. Jennifer Doudna); Joseph Morton, Fortenberry Shares
Story of Daughter’s Heart Defects During Talks of Human Gene Editing Research, OMAHA
WORLD-HERALD (Jun. 5, 2019), https://www.omaha.com/livewellnebraska/health/
fortenberry-shares-story-of-daughter-s-heart-defects-during-talks/article_412afcacfeaa-597a-a00c-8cdbd58ce65d.html (Congressman Fortenberry “reiterated that
science has to be tied to ethical considerations and that lifting the prohibitions [on
germline gene editing] would send a signal to maverick researchers that the restraints
are off, a move that would endanger everyone”). See comments of Congressmembers
discussed supra note 131 and infra notes 236–37.
147 See, e.g., 21 U.S.C. § 355(a); 21 U.S.C. § 393(b)(2)(B); Jeffrey M. Drazen et al., The
FDA, Politics, and Plan B, 350 NEW. ENG. J. MED. 1561, 1561–62 (2004); Lisa Heinzerling,
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effectiveness,” they are actually incorporating political and social
concerns instead of keeping them separate.148 As will be discussed infra,
if a product is deemed “safe and effective,” this does not mean that the
product or technology is completely “safe,” but rather, that its benefits
and risks have been identified, and the risks merit the potential
reward.149
In prior works, I have argued that the FDA’s jurisdiction over
techniques involving reproduction and genetic modification is
misplaced. In those prior works, I have emphasized that political and
social views influence the FDA’s already problematic decision-making
process, already noted for its obscurity, especially as it relates to
techniques that combine ART with genetic modification.150 Further, a
number of recent events, as chronicled in the medical and legal
literatures, have emphasized the impacts of politics on scientific
decision-making.151 This Article separates those safety, efficacy, and
morality concerns. This Part, combined with Part IV, aims to show that
The FDA’s Plan B Fiasco: Lessons for Administrative Law, 102 GEO. L.J. 927, 939–48
(2014); Alastair J.J. Wood et al., A Sad Day for Science at the FDA, 353 NEW. ENG. J. MED.
1197, 1197–98 (2005). The term “safety and efficacy” also arises in other countries’
analysis of the appropriateness of gene editing. See, e.g., GERMAN ETHICS COUNCIL, supra
note 45, at 57 (“In principle, the less obvious any medical need is, the stricter the safety
and efficacy requirements and, by extension, the innocuousness requirements for
germline interventions will have to be.”).
148 See Kathryn A. Watts, Controlling Presidential Control, 114 MICH. L. REV. 683, 709
(2016) (providing the statement of FDA Commissioner Hamburg: “It is our
responsibility at FDA to approve drugs that are safe and effective for their intended use
based on the scientific evidence”). Outside of the reproductive context, there is
increasing concern about the impacts of politics on the decisions of public health
agencies. For examples of this, see the following: Helen Branswell, As Controversies
Swirl, CDC Director Is Seen as Allowing Agency to Buckle to Political Influence, STAT NEWS
(Sept. 16, 2020), https://www.statnews.com/2020/09/16/as-controversies-swirl-cdcdirector-is-seen-as-allowing-agency-to-buckle-to-political-influence; Nick Valencia &
Kristen Holmes, Trump’s HHS Alters CDC Documents for Political Reasons, Official Says,
CNN (Sept. 12, 2020, 8:06 PM), https://www.cnn.com/2020/09/12/politics/cdctrump-science-reports/index.html.
149 See 21 U.S.C. § 355(a); NUFFIELD COUNCIL ON BIOETHICS, GENOME EDITING AND HUMAN
REPRODUCTION: SOCIAL AND ETHICAL ISSUES, supra note 26, at 139; Baltimore et al., supra note
43, at 37 (“As with any therapeutic strategy, higher risks can be tolerated when the
reward of success is high, but such risks also demand higher confidence in their likely
efficacy. And, for countries whose regulatory agencies focus on safety and efficacy but
not on broader social and ethical concerns, another venue is needed to facilitate public
conversation.”); Barbara J. Evans, Seven Pillars of a New Evidentiary Paradigm: The Food,
Drug, and Cosmetic Act Enters the Genomic Era, 85 NOTRE DAME L. REV. 419, 457–58, 502
(2010).
150 See, e.g., Lewis, The American Democratic Deficit, supra note 8, at 149–56, 166–69.
151 Id. at 144, 149; see also Drazen et al., supra note 147, at 1561–62; Wood et al.,
supra note 147, at 1197–98; Heinzerling, supra note 147, at 930–58.
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many of the bioethical and safety concerns that accompany germline
gene editing are the same or similar to the concerns that accompany
reproduction, drugs, and biologics, including gene therapy.152 As such,
the regulatory regime does not need to respond to germline gene editing
as if it were an exceptional technology requiring substantially different
regulation than traditional ART or products the FDA regulates. This
Article dispels those “morality concerns” and explains why they should
not lead to gene editing’s treatment as an exceptional medical product,
especially if the safety of germline gene editing merits its use.153
This Article presents a comprehensive, balanced view of the
bioethical debates surrounding germline gene editing. There are many
sources of bioethical opposition to assisted reproduction (including
IVF) and germline gene editing. This Part of the Article is both
descriptive and normative. This Part of the Article identifies and
thematizes the commonly occurring ethical objections to germline gene
editing. There are at least ten commonly occurring objections to
germline gene editing. Many of those reasons are common to ART,
including IVF, a technique that is widely available (and legal) in the
United States. These “ethical” reasons are also referred to as “societal”
or “moral” concerns. This Part of the Article groups those commonly
occurring ethical concerns and notes the interrelated nature of many of
those concerns. This Article groups those commonly occurring
bioethical debates that can influence regulation. This Part shows how
the ethical concerns of ART are similar to the ethical concerns that
accompany germline gene editing; these ethical concerns have not
prohibited the legality of traditional ART. This Part also presents the
germline gene editing-specific concerns before arguing that those
concerns should not prohibit the legality of germline gene editing. After
laying this foundation, Part IV focuses on the safety concerns common

152 See What is Gene Therapy?, U.S. FOOD AND DRUG ADMIN. (July 25, 2018),
https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/whatgene-therapy (“Gene therapy products are biological products regulated by the FDA’s
Center for Biologics Evaluation and Research (CBER). Clinical studies in humans require
the submission of an investigational new drug application (IND) prior to initiating
clinical studies in the United States. Marketing a gene therapy product requires
submission and approval of a biologics license application (BLA).”).
153 As discussed infra notes 319–21, even FDA approval does not guarantee that a
technique or a product is “safe” as all medical procedures and products are accompanied
by risk. Some commentators, such as Marcy Darnovsky, would still aim to prohibit
germline gene editing even if it were characterized as “safe.” See, e.g., Rob Stein,
Breaking Taboo, Swedish Scientist Seeks to Edit DNA of Healthy Human Embryos, NPR
(Sept. 22, 2016), https://www.gmwatch.org/en/news/archive/2016/17227-breakingtaboo-swedish-scientist-seeks-to-edit-dna-of-healthy-human-embryos.
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to germline gene editing and somatic gene editing and how common
these concerns are to both, then argues that even the germline gene
editing-specific concerns should not be construed to support federal
regulation of the technique.
A. Concerns Related to Autonomy: The Consent of Future Persons
and Parental Autonomy
Concerns related to autonomy tend to fall within two larger
threads: those related to the autonomy of future generations and those
related to the autonomy of parents over their future children. With ART,
those concerns tend to focus on both the concerns of the children who
would be conceived using ART and their inability to consent to their
parents’ actions, and the concerns of the parents who generally have
broad abilities to make decisions for their future children. These
concerns are exacerbated by germline gene editing, which implicates
not only future children but also the children who would come after
those children because the changes would affect future generations.
These intergenerational concerns will be discussed in this Section and
Section D.
1. Consent for Future Persons and Parental Autonomy
One objection to both germline gene editing and ART is the impact
on future generations without their consent.154 Concerns for future
persons not only include their lack of consent but also what impacts
their parents’ decision-making might have on them. For example, if
parents can select future traits, then children who were selected for
those purposes, such as enhanced intelligence or height, may feel
pressure to “live up to” those genetic traits.155 While consent-based
discussions tend to focus on the child who would be immediately
produced as a result of germline modification, extending the argument
about the “shared human identity” reveals that there is also a concern
for subsequent generations who would be produced by someone who
had undergone genetic modification.156

154

Polcz & Lewis, supra note 42, at 415.
Suter, supra note 13, at 963, 968.
156 See The Science and Ethics of Genetically Engineered Human DNA, supra note 22, at
44. For more on the bioethical concept of the “shared human identity,” see infra Section
III.D.3.
155
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On the other hand, others would argue that germline gene editing
and genetic modification are part of a larger trajectory that focuses on
both scientific discovery and parental autonomy. This idea of parental
autonomy is often invoked to counter the argument that germline gene
editing could “interfere with a child’s ‘right to an open future’” as many
parental choices do.157 While parental decision-making does face
limitations such as those that aim to protect children from child abuse
and neglect, parents have significant autonomy in the rearing of their
children and reproductive decision-making.158 For example, as Julian
Savulescu has noted, parents have tried for centuries to improve the
health and intellect of their children.159 Professor Savulescu has gone as
far as to say that parents have a duty to improve the intellect and
physical health of their children.160
This argument has been
summarized as “do good, whenever possible.”161
Parents are already able to select desirable embryos through
various non-gene modifying forms of ART techniques that permit
parents to select embryos with genetically desirable traits or even
preferred genders, which often leads to scholarly and public critique of
whether parents should undertake such actions.162 Procreative
autonomy is often discussed in the context of parental decision-making,
including prenatal testing and other decisions that enable parents to

157 R. Alta Charo, Who’s Afraid of the Big Bad (Germline Editing) Wolf?, 63 PERSPS. IN
BIOLOGY & MED. 93, 95 (2020) (citing J. FEINBERG, FREEDOM AND FULFILLMENT (1992)).
158 See generally Prince v. Massachusetts, 321 U.S. 158, 165 (1944); Troxel v.
Granville, 530 U.S. 57, 65 (2000); Doriane L. Coleman, Kenneth A. Dodge & Sarah K.
Campbell, Where and How to Draw the Line Between Reasonable Corporal Punishment
and Abuse, 73 L. & CONTEMP. PROBS. 107, 107–08 (2010); Rebecca Vermette, A Case for an
Exception in the Domain of Parental Autonomy with Testing for Huntington Disease, 18
MICH. ST. J. MED. & L. 29, 31 (2014); Cara D. Watts, Asking Adolescents: Does a Mature
Minor Have a Right to Participate in Health Care Decisions, 16 HASTINGS WOMEN’S L.J. 221,
224 (2005).
159 See Julian Savulescu, Genetic Interventions and the Ethics of Enhancement of
Human Beings, 32 GAZETA DE ANTROPOLOGIA, Nov. 2016, http://www.gazetaantropologia.es/wp-content/uploads/GA-32-2-07-Julian-Savulescu.pdf.
160 See Julian Savulescu, Procreative Beneficence: Why We Should Select the Best
Children, 15 BIOETHICS 413, 413–16 (2001).
161 ETHICS COMM. OF THE AM. SOC’Y FOR REPROD. MED., Transferring Embryos with Genetic
Anomalies Detected in Preimplantation Testing: An Ethics Committee Opinion, 107
FERTILITY & STERILITY 1130, 1134 (2017) (noting that “good” is determined through the
eyes of the parents who would be exercising procreative beneficence).
162 Julia D. Mahoney & Gil Siegal, Beyond Nature? Genomic Modification and the Future
of Humanity, 81 LAW & CONTEMP. PROBS. 195, 205 (2018) (discussing “the present
generation’s use of PGD and selective termination”).
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decide which children they would like to have.163 Prenatal testing,
similarly to germline gene editing, leads to concerns that parents may
feel that they should obtain prenatal testing or terminate their
pregnancies due to the existence of detected abnormalities that cannot
be resolved with in utero treatment.164 The scope of procreative
autonomy, however, remains undefined.165
At the same time, some scholars note that an underemphasized
aspect of embryo selection through PGD and selective termination of
undesirable fetuses after prenatal testing is that doing so “affects the
genetic profiles of future generations[, thus, while] one argument
against human germline editing is that it may lead to the modification of
genes that confer benefits as well as cause harm[,] . . . it is . . . a risk that
we are already running.”166
The continued legality of traditional ART in many ways responds
to the issue of parental decision-making (albeit without the genetic
component in most instances) by deferring to parental autonomy.167
Generally, parents make decisions for their children, and parental
decision-making falls within the constitutional right to parental
autonomy.168 Parents even make decisions for fetuses when they
decide, for example, to use pre-birth interventions such as fetal

163 See, e.g., Suter, supra note 13, at 924 n. 154; see also NAT’L ACADS. SCI., HERITABLE
HUMAN GENOME EDITING, supra note 52, at 42–52.
164 Id. at 927–28; Samuel R. Bagenstos, Disability, Life, Death, and Choice, 29 HARV. J.L.
& GENDER 425, 438–39 (2006).
165 John A. Robertson, Embryos, Families, and Procreative Liberty: The Legal Structure
of the New Reproduction, 59 S. CAL. L. REV. 939, 955 (1986) (discussing procreative
liberty).
166 Julia D. Mahoney and Gil Siegal, Beyond Nature? Genomic Modification and the
Future of Humanity, 81 LAW & CONTEMP. PROBS. 195, 205 (2018) (citations omitted). For
more on PGD and prenatal testing, see NAT’L ACADS. SCIS., ENG’G & MED., HUMAN GENOME
EDITING: SCI., ETHICS, AND GOVERNANCE, supra note 50, at 113.
167 Traditional ART does not involve genetic modification; however, two techniques
of ART do involve genetic modification, cytoplasmic transfer and mitochondrial transfer.
For more on cytoplasmic transfer and mitochondrial transfer (and the regulatory
system’s response to the techniques), see infra Section II.B.2.
168 For more on parental autonomy, see Elaine M. Chiu, The Culture Differential in
Parental Autonomy, 41 U.C. DAVIS L. REV. 1773, 1792 (2008); E. Gary Spitko, Reclaiming
the “Creatures of the State”: Contracting for Child Custody Decisionmaking in the Best
Interests of the Family, 57 WASH. & LEE L. REV. 1139, 1181–89 (2000); see also Bosley et
al., supra note 41, at 478, 482 (providing the statement of Robin Lovell-Badge at The
Francis Crick Institute: “[P]arents are always seeking ways to give their children an
advantage in life, and we do not consider this unethical. Sending a kid to a good school,
for example, can have a transgenerational effect. However, a germline genetic change
may be passed down without subsequent generations having a choice (except the same
technology could be used to reverse the enhancement).”).
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surgeries to improve their future children’s health.169 While physicians
perform surgical techniques on existing individuals who can consent to
the procedures; traditional ART, in utero treatments, and treatments of
children all involve the inability of children to consent.
Parents can influence their children’s genetic makeup in many
ways other than by using germline gene editing, such as through natural
reproduction, selection of sperm and egg donors, and genetic
screening.170
Critics of assisted reproduction, like Leon Kass,
characterize natural reproduction as “a combination of nature and
chance, not human design”; however, that characterization lacks some
nuance.171 In natural reproduction, trait selection tends to be
uncriticized, unmentioned, and unregulated: the idea that parents
choose mates based on the traits that they would like to pass on to their
children has not led society (and the law) to try to regulate these
reproductive matters.172 Similarly, parents’ “selective breeding” in
which parents decide with whom they would like to reproduce has
generally not been the focus of ethical opposition in the realm of
reproduction.173 Thus, there is no regime to prevent people from
reproducing on the basis that doing so would pass on “undesirable” or
“desirable” traits to offspring.174
169 See, e.g., Ahmet Baschat, Preventing and Treating Birth Defects: What You Need to
Know, JOHNS HOPKINS MED., https://www.hopkinsmedicine.org/health/treatment-testsand-therapies/preventing-and-treating-birth-defects-what-you-need-to-know (last
visited Nov. 5, 2019). For more on fetal surgery in the context of germline gene editing,
see NAT’L ACADS. SCIS., ENG’G & MED., HUMAN GENOME EDITING: SCI., ETHICS, AND GOVERNANCE,
supra note 50, at 107–09.
170 I. Glenn Cohen, What (If Anything) Is Wrong with Enhancement? What (If
Anything) Is Right with It?, 49 TULSA L. REV. 645, 648, 682 (2014); Rakowski, supra
note 11, at 1367.
171 Leon R. Kass, The Wisdom of Repugnance, NEW REPUBLIC, June 2, 1997, at 21.
172 See, e.g., Rakowski, supra note 11, at 1345. But see JUDITH AREEN ET AL., FAMILY LAW:
CASES AND MATERIALS 71–72 (6th ed. 2012) (discussing prohibitions on incest).
173 See, e.g., The Science and Ethics of Genetically Engineered Human DNA, supra
note 22, at 6 (providing the statement of Subcommittee Chairwoman Barbara Comstock
that “humans have been altering the genomes of species through selective breeding for
thousands of years”); Julian Savulescu, New Breeds of Humans: The Moral Obligation to
Enhance, 10 REPROD. BIOMED. ONLINE 36, 36 (2005) (“Selective mating has been occurring
in humans ever since time began.”); see also John A. Robertson, Procreative Liberty in the
Era of Genomics, 29 AM. J.L. & MED. 439, 450–52 (2003); Savulescu, supra note 160, at
418 (defining “procreative autonomy”).
174 Rima Kundnani, Protecting the Right to Procreate for Mentally Ill Women, 23 S. CAL.
REV. L. & SOC. JUST. 59, 67–70 (2013). But see AREEN ET AL., supra note 172, at 71–72
(discussing prohibitions on incest); Mindy K. Fersel, Liberty and Justice for All?
Protecting the Right to Privacy for Incapacitated Individuals: The Need for Comprehensive
Sterilization Legislation in All Fifty States, 20 CARDOZO J.L. & GENDER 827, 828–30, 839–49
(2014); Greely, supra note 54, at 161 (noting that “the Common Rule has special
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B. Concerns Related to Disability Rights and Eugenics
Disability-related and eugenics concerns accompany techniques
involving ART and germline gene editing. At the outset, it is important
to note that “[t]he disability rights community is not monolithic, and its
attitudes toward genetic technologies such as prenatal screening can
vary from supportive to skeptical.”175 As will be discussed infra, many
individuals are concerned about the implications of techniques that
deem certain traits desirable or undesirable. For some, those concerns
are rooted in the particularly negative connotation of the word
“eugenics,” which is associated with discriminatory practices, including
genocide, forced sterilization, institutionalization, and antimiscegenation laws in the United States, Germany, and the United
Kingdom.176 Proponents of these discriminatory practices aimed to rid
society of certain races or traits that more powerful groups deemed
“undesirable”; these practices existed before the advent of ART.
Parents often combine ART with PGD which allows them to choose
“suitable” embryos for implantation and to discard unsuitable embryos.
Like germline gene editing, PGD has been criticized for the possibility
that it could “exacerbate a social environment that is hostile to people
with disabilities more generally.”177 Further, fetal diagnostic techniques
allow parents to terminate pregnancies when testing reveals that the
fetuses have diseases that the parents do not want their future children
to have.178 At the same time, supporters of germline gene editing note

requirements for” research involving children, fetuses, and embryos intended for
implantation); Corey G. Johnson, Female Inmates Sterilized in California Prisons Without
Approval, NBC BAY AREA (July 8, 2013, 11:27 AM), https://www.nbcbayarea.com/news/
california/Female-Inmates-Sterilized-in-California-Prisons-Without-Approval-21463
4341.html; Kalhan Rosenblatt, Judge Offers Inmates Reduced Sentences in Exchange for
Vasectomy, NBC NEWS (July 21, 2017), https://www.nbcnews.com/news/us-news/
judge-offers-inmates-reduced-sentences-exchange-vasectomy-n785256.
175 NAT’L ACADS. SCIS., ENG’G & MED., HUMAN GENOME EDITING: SCI., ETHICS, AND GOVERNANCE,
supra note 50, at 126 (citations omitted).
176 Id. at 153–56; NUFFIELD COUNCIL ON BIOETHICS, GENOME EDITING AND HUMAN
REPRODUCTION: SOCIAL AND ETHICAL ISSUES, supra note 26, at 79–80, 118; Paul A. Lombardo,
Taking Eugenics Seriously: Three Generations of ??? Are Enough?, 30 FLA. ST. U. L. REV. 191,
215–16 (2003); Paul A. Lombardo, Medicine, Eugenics, and the Supreme Court: From
Coercive Sterilization to Reproductive Freedom, 13 J. CONTEMP. HEALTH L. & POL’Y 1, 6
(1996).
177 NUFFIELD COUNCIL ON BIOETHICS, GENOME EDITING AND HUMAN REPRODUCTION: SOCIAL AND
ETHICAL ISSUES, supra note 26, at 82.
178 NAT’L ACADS. SCIS., ENG’G & MED., HUMAN GENOME EDITING: SCI., ETHICS, AND GOVERNANCE,
supra note 50, at 6; NUFFIELD COUNCIL ON BIOETHICS, GENOME EDITING AND HUMAN
REPRODUCTION: SOCIAL AND ETHICAL ISSUES, supra note 26, at xv.
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that “few would lament the elimination of many inherited disease
characteristics” which often result in suffering.179
Germline gene editing combines these eugenics and disabilityrelated concerns with concerns for the ability to prevent certain traits
not only in a parent’s child but also in future generations.180 The
significant impact on future generations raises concerns about the
direction of the human race and what that might mean for future
generations or a future society. Concerns such as these have existed for
decades, even before the advent of germline gene editing.
1. Disability-Related Concerns
There is some debate over what traits are deemed “undesirable”
and should be targeted for treatment using genetic technologies. This
concern regarding the desirability of traits implicates eugenics and
disability concerns.181 In the disability context, for example, scholars
have noted that many people in the deaf community have not chosen
cochlear implants for their children or themselves for various reasons,
including the desire to have a child who has the same condition as the
parent and the view that deafness is not a disability that needs to be
corrected.182 The same dispute exists among those in various disability
communities and the public for other traits, such as dwarfism.183
179

Id. at 82.
See, e.g., Roberto Andorno et al., Geneva Statement on Heritable Human Genome
Editing: The Need for Course Correction, 38 TRENDS BIOTECH. 351, 351–54 (2020),
https://www-sciencedirect-com.proxy.wm.edu/science/article/pii/S016777991930
3178; Françoise Baylis, Counterpoint: The Potential Harms of Human Gene Editing Using
CRISPR-Cas9, 64 CLINICAL CHEMISTRY 489, 489–91 (2018).
181 Suter, supra note 13, at 955–58.
182 ETHICS COMM. OF THE AM. SOC’Y FOR REPROD. MED., Transferring Embryos with Genetic
Anomalies Detected in Preimplantation Testing: An Ethics Committee Opinion, 107
FERTILITY & STERILITY 1130, 1131 (2017) (noting that the phenomenon in which parents
wish to raise children who have the same genetic conditions as they do is “sometimes
referred to as ‘intentional diminishment’ and primarily involves selection for sensory or
mobility disorders such as deafness or achondroplasia (dwarfism)” (citation omitted));
Polcz & Lewis, supra note 42, at 420–21; see also Allegra Ringo, Understanding Deafness:
Not Everyone Wants To Be ‘Fixed’, ATLANTIC (Aug. 9, 2013), https://www.the
atlantic.com/health/archive/2013/08/understanding-deafness-not-everyone-wantsto-be-fixed/278527.
183 Bosley et al., supra note 41, at 482 (“[I]n some instance—[like] correction of
hearing deficits or enhancement of stature—patient groups have argued that the ‘defect’
is a perfectly acceptable form of human variation that should not be subjected to genetic
cleansing.”); Robertson, supra note 173, at 441, 460, 480. For both sides of the debate
of how dwarfism should be treated, see Damian Garde, A New Treatment Promises To
Make Little People Taller. Is It An Insult to ‘Dwarf Pride’?, STAT NEWS (Nov. 18, 2019),
https://www.statnews.com/2019/11/18/a-new-treatment-promises-to-make-littlepeople-taller-is-it-an-insult-to-dwarf-pride.
180
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Further, majoritarian views about what society deems disabilities, such
as dwarfism or deafness, may lead to a perspective that discourages
those with disabilities from choosing embryos that have traits similar to
themselves.184 Physicians who provide PGD tend to oppose the use of
PGD to affirmatively select embryos with those traits that society has
deemed as disabilities.185 Nevertheless, the regulatory regime has not
instituted additional limitations on these uses of PGD, even though
many people find some uses of PGD objectionable.
2. Eugenics Concerns
As a related matter, there is also a concern that gene editing could
create an “arms race” of sorts where “parents will feel obligated to
engage in pre-birth genetic engineering, because other parents are
doing so, just as SAT prep courses have become routine and some
athletes feel obligated to use steroids if other athletes are gaining an
advantage from them.”186 This concern already exists with other
technologies involving ART, such as PGD.187 For example, Professor
Leon Kass characterizes genetic screening and PGD as “negative eugenic
selection.”188 Enhancement has also been analogized to “positive
eugenics.”189
Applying eugenics concerns to germline gene editing, there is a
concern that those who are germline gene edited will be regarded as
“superior” to those who have not been changed with germline gene
editing before birth.190 Further, this concern about desirable traits may
184 See Darshak M. Sanghavi, Wanting Babies Like Themselves, Some Parents Choose
Genetic Defects, N.Y. TIMES (Dec. 5, 2006), https://www.nytimes.com/2006/12/05/
health/05essa.html (discussing the efforts of parents to use PGD and donor selection in
order to create children who have traits that are viewed as “disabilities” such as
deafness and reactions of physicians and others to parental efforts); see also Garde,
supra note 183.
185 Id.
186 Robertson, supra note 173, at 479; see also NUFFIELD COUNCIL ON BIOETHICS, GENOME
EDITING AND HUMAN REPRODUCTION: SOCIAL AND ETHICAL ISSUES, supra note 26, at 81; Michael
Sandel, The Case Against Perfection, ATLANTIC (Apr. 2004), https://www.the
atlantic.com/magazine/archive/2004/04/the-case-against-perfection/302927 (“The
real question is whether we want to live in a society where parents feel compelled to
spend a fortune to make perfectly healthy kids a few inches taller.”).
187 See King, supra note 70, at 312.
188 Leon R. Kass, The Wisdom of Repugnance, NEW REPUBLIC, June 2, 1997, at 24.
189 Id. at 25.
190 See Marcy Darnovsky & Katie Hasson, CRISPR’s Twisted Tales: Clarifying
Misconceptions about Heritable Genome Editing, 63 PERSPS. IN BIOLOGY & MED. 155, 163
(2020); Seema Mohapatra, Politically Correct Eugenics, 12 FL. INT’L UNIV. L. REV. 51, 69
(2016) (citing to Rob Stein, Breaking Taboo, Swedish Scientist Seeks to Edit DNA of
Healthy Human Embryos, NPR (Sept. 22, 2016, 5:07 AM), http://www.npr.org/sections/
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extend to a concern about whether certain races may be targeted for
exclusion within the germline gene editing context. While the term
“eugenics,” is often viewed as a loaded term with negative connotations
due to historical examples, Professor Sonia Suter has observed that “this
alone does not support the implication that eugenics is per se
problematic.”191 Nevertheless, in America, the eugenics movement was
implicated in the efforts of certain organizations to increase
contraceptive usage by certain races, notably African-Americans, under
the theory that “this population was unfit to have children.”192 These
same eugenics concerns from the contraceptive context also arise in the
context of germline gene editing, although it is expected that the
relevant actors will be private actors and not government actors.193
Germline gene editing technologies have led to a subset of eugenics
concerns, referred to as “neoeugenics” or “liberal eugenics.”194
Neoeugenics or liberal eugenics, unlike the eugenics of the past, which
focused on state action, would arise from private action.195 Neoeugenics
also encompasses a broader effort to select or design children.196
Because neoeugenics implicates private action instead of state action
and “fundamental decisions about parenting[,] . . . some aspects of it
arguably fall within a fundamental liberty or privacy interest.”197 At the
same time, because neoeugenics focuses on private actors, it leads to
concerns that those with more financial resources will have an
advantage over those with fewer resources.198 To the extent that ART
health-shots/2016/09/22/494591738/breaking-taboo-swedish-scientist-seeks-toedit-dna-of-healthy-human-embryos).
191 See Suter, supra note 13, at 899. For more on eugenics practices that led to a
negative connotation of the word, see id. at 901–02, 906–16.
192 See Mohapatra, supra note 190, at 55, 57 (discussing the sterilization of minority
women “without their knowledge or consent”).
193 Id. at 55 (“Americans were themselves interested in how to create a perfect child
that lacked heritable conditions such as feeblemindedness or alcoholism.” One could
expect that Americans would be interested in preventing the passage of certain heritable
conditions that would be viewed as disabilities by the majority but not necessarily as
such by those who are affected by those conditions, both directly or indirectly (such as
those who have family members with the condition).”); see also id. at 73–78 (discussing
“ableism” and neglected disability perspectives in medical discussions).
194 See Nicholas Agar et al., The Debate over Liberal Eugenics, 36 HASTINGS CTR. REP. 4,
4–7 (Mar.–Apr. 2006); Nicholas Agar, Liberal Eugenics, 12 PUB. AFF. Q. 137, 137 (1998);
Suter, supra note 13, at 898.
195 See Agar, Liberal Eugenics, supra note 194; Suter, supra note 13, at 900.
196 See, e.g., id. at 937.
197 Id. at 949; see also Michael Sandel, The Case Against Perfection, ATLANTIC (Apr.
2004), https://www.theatlantic.com/magazine/archive/2004/04/the-case-againstperfection/302927 (discussing “‘privatized’ or ‘free-market’ eugenics”).
198 Agar, Liberal Eugenics, supra note 194; Suter, supra note 13, at 959.
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users tend to be wealthier individuals, a group with fewer minorities in
the U.S., these eugenics concerns connect to concerns about access and
use of gene editing technologies similar to those related to ART.199
In addition to concerns about how views on superior or preferred
traits (or even races) might impact those who would be seen as
undesirable by the majority (or those who would regulate access to gene
editing technologies), there is also a concern that some individuals may
feel forced to use germline gene editing technologies.200 Under that
theory, parents who refused to use germline gene editing technologies
to correct genetic disadvantages might be denied access to societal aid
“because they could not fairly push the cost of their choices off on other
members of the insurance pool” or avail themselves of other common
societal measures, such as special education and some forms of public
assistance.201 This concern also connects to a broader concern about
access to healthcare and disparities in access to healthcare, as analyzed
through the lenses of race and economics.202
3. Disparities and Inequality
There are also concerns regarding economic disparities, as well as
physical, intellectual, and social disparities, which might arise or
broaden with the advent of gene editing technologies. The Nuffield
Council on Bioethics, for example, has recommended that heritable
genome editing only be used “in circumstances in which it cannot
reasonably be expected to produce or exacerbate social division or the
unmitigated marginalization or disadvantage of groups within
society.”203 While this is certainly a noble goal, it is hard to see how one
could orchestrate such a position. Thus, this concern about disparities
and inequality connects to concerns about disability and a hierarchy of
disease, which will be discussed infra. Concerns about economic
disparities are also connected to concerns about racial disparities and
eugenics. Additionally, somatic and germline gene editing technologies

199 See MARSH & RONNER, supra note 17, at 5 (discussing the racial shift in ART use);
Mohapatra, supra note 190, at 69–70.
200 See id. at 79.
201 Rakowski, supra note 11, at 1345, 1353, 1392, 1398.
202 Kimberly M. Mutcherson, Procreative Pluralism, 30 BERKELEY J. GENDER L. & JUST. 22,
43 (2015).
203 NUFFIELD COUNCIL ON BIOETHICS, GENOME EDITING AND HUMAN REPRODUCTION: SOCIAL AND
ETHICAL ISSUES, supra note 26, at 87.
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are similar to other forms of ART, health care policy, and law in general,
insofar as they are accompanied by access-related concerns.204
In addition to concerns about disparities, there are other broader
equality concerns. For example, one scholar argues that parents who
could transmit genes that would “reduce their children’s life expectancy
or greatly impair their quality of life” should have a right to funding for
fertility treatments, or else their children would be unequal to other
children.205 This argument suggests that gene editing should not only
be legally available but subsidized—an argument that has also been
made about IVF.206 While the number of states mandating insurance
coverage of ART is increasing, generally, polities do not agree that
parents have a right to funding for fertility treatment.207 That being said,
“genes are not all-determining: ‘[h]eritability and determinism are very
different things.’”208
More broadly, while certain uses of germline gene editing may
ameliorate inequality, such as when parents can give birth to children
who do not have devastating conditions, uses of germline gene editing
that might lead to enhancement or the idea that some children have
“better” traits than others, such as increased intelligence or better
athletic ability, could exacerbate inequality.209 In sum, ART and—by
extension—germline gene editing, will continue to be accompanied by
equality-based concerns related to “equality of access to ARTs (and thus
parenthood), equal treatment in the resolution of disputes arising from
204 See, e.g., Jorge L. Contreras & Jacob S. Sherkow, CRISPR, Surrogate Licensing, and
Scientific Discovery, 355 SCIENCE 698 (2017) (discussing litigation related to ownership
of and access to gene editing technologies); Arti K. Rai, Genetic Interventions: (Yet)
Another Challenge to Allocating Health Care, 39 SAN DIEGO L. REV. 657, 664–67 (2002)
(discussing distributive justice in the context of genetic interventions).
205 Lauren R. Roth, Reproductive Selection Bias, 27 HEALTH MATRIX 263, 267 (2017).
206 MARSH & RONNER, supra note 17, at 206.
207 See, e.g., State Laws Related to Insurance Coverage for Infertility Treatment, NAT’L
CONF. OF ST. LEGISLATURES (June 12, 2019), https://www.ncsl.org/research/health/
insurance-coverage-for-infertility-laws.aspx; Maridel Reyes, New Law in New York
Means Most Insurance Plans Will Now Cover IVF, N.Y. POST (Oct. 7, 2019),
https://nypost.com/2019/10/07/new-law-in-new-york-means-most-insuranceplans-will-now-cover-ivf.
208 See, e.g., Suter, supra note 13, at 940.
209 See Mary Crossley, Dimensions of Equality in Regulating Assisted Reproductive
Technologies, 9 J. GENDER, RACE, & JUST. 273, 273–74 (2005) (noting that ART can
exacerbate or ameliorate inequality); King, supra note 70, at 346–48 (discussing various
countries’ regulation of PGD to limit it to “devastating” conditions or those causing
“severe impairment” and other terms that establish a hierarchy in diseases and limit the
application of PGD to some of the conditions that it could be used to select for); see also
infra notes 213–20 and accompanying text (discussing efforts to distinguish between
various diseases).
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the use of ARTs, and equality issues raised by trait-selection
practices.”210 While many would argue that these disparity-based
concerns should prohibit germline gene editing, these concerns have
not been sufficient to prohibit many other forms of ART and health care
in general.211
4. Hierarchy of Disease
Not only is there a dispute related to what constitutes a “disease,”
there is also a debate as to which “diseases” merit prioritization.212 For
example, as illuminated by the response to the announcement of the
birth of the first “CRISPR babies,” Lulu and Nana in China, many
researchers further divide “disease” into categories where some merit
interventions or intellectual focus faster or “more than” other
diseases.213 For example, part of the opposition to the use of germline
gene editing in embryos by Dr. He Jiankui in China, which was
purportedly motivated by a desire to confer HIV immunity so that the
children would not be affected by their father’s HIV-positive status, was
that other methods existed for preventing the transmission of HIV to
embryos.214 Specifically, ART (without genetic modification) could have
achieved prevention of HIV transmission to the offspring or the HIVnegative parent.215 Some observers within the medical communities
were surprised that germline gene editing was used to target HIV, for
which effective methods of avoiding transmission from parent to child
210

Crossley, supra note 209, at 274.
Darnovsky & Hasson, supra note 42, at 164.
212 NAT’L ACADS. SCIS., ENG’G & MED., HUMAN GENOME EDITING: SCI., ETHICS, AND GOVERNANCE,
supra note 50, at 148 (2017) (“Everyone would agree that the manifestation of TaySachs disease is not normal and constitutes a disease, but opinions differ as to whether
genetically caused deafness should be considered a disease.”).
213 See, e.g., The Science and Ethics of Genetically Engineered Human DNA, supra
note 22, at 20 (providing the Prepared Statement of Dr. Jennifer Doudna, which refers
to “severe diseases in humans”).
214 For more on the opposition to the work of Dr. He Jiankui in the creation of the
“first CRISPR babies,” see, for example Greely, supra note 54; Kolata & Belluck, supra
note 55; see also Maryam Zafer et al., Effectiveness of Semen Washing to Prevent HIV
Transmission and Assist Pregnancy in HIV-Discordant Couples: A Systematic Review and
Meta-Analysis, 105 FERTIL STERIL 645 (2016) (showing that there are other ways to
prevent transmission of HIV in ART and reproduction, namely “sperm washing”); Pam
Belluck, How to Stop Rogue Gene-Editing of Human Embryos?, N.Y. TIMES (Jan. 23, 2019),
https://www.nytimes.com/2019/01/23/health/gene-editing-babies-crispr.html; SuiLee Wee & Elsie Chen, In China Gene-Edited Babies Are the Latest in a String of Ethical
Dilemmas, N.Y. TIMES (Nov. 30, 2018), https://www.nytimes.com/2018/11/30/world/
asia/gene-editing-babies-china.html.
215 But see id. (noting difficulties in obtaining access to IVF for those with “sexual
diseases,” including HIV, in China).
211
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in ART already exist, instead of other diseases.216 When the NAS
analyzed the propriety of germline gene editing, for example, it
recommended that clinical trials related to gene editing technologies be
restricted to “preventing a serious disease or condition.”217 The NAS
report did not define what would constitute a “serious disease or
condition,” but instead noted that different societies would have
different interpretations of the concept.218 Some professors, like Julian
Savulescu and Peter Singer, have argued for a hierarchy that prioritizes
“catastrophic single- gene disorders (like Tay-Sachs disease), then
severe single-gene disorders (like Huntington’s disease), then reduction
in the genetic contribution to common diseases (like diabetes and
cardiovascular disease), then enhanced immunity and perhaps even
delaying ageing.”219
The NAS report also expressed that the criteria for human germline
gene editing should include a regulatory system with “reliable oversight
mechanisms to prevent extension to uses other than preventing a
serious disease or condition.”220 While the FDA’s definition of “serious
disease or condition” was mentioned as a possible starting point for a
definition, the experience of the FDA with off-label uses of approved
drugs might also show how difficult such a criterion would be to
implement in practice.221 Once a product is approved for one use by the
FDA, it can be prescribed by doctors for other uses. In such an instance,
the FDA has very few options to prevent these uses, other than
providing restrictions on the marketing of the drugs for such purposes,
in the absence of any adverse events.222

216 See David Cyranoski, CRISPR-Baby Scientist Fails to Satisfy Critics (Nov. 30, 2018),
NATURE, https://www.nature.com/articles/d41586-018-07573-w; Greely, supra note 6,
at 139–40, 168 (noting that “HIV infection must be counted as a ‘serious disease or
condition,’ although not nearly as serious as it used to be”).
217 NAT’L ACADS. SCIS., ENG’G AND MED., HUMAN GENOME EDITING: SCIENCE, ETHICS, AND
GOVERNANCE, supra note 50, at 7.
218 Id. at 8.
219 Julian Savulescu & Peter Singer, An Ethical Pathway for Gene Editing, 33 BIOETHICS
221, 222 (2019).
220 NAT’L ACADS. SCIS., ENG’G & MED., HUMAN GENOME EDITING: SCI., ETHICS, AND GOVERNANCE,
supra note 50, at 8.
221 See, e.g., id.
222 See, e.g., Darnovsky & Hasson, supra note 42, at 161; Randall S. Stafford,
Regulating Off-Label Drug Use—Rethinking the Role of the FDA, 358 N. ENG. J. MED. 1427,
1427 (2008).
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Julia Mahoney and Gil Siegal observe that germline gene editing
could reduce inequalities by “lead[ing] to the births of fewer humans
with serious genetic diseases.”223 While this would not minimize access
concerns, it would lead to the question of whether parents should feel
obligated to use genome editing to prohibit the transmission of harmful
genetic traits.224 At the same time, an often-neglected aspect of the
debate is whether those with disabilities or traits that the mainstream
public considers “undesirable,” an issue that was discussed earlier in
this Part, might decide that this is a trait that they would like to
perpetuate in future generations as parents.225
C. Morality Concerns Related to the “Moral Status” of Embryos and
the Proper Role of Humans
Abortion is a significant part of the United States debate related to
reproductive rights.226 For many, their opposition to abortion stems
from the idea that a fetus is a person and/or that embryos occupy a
special or moral status that should disfavor experimentation, the
creation of embryos, or the destruction of embryos.227 As a result,
debate over the origin of life and whether techniques that lead to the
destruction of embryos or experimentation on embryos (which often
leads to their destruction) surfaces in opposition to ART and germline

223 Mahoney & Siegal, supra note 142, at 210 (discussing “the present generation’s
use of PGD and selective termination); see also American Society of Hematology,
Transplant Community & Sickle Cell Disease Advocates Urge Congress to Advance Policies
Supporting Sickle Cell Disease Research and Treatment, PR NEWSWIRE (June 7, 2017),
https://www.prnewswire.com/news-releases/transplant-community--sickle-celldisease-advocates-urge-congress-to-advance-policies-supporting-sickle-cell-diseaseresearch-and-treatment-300470496.html (quoting Congresswoman Doris Matsui: “Too
often, people with devastating blood disorders like sickle cell disease face significant
barriers to treatment. We need to be opening up more options for patients and making
the federal investments in research that will accelerate the development of cures.”).
224 See Polcz & Lewis, supra note 42, at 419, 425 (discussing disability concerns in the
context of somatic (non-germline) use of CRISPR-Cas9).
225 See, e.g., Pontin, supra note 16 (quoting Professor Henry T. Greely of Stanford
University) (“What if there are parents who wanted to select for Tay-Sachs disease?
There are plenty of people in Silicon Valley who are somewhere on the spectrum, and
some of them will want children who are neuro-atypical.”); see also Polcz & Lewis, supra
note 42, at 420, 425.
226 NUFFIELD COUNCIL ON BIOETHICS, GENOME EDITING AND HUMAN REPRODUCTION: SOCIAL AND
ETHICAL ISSUES, supra note 26, at 109.
227 See, e.g., Dan W. Brock, Creating Embryos for Use in Stem Cell Research, J.L., MED. &
ETHICS 229, 229–37 (2010); Dan W. Brock, Is a Consensus Possible on Stem Cell Research?
Moral and Political Obstacles, 32 J. MED. ETHICS 36, 36–42 (2006); Henry T. Greely, Human
Germline Genome Editing: An Assessment, 2 CRISPR J. 253, 258–59 (2019) (discussing the
“moral status” of the embryo).
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gene editing.228 Often these concerns about the status of embryos and
the proper role of humans in using scientific and medical innovation to
change future outcomes are based on or related to religious views.229
1. Hubris, Sanctity of Nature, and Religious Concerns
The notion that germline gene editing is not an action that humans
should undertake is sometimes grounded in the idea that humans are
“playing God” by editing the human germline, which is seen as common
to humanity.230 Concerns about the proper actions of humans in relation
to a higher power, the “hubris” of humans, and the idea that they are
“playing God” are expressed in varying language including references to
the “sanctity of nature.”231
These concerns surface in various sects’ religious views, which also
often oppose ART in general, in addition to secular views. For example,
the idea of “dignity” is often mentioned in documents issued by the
Catholic Church in relation to its condemnation of IVF and the storage
and manipulation of embryos.232 The U.S. Council of Catholic Bishops
has noted that IVF is “[o]ne reproductive technology which the Church
228 NUFFIELD COUNCIL ON BIOETHICS, GENOME EDITING AND HUMAN REPRODUCTION: SOCIAL AND
ETHICAL ISSUES, supra note 26, at 109, 174.
229 Id. at 109.
230 See, e.g., NAT’L ACADS. SCIS., ENG’G & MED., HUMAN GENOME EDITING: SCI., ETHICS, AND
GOVERNANCE, supra note 50, at 124; Sarah M. Markwood, Creating a Perfect Human Is Not
So Perfect: The Case for Restricting Genetic Enhancement Research, 110 PENN ST. L. REV.
473, 487–88 (2005); Kelly E. Ormond et al., Human Germline Genome Editing, 101 AM. J.
HUM. GENETICS 167, 172 (2017); Savulescu, supra note 159; Arthur Caplan & Carolyn
Plunkett, Get Out of the Way of Human Genetic Engineering? Unwise and Uncalled For,
FORBES (June 7, 2016), https://www.forbes.com/sites/arthurcaplan/2016/06/07/getout-of-the-way-of-human-genetic-engineering-unwise-and-uncalled-for.
231 See, e.g., NAT’L ACADS. SCIS., ENG’G & MED., HUMAN GENOME EDITING: SCI., ETHICS, AND
GOVERNANCE, supra note 50, at 112, 124; Caplan & Plunkett, supra note 230.
232 See, e.g., Anna Louie Sussman, When the Government Seizes Your Embryos, NEW
YORKER (Oct. 22, 2019), https://www.newyorker.com/tech/annals-of-technology/
when-the-government-seizes-your-embryos (discussing the Vatican’s Instruction
Dignitas Personae on Certain Bioethical Questions); see also Congregation for the Doctrine
of the Faith: Instruction on Respect for Human Life and in its Origin and on the Dignity of
Procreation Replies to Certain Questions of the Day, HOLY SEE, http://www.vatican.va/
roman_curia/congregations/cfaith/documents/rc_con_cfaith_doc_19870222_respectfor-human-life_en.html (endnote omitted) (citing Charter of the Rights of the Family, 4b:
L’Osservatore Romano, HOLY SEE (Nov. 25, 1983), http://www.vatican.va/roman_curia/
pontifical_councils/family/documents/rc_pc_family_doc_19831022_familyrights_en.html) (“The Charter of the Rights of the Family published by the Holy See
affirms: ‘Respect for the dignity of the human being excludes all experimental
manipulation or exploitation of the human embryo.’”); see also Congregation for the
Doctrine of the Faith: Instruction Dignitas Personae on Certain Bioethical Questions, HOLY
SEE (Dec. 2008), http://www.vatican.va/roman_curia/congregations/cfaith/
documents/rc_con_cfaith_doc_20081208_dignitas-personae_en.html.
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has clearly and unequivocally judged to be immoral,” although the
Church states that “[l]ike all children, regardless of the circumstances of
their conception and birth, they should be loved, cherished and cared
for.”233 IVF has also been construed as “do[ing] violence to human
dignity and to the marriage act.”234 Despite these views, ARTs, including
artificial insemination and IVF, are permissible in many countries,
including the United States, and not condemned by all sects of
Christianity or by many other religions, with certain complexities.235
Dignity also arises in discussions of germline modification. Some
worry that germline gene editing could result in the possibility of
“legally devalu[ing]” or “violat[ing] . . . [the] dignity” of those who are
conceived using human germline editing or could be conceived using
germline gene editing.236 Secular views on the possibility that germline
gene editing could violate principles of dignity tend to emphasize the
lack of autonomy on the part of the germline gene edited person.237 On
the other hand, there is a concern that prohibiting germline gene editing
could violate the dignity of future persons by not preventing suffering
when possible.
Many observers, including politicians, government employees, and
scientists, have expressed opposition to technologies that modify the
genetic makeup of humans on various grounds. For example, during the
debate over the 2017 Federal Appropriations Bill, Congressman
Aderholt, a Republican from Alabama, noted, “The bill also includes a
prohibition on gene editing of human embryos. This is a tremendous

233 John M. Haas, Begotten Not Made: A Catholic View of Reproductive Technology,
UNITED STATES COUNCIL OF CATHOLIC BISHOPS (1998), http://www.usccb.org/issues-andaction/human-life-and-dignity/reproductive-technology/begotten-not-made-acatholic-view-of-reproductive-technology.cfm.
234 Id.
235 See Ariana Eunjung Cha, Fertility Frontiers: Gifts from God: How Religion is Coming
to Terms with Modern Fertility Methods, WASH. POST (Apr. 27, 2018),
https://www.washingtonpost.com/graphics/2018/national/how-religion-is-comingto-terms-with-modern-fertility-methods (discussing Catholic, Islamic, and Jewish views
on ART’s acceptability); see also Cynthia B. Cohen, Protestant Perspectives on the Uses of
the New Reproductive Technologies, 30 FORDHAM URB. L.J. 135, 135–37, 145 (2002); H.N.
Sallam & N.H. Sallam, Religious Aspects of Assisted Reproduction, 8 FACTS, VIEWS & VISION
IN OBGYN 33, 33 (2016).
236 GERMAN ETHICS COUNCIL, supra note 45, at 17. But see id. at 26 (“[T]he withholding
of a possible germline intervention could be interpreted as a violation of the future
child’s dignity, since the child would be unable to benefit from an important therapeutic
possibility.”).
237 Charo, supra note 65, at 95.
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victory for those who are concerned about life.”238 At the same time,
while Representative Aderholt referred to “life” and how preventing
germline gene editing would be a victory, in another statement he did
not mention life and instead combined scientific and ethical concerns:
“‘The ethics hadn’t caught up with the science, and . . . the science has
not caught up with the science,’ . . . for now, genetically editing embryos
had ‘too many unknowns, too many unintended consequences.’”239 This
is one of many statements that represents the tendencies of legislators
and regulators to combine safety and ethical concerns when faced with
technologies that they find politically and ethically objectionable. Some
of the views discussed in this subsection resurface in discussions about
the inviolability of the human germline and the shared human
identity.240
2. Commodification
Opposition to germline gene editing is often connected to
opposition to the commodification of humanity, the human body, human
traits more broadly, or opposition to assisted reproduction.241 Many of
these concerns arise with various forms of assisted reproduction. For
example, gestational surrogacy, which also uses IVF, led to predictions
that “baby brokers could begin to advertise their babies [similar to how
chicken producers advertise their chickens based on superior breeding
and feeding]: brand-name, state-of-the-art babies produced from the
‘finest’ of genetic materials and an all-natural vitamin-enriched diet.”242
Surrogacy also raises the specter of exploitation, as many object to it on
the theory that richer individuals take advantage of poor women.243
Those who express commodification-related objections to ART also
note that permitting these techniques, which have commercial aspects,

238 163 CONG. REC. H3071 (2017); see also Representative Robert B. Aderholt,
CONGRESS.GOV, https://www.congress.gov/member/robert-aderholt/A000055.
239 Andrew Joseph, Congress Revives Ban on Altering the DNA of Human Embryos Used
for Pregnancies, SCI. AM. (June 5, 2019), https://www.scientificamerican.com/article/
congress-revives-ban-on-altering-the-dna-of-human-embryos-used-for-pregnancies.
240 See supra Section III.C.1.
241 See, e.g., Caplan & Plunkett, supra note 230. For more on the imprecision of the
term “commodification,” as commonly used, see I. Glenn Cohen, Note, The Price of
Everything, the Value of Nothing: Reframing the Commodification Debate, 117 HARV. L.
REV. 689 (2003).
242 Karen Busby & Delaney Vun, Revisiting The Handmaid’s Tale: Feminist Theory
Meets Empirical Research on Surrogate Mothers, 26 CAN. J. FAM. L. 13, 42 (2010) (citing
BARBARA KATZ ROTHMAN, RECREATING MOTHERHOOD, IDEOLOGY AND TECHNOLOGY IN A
PATRIARCHAL SOCIETY 237 (1989)).
243 Charo, supra note 65, at 96.
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will lead to parental relationships in which “children [are] commodities
rather than subjects of parental love, and that it will lead to the
stigmatization of the disabled.”244 Professor Alta Charo has noted that
these concerns related to commodification and the stigmatization of
disabilities have accompanied “prenatal screening, gamete donation,
IVF, surrogacy, PGD, and cloning.”245
Thus, issues related to
commodification often implicate other ethical concerns that arise in the
context of germline gene editing. So far, these ethical concerns have not
prohibited the use of ART or the fertility industry generally: the United
States has almost 500 fertility clinics and the revenue of the worldwide
fertility market is estimated to be $25 billion today, with the expectation
that “by 2026 the global fertility industry could rake in $41 [billion] in
sales.”246
D. Concerns Related to the Future of the Human Race
Objections to germline gene editing also encompass the idea that
humans are interfering with the will of God or nature.247 These
objections have also arisen with medicine in general and more
specifically, ART and techniques permitting parents to “select” for
certain children, both using IVF and PGD, and also using prenatal
testing. As noted by the Nuffield Council on Bioethics, many academic
sources and international legal documents such as those promulgated
by the United Nations have connected the idea of the human genome
“and the enjoyment of human rights (or the possession of human
dignity)” although, this connection “does not appear necessary.”248 The
ideas of human dignity and human rights tend to surface more in nonU.S. traditions.249
244

Id. at 95.
Id.
246 The Fertility Business is Booming, ECONOMIST (Aug. 8, 2019),
https://www.economist.com/business/2019/08/08/the-fertility-business-isbooming; see also Rebecca Robbins, Investors See Big Money in Infertility. And They’re
Transforming the Industry, STAT NEWS (Dec. 4, 2017), https://www.statnews.com/
2017/12/04/infertility-industry-investment. For more on commodification in relation
to the fertility market, see Martha M. Ertman, What’s Wrong with a Parenthood Market?
A New and Improved Theory of Commodification, 82 N.C. L. REV. 1, 3–21 (2003).
247 NUFFIELD COUNCIL ON BIOETHICS, GENOME EDITING AND HUMAN REPRODUCTION: SOCIAL AND
ETHICAL ISSUES, supra note 26, at 67.
248 Id. at xvii, 93–94 (discussing human dignity in the context of the United Nations’
Universal Declaration of Human Rights).
249 Id. at xvii–xviii, 114–32.
It is worth noting that many international legal
frameworks addressed by the Nuffield Council on Bioethics do not apply to the United
States. Further, international law includes both “hard law” (binding law) and “soft law”
(non-binding documents and norms). For more on international laws related to
245
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1. The Morality of Enhancement
There is also a concern that germline gene editing could be used for
human enhancements, to the extent that one could define an
enhancement, which then leads to objections to germline gene
editing.250 Such a concern is often classified as a “slippery slope”
concern.251 Applying Professor Eugene Volokh’s analysis of slippery
slopes to germline gene editing, one might think that idea A, using
germline gene editing to prevent the birth of children with harmful
genetic diseases like Tay-Sachs or sickle cell anemia, may sound like a
good idea, “or at least not a very bad one. But you’re afraid that A might
eventually lead other legislators, voters, or judges to implement policy
B, [germline gene editing for enhancement purposes such as aboveaverage intelligence or greater height,] which you strongly oppose.”252
While slippery slopes can be used in support of opposition to germline
gene editing, as acknowledged by the National Academies of Sciences,
supporters of germline gene editing also invoke arguments related to
slippery slopes.253 These slippery slope arguments are connected to
contentions such as those related to hierarchies of disease and an
germline gene editing, see, for example id. at 106–09; NAT’L ACADS. SCIS., ENG’G & MED.,
HUMAN GENOME EDITING: SCI., ETHICS, AND GOVERNANCE, supra note 50, at 132–33.
250 Kohn et al., supra note 23, at 2554 (“Given that our understanding of the genome
is still rudimentary, editing with intent to ‘improve’ is fraught with many caveats, not
the least of which is that we do not know, may never know, or nor even be able to define
what an ‘improved’ genome would look like.”); Suter, supra note 13, at 898, 933–34
(2007); Antonio Regalado, Engineering the Perfect Baby, TECH. REV. (Mar. 5, 2015),
https://www.technologyreview.com/s/535661/engineering-the-perfect-baby
[https://perma.cc/4Z95-N87G] (archived Jan. 26, 2017); The Science and Ethics of
Genetically Engineered Human DNA, supra note 22, at 32–33 (providing Testimony of Dr.
Jeffrey Khan which highlighted the concern for the use of gene editing for reasons
related to selecting “physical or behavioral traits or even enhancements” instead of for
disease treatment or avoidance). For more on the debate over the term “enhancement,”
see, for example Savulescu, supra note 159; see also Wesley W. Chen, Human Germline
Gene Editing: Engineering an Unstoppable Train, 28 S. CAL. INTERDISC. L.J. 523, 535 (2019)
(“[C]ritics might argue that eugenics sits on a slippery slope and if we allow the
possibility of ‘breeding out’ negative characteristics, we will eventually find ourselves
back in the 1940s alongside the atrocities of the Holocaust . . . [and] even if society does
not descend to such depths, the very concept of eugenics is discriminatory because it
suggests that some lives are not worth living.”); see, e.g., NAT’L ACADS. SCIS., ENG’G & MED.,
HUMAN GENOME EDITING: SCI., ETHICS, AND GOVERNANCE, supra note 50, at 9 (also noting the
difficulty of defining an enhancement).
251 Eugene Volokh, The Mechanisms of the Slippery Slope, 116 HARV. L. REV. 1026, 1028
(2002); NUFFIELD COUNCIL ON BIOETHICS, GENOME EDITING AND HUMAN REPRODUCTION: SOCIAL
AND ETHICAL ISSUES, supra note 26, at 53–55; Baltimore et al., supra note 43, at 37.
252 Volokh, supra note 251, at 1028; see also id. at 1103–04 (discussing “attitudealtering slippery slopes” and “small change tolerance slippery slopes”).
253 NAT’L ACADS. SCIS., ENG’G & MED., HUMAN GENOME EDITING: SCI., ETHICS, AND GOVERNANCE,
supra note 50, at 128–30.

LEWIS_FORMATTED (DO NOT DELETE)

2021]

12/29/2020 8:27 PM

IS GERMLINE GENE EDITING EXCEPTIONAL?

785

acknowledgment that germline gene editing can be used for benevolent
and potentially malevolent uses (as “enhancement” related uses might
be categorized).254 In other words, the continuum that is used to
categorize various uses of ART is related to the “slippery slope” style
argument discussed above.255
This Article does not argue for a moratorium on germline gene
editing because of its potentially malevolent uses. Some scientists,
regulators, and observers would ban all uses of germline gene editing so
as to avoid the possibility of its use for human enhancement, such as
improving intelligence beyond naturally occurring capacities,
increasing height, or even changing a child’s eye color or muscle
composition.256 Arguments related to the morality of enhancement take
varying forms. Some observers are concerned that once enhancement
is permitted for “clear” medical or therapeutic purposes, such as specific
genetic diseases, that there will be a “slippery slope” to enhancementrelated uses such as increased height or intentionally improved
intelligence.257 For the purposes of this Article, the debate between the
morality of enhancement and medical treatment, as a baseline, will start
with the idea that medical treatment “aims to eradicate diseases . . .
whereas [enhancement] aims to improve what is ‘normal.’”258 As a
result, discussions of germline gene editing involve the same debates
about enhancement, eugenics, and “designer babies” that other
technologies, such as Recombinant DNA and some forms of ART, have
invoked.259
To the extent that germline gene editing would be used for nondisease related purposes, for many, there would be additional
opposition or the expectation that genetic “enhancement” should be
treated differently than genetic editing to address disease.260 For
example, the National Academies of Sciences similarly noted this
concern and recommended that germline gene editing be used only to
254

Id. See discussion infra Section III.B.4. (“Hierarchy of Disease”).
NAT’L ACADS. SCIS., ENG’G & MED., HUMAN GENOME EDITING: SCI., ETHICS, AND GOVERNANCE,
supra note 50, at 128.
256 See Lander, infra note 284.
257 See, e.g., Caplan & Plunkett, supra note 230.
258 Suter, supra note 13, at 933.
259 Carolyn P. Neuhaus & Arthur L. Caplan, Genome Editing: Bioethics Shows the Way,
PLOS ONE (2017), https://journals.plos.org/plosbiology/article?id=10.1371/journal.
pbio.2001934; Joseph Fletcher, Ethics and Recombinant DNA Research, 51 S. CAL. L. REV.
1131, 1133–38 (1978); Robertson, supra note 34, at 441; Judith P. Swazey, James R.
Sorenson & Cynthia B. Wong, Risks and Benefits, Rights and Responsibilities: A History of
the Recombinant DNA Research Controversy, 51 S. CAL. L. REV. 1019, 1046–51 (1978).
260 Rai, supra note 204, at 665.
255
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prevent disease or disability.261 A few public opinion polls exist on the
subject of germline gene editing.262 Some polls indicate large-scale
public support for “genome editing to prevent genetic disease, if
determined to be safe,” but not gene editing for enhancement
purposes.263 At the same time, it is acknowledged that this “largely
unenthusiastic” position on enhancement could stem from a number of
sources of skepticism, as many commonly accepted phenomena were
the subject of skepticism early in their inception.264
Many enhancement-related arguments tend to jump straight to the
creation of individuals who would be exponentially superior to existing
humans, although there are also concerns about incremental changes.
Genetic enhancement for many traits is unlikely. For example,
“intelligence,” is a trait that is based on “complex interactions among
multiple genes and environments.”265 At the same time, arguments
about enhancement tend to ignore how “enhancement” might fit within
the purview of the many “unnatural” actions that doctors undertake
every day, such as transplanting organs, creating and using vaccines that
convey unnatural immunities, and other medical treatments that undo
the natural progression of diseases, such as LASIK eye surgery.266
Nevertheless, the above discussion of the difficulty of identifying a
“serious disease or condition,” see supra Section III.B.4., parallels the
difficulty of defining the difference between a therapeutic use and an
enhancement-based use.267 These difficulties have not, however,
prohibited parents from being permitted to selectively choose
reproductive partners or gamete donors based on certain desirable
traits, or from selecting certain embryos based on their genetic or sexbased preferences.268 Slippery slope concerns have surfaced not only in
261 NAT’L ACADS. SCIS., ENG’G & MED., HUMAN GENOME EDITING: SCI., ETHICS, AND GOVERNANCE,
supra note 50, at 13.
262 See id. at 140–43.
263 Daley et al., supra note 49, at 899.
264 NAT’L ACADS. SCIS., ENG’G & MED., HUMAN GENOME EDITING: SCI., ETHICS, AND GOVERNANCE,
supra note 50, at 144.
265 Id.; see also Savulescu & Singer, supra note 219, at 222 (noting that “China is
currently funding research that is trying to unravel the genetics of high intelligence”)
(citation omitted).
266 See, e.g., Kenan Malik, The Three-Parent Baby’s First Step, N.Y. TIMES (Feb. 22,
2015), http://www.nytimes.com/2015/02/23/opinion/the-three-parent-babys-firststep.html; LASIK Eye Surgery (Nov. 8, 2019), https://www.mayoclinic.org/testsprocedures/lasik-eye-surgery/about/pac-20384774
267 But see Cohen, supra note 170, at 676 (challenging the usefulness of the
enhancement distinction).
268 See, e.g., NUFFIELD COUNCIL ON BIOETHICS, GENOME EDITING AND HUMAN REPRODUCTION:
SOCIAL AND ETHICAL ISSUES, supra note 26, at 13; Cohen, supra note 170, at 678
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the context of genetic modification (including a possible slippery slope
from research to reproduction) but also in the context of ART and
PGD.269 The National Academies of Sciences, for example, noted in its
study of genome editing:
IVF, for example, was originally developed to circumvent
fallopian tube blockage. It soon was extended, however, to
circumventing naturally age-related decline in fertility and
even postmenopausal infertility, and later became an enabling
technology for PGD. Likewise, PGD was originally designed to
select against embryos with serious deleterious mutations but
later was expanded to conditions that not all agree are
diseases or disabilities, as well as to sex selection.270
Ultimately, as a matter of the potential widespread effects of
reproductive technologies, especially those using genetic modification,
many members of society have not decided to use arguably
enhancement-related options such as using ART instead of sex, sex
selection of embryos, or selection of certain gamete donors based on
certain enhancement-related traits such as Nobel Prize wins.271
2. The “Inviolability” of the Human Germline
Like concerns about the dignity of the human race and whether
humans should cross certain lines, many opponents of germline gene
editing simply state that the human germline is an inviolable line that
“should not be crossed.”272 These arguments assert that there is a
significance to the human germline which leads to a determination that
interventions affecting the human germline should not occur.273
Nevertheless, positions on the inviolability of the human germline are
changing. In May 2019, the German Ethics Council announced that it
unanimously disagrees with the idea that the human germline is
(“[E]specially in terms of enhancing our children, it is important to emphasize that we
are already deep into a system of enhancement through our marital and non-marital
reproductive mate choices.”).
269 NAT’L ACADS. SCIS., ENG’G & MED., HUMAN GENOME EDITING: SCI., ETHICS, AND GOVERNANCE,
supra note 50, at 129, 156; Kane, supra note 38, at 320.
270 NAT’L ACADS. SCIS., ENG’G & MED., HUMAN GENOME EDITING: SCI., ETHICS, AND GOVERNANCE,
supra note 50, at 129.
271 Cohen, supra note 170, at 679 (“So if enhancement by selection of gamete
providers is the main way to enhance our children genetically these days, for many
potential parents the costs may outweigh the benefits.”); Jennifer Ludden, Telling the
Full Story of ‘The Genius Factory,’ NPR (June 12, 2005), https://www.npr.org/templates/
story/story.php?storyId=4700156 (discussing the “Nobel Prize sperm bank”).
272 GERMAN ETHICS COUNCIL, supra note 45, at 17, 18 (referencing “a ‘dignity of the
human species.’”); see also Caplan & Plunkett, supra note 230.
273 GERMAN ETHICS COUNCIL, supra note 45, at 31.
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“categorically inviolable.”274 It disagreed with the assertion that the
germline was inviolable based on the inability of the germline to “be the
object or the substrate of the protection of dignity or life,” and the fact
that “the germline is nonetheless constantly being altered as a
consequence of natural processes and human action.”275 For example,
germline gene editing would target disease-causing mutations in a
manner that would lead to inheritable changes in the human genome.276
Yet mutations occur spontaneously in the human genome, and as such,
“the genotoxic risk of the editing process . . . should be put into the
context of the natural, ongoing genomic mutations that are occurring in
cells all of the time.”277 While some individuals are concerned that
changes to the human germline are irreversible, the German Ethics
Council has noted that one could theoretically use human germline
modification on the children of the genetically modified to reverse the
germline gene editing that their genetically modified parent or parents
were subjected to.278
3. The “Shared Human Identity”
The idea of the “shared human identity” surfaces, with some
objecting to the idea that germline gene editing would lead to
inheritable changes and “introduce . . . modified genomes into the
human genome pool.”279 For example, discussions of evolution and
inheritance often center on the idea of a “Mitochondrial Eve,” a
hypothetical common ancestor of all members of the human race.280 In
2019, Senator Dianne Feinstein introduced a resolution noting that “the
question of whether to proceed with heritable genome editing touches
on all humanity,” as part of a condemnation of the actions of Dr. He

274

Id. at 39.
Id.
276 NAT’L INSTS. OF HEALTH, U.S. NAT’L LIBR. OF MED., supra note 49.
277 Kohn et al., supra note 23, at 2556–57.
278 GERMAN ETHICS COUNCIL, supra note 45, at 10.
279 Kohn et al., supra note 23, at 2554.
280 See, e.g., Ewen Callaway, Genetic Adam and Eve Did Not Live Too Far Apart in Time,
NATURE (Aug. 6, 2013), https://www.nature.com/news/genetic-adam-and-eve-did-notlive-too-far-apart-in-time-1.13478; Joshua Rapp Learn, No, a Mitochondrial “Eve” Is Not
the First Female in a Species, SMITHSONIAN MAG. (June 28, 2016),
https://www.smithsonianmag.com/science-nature/no-mitochondrial-eve-not-firstfemale-species-180959593/#bM6tveasw3S8mRrJ.99; see also Michael Slezak, Found:
Closest Link to Eve, Our Universal Ancestor, NEW SCIENTIST (Oct. 8, 2014),
https://www.newscientist.com/article/mg22429904-500-found-closest-link-to-eveour-universal-ancestor/#ixzz5zcftKvSB.
275
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Jiankui who purportedly created the first germline gene-edited
babies.281
This idea of “damage” to the shared human identity is connected to
earlier arguments related to hubris and humanity. Nevertheless, these
modified genomes would still be human genomes, which separates gene
editing from other extraordinary, non-reproductive technologies that
could implicate animal traits, such as those that aim to create humananimal hybrids.282 Some observers, including Professor Hank Greely,
note that:
The human germline genome is not the holy essence of
humanity. For one thing, it doesn’t really exist. There are 7.3
billion human germline genomes; each of us has a different
one. And those genomes change every generation. . . . The
DNA changed, through mutation, during each generation.283
In some instances, the concern is that these modifications will be
introduced into the “gene pool,” and these introduced heritable
modifications are said to be irreversible unless the children of germline
editing agree not to reproduce or to avail themselves of techniques such
that they do not pass on their modifications in reproduction.284 Yet, as
noted earlier, gene editing is not necessarily irreversible.285
While there is a reference to the “gene pool,” it is worth noting that
human germline modification does not automatically impact all
humans.286 As of September 2020, the current world population is 7.68
281 Senate Resolution 275—Calling for International Ethical Standards in Genome
Editing Research, 165 CONG. REC. S4813, S4824 (2019); see also Greely, supra note 6, at
111, 151–69 (explaining why the author characterized Dr. Jiankui’s experiment as
“criminally reckless . . . grossly premature, and deeply unethical”).
282 See Brock Bastian, The Uneasy Truth About Human-Animal Hybrids, BBC NEWS
(Feb. 22, 2017), http://www.bbc.com/future/story/20170222-the-uneasy-truthabout-human-animal-hybrids; Erin Blackemore, Human-Pig Hybrid Created in the Lab—
Here Are the Facts, NAT’L GEOGRAPHIC (Jan. 26, 2017), https://www.national
geographic.com/news/2017/01/human-pig-hybrid-embryo-chimera-organs-healthscience/#close; L-M Houdebine, Use of Transgenic Animals to Improve Human Health and
Animal Production, 40 REPRODUCTION DOMESTIC ANIMALS 269 (2005); see also Rebecca A.
Ballard, Animal/Human Hybrids and Chimeras: What Are They—Why Are They Being
Created—And What Attempts Have Been Made to Regulate Them, 12 MICH. ST. U. J. MED. &
L. 297 (2008).
283 Hank Greely, Why the Panic Over “Designer Babies” Is the Wrong Worry (Oct. 30,
2017), https://leapsmag.com/much-ado-about-nothing-much-crispr-for-humanembryo-editing; see also Greely, supra note 227, at 253, 256–57.
284 See Eric S. Lander et al., Adopt a Moratorium on Heritable Genome Editing, 567
NATURE 165 (2019); see also Bosley et al., supra note 41, at 481.
285 GERMAN ETHICS COUNCIL, supra note 45, at 10.
286 Polcz & Lewis, supra note 42, at 423; NAT’L ACADS. SCIS., ENG’G & MED., HUMAN GENOME
EDITING: SCI., ETHICS, AND GOVERNANCE, supra note 50, at 117–18.
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billion people.287 Additionally, current estimates indicate that the
“number of [gene editing] users would likely be so small as to have little
or no effect on population diversity and distribution of traits.”288 The
National Academies of Sciences took a similar position in its 2017 report
and noted that, if germline gene editing were approved, there would be
a “very small” number of cases and “there is little chance of any
significant effects on the gene pool in the foreseeable future.”289
***
The foregoing discussion has emphasized bioethical
considerations that are the source of opposition to germline gene
editing technologies, yet there are competing bioethical concerns that
weigh in favor of germline gene editing. This Section has highlighted
how much of the bioethical opposition to germline gene editing is the
same as opposition to ART, which is legally permissible. Further, claims
that are often deemed unique to germline gene editing are similar to
those accompanying traditional ART. In light of these similarities, the
regulatory system, even when incorporating ethical views into
regulatory decisions, should not treat germline gene editing differently
than ART. This Part has addressed the concerns related to traditional
ART that also accompany germline gene editing, before focusing on
some concerns that are specific to gene editing.
Autonomy, for example, is a value that emphasizes the decisions of
the individual.290 Procreative autonomy or procreative liberty, more
specifically, focuses on the rights of parents within procreation,
including their decisions before a future child is born.291 This
procreative autonomy has been used to justify parents’ selection of
embryos with certain traits, which is different from modification, but in
some cases has the same effect. These two forms of autonomy can be in
tension for many philosophers, and for some philosophers or observers,
this tension should be resolved in favor of the future child (and in favor
of not modifying, or more specifically, enhancing, the child).292
287 See U.S. and World Population Clock, U.S. CENSUS BUREAU, https://www.census.gov/
popclock.
288 See also Bosley et al., supra note 41, at 481 (providing the statement of R. Alta
Charo on population genetics and germline engineering); Greely, supra note 283.
289 NAT’L ACADS. SCIS., ENG’G & MED., HUMAN GENOME EDITING: SCI., ETHICS, AND GOVERNANCE,
supra note 50, at 118.
290 See Suter, supra note 13, at 900, 921.
291 Robertson, supra note 165, at 953–55.
292 NUFFIELD COUNCIL ON BIOETHICS, GENOME EDITING AND HUMAN REPRODUCTION: SOCIAL AND
ETHICAL ISSUES, supra note 26, at 69 (summarizing the views of Michael Sandel, as it
relates to the harms of enhancing a future child, and Joel Feinberg as it relates to
“anticipatory autonomy rights”).
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Concerns related to disability rights and eugenics have also
persisted with ART and healthcare innovation in general. Nevertheless,
these concerns have not merited federal control over reproduction, or
more specifically, ART in the United States. Similarly, while both federal
and state debates have centered on morality concerns related to the
moral status of embryos, as noted in the longstanding abortion debate
in the United States and the broader field of reproductive rights, the fact
that embryos can be discarded in ART and experimented on has not
prohibited the legality of ART in the United States, although it has
corresponded with funding restrictions and some state-based research
restrictions as well.293
Ultimately, many of the bioethical concerns that accompany
germline gene editing are the same concerns that have accompanied
IVF. Many note that physicians (and society) reject concerns related to
hubris and interference with nature by “screen[ing] embryos and
fetuses for diseases . . . vaccinat[ing], provid[ing] pain relief to women
in labour (despite objections of some earlier Christians that these
practices thwarted God’s will)[,] and treat[ing] cancer.”294 Moreover,
concerns that have been identified as unique to or possibly exacerbated
by germline gene editing still fall within the realm of parental or
reproductive autonomy and are similar to the risks imposed by natural
reproduction or medicine and pharmaceuticals more generally. In
general, the regulatory state has not inquired into parents’ motives in
making certain reproductive decisions such as sex selection, using PGD
to select for traits that the majority may deem undesirable, or choosing
reproductive partners based on physical traits that they would like their
children to have. Extending that lack of inquiry to germline gene editing,
one could posit that not distinguishing between genetic enhancement
and genetic treatment could have some benefits. This Article’s
normative argument has emphasized the similarities between currently
permitted techniques, federally-regulated products, and germline gene
editing.

293 See, e.g., Sheryl Gay Stolberg, States Pursue Cloning Laws as Congress Debates, N.Y.
TIMES (May 26, 2002), https://www.nytimes.com/2002/05/26/us/states-pursuecloning-laws-as-congress-debates.html.
294 Savulescu, supra note 159; see also Associated Press, First Use of CRISPR Against
Cancer in Patients Clears Early Safety Hurdles, STAT NEWS (Nov. 6, 2019),
https://www.statnews.com/2019/11/06/first-use-of-crispr-against-cancer-inpatients-clears-early-safety-hurdles (discussing trials using gene editing in cancer
patients in order to “remove, alter and give back to the patient cells that are superpowered to fight their cancer—a form of immunotherapy,” not change a person’s DNA).
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Additionally, regulating germline gene editing like IVF could
reduce the need to differentiate between therapy and enhancement.
First, scholars have acknowledged the difficulty in differentiating
between curing diseases and augmenting humans.295 Some have asked
whether vaccines are enhancements, as they enhance the immune
system so that it can ward off disease.296 George Church, an innovator
in the field of genetics, has noted that gene therapies, which are FDA
approved, constitute modifications.297 Others have noted that doctors
“play God” every day, so efforts at genetic modification fall within the
realm of what is expected of medical professionals.298 The idea that gene
editing is another part of medical treatment renders it more similar to
natural reproduction, which tends to fall within the “standard” medical
regulatory regime, such as through malpractice regulation. Concerns
related to commodification and the role of “baby brokers” offering
“state-of-the-art babies produced from the ‘finest’ of genetic materials
and . . . diet,” due to the use of gestational surrogacy, have also proven
to be unfounded.299 That being said, many scholars continue to think
that surrogacy, which is permitted in many American states, possibly
exploits women and is accompanied by “serious issues of
commodification—of sex, of childbirth, of birthmothers, and of
children—by allowing contracts, sales, and money to govern these once
noncommercialized areas of life.”300 Nevertheless, access to surrogacy
is broadly permitted within the United States and around the world.301
295 See, e.g., Savulescu, supra note 159, at 38 (“Enhancement is a misnomer. It
suggests luxury. But enhancement is no luxury. In so far as it promotes well-being, it is
the very essence of what is necessary for a good human life.”).
296 See Mohapatra, supra note 190, at 63 (citation omitted).
297 See David Cyranoski, Ethics of Embryo Editing Divides Scientists, NATURE (Mar. 18,
2015), https://www.nature.com/news/ethics-of-embryo-editing-divides-scientists1.17131; George Church, Ph.D., WYSS INSTITUTE, https://wyss.harvard.edu/team/corefaculty/george-church; see also infra Section IV.A. (discussing FDA-approved gene
therapies which modify somatic cells, but do not result in heritable modifications).
298 See Malik, supra note 266.
299 Busby & Vun, supra note 242, at 42 (citing to BARBARA KATZ ROTHMAN, RECREATING
MOTHERHOOD, IDEOLOGY AND TECHNOLOGY IN A PATRIARCHAL SOCIETY 237 (1989)).
300 See, e.g., Field, supra note 67, at 1155; see id. at 1158–59, 1161, 1164–65.
301 For an overview of surrogacy law in the United States and access to surrogacy
worldwide, see COLUM. L. SCH. SEXUALITY & GENDER L. CLINIC, SURROGACY LAW AND POLICY IN
THE U.S.: A NATIONAL CONVERSATION INFORMED BY GLOBAL LAWMAKING 8–17 (2016),
https://web.law.columbia.edu/sites/default/files/microsites/gender-sexuality/files/
columbia_sexuality_and_gender_law_clinic_-_surrogacy_law_and_policy_report__june_2016.pdf; see also Michael Alison Chandler, With New Surrogacy Law, D.C. Joins
Jurisdictions That Are Making It Easier for Gay and Infertile Couples to Start Families,
Social Issues, WASH. POST (June 3, 2017), https://www.washingtonpost.com/local/
social-issues/with-new-surrogacy-law-dc-joins-jurisdictions-that-are-making-it-
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Further, the regulatory regime for ART (or lack thereof, as many
characterize it), recognizes that ART generally has the same goals as
traditional reproduction and attempts to treat it in that manner.
Germline gene editing is accompanied by some technique-specific
moral concerns, including those related to the “inviolability” of the
human germline and the idea that some “shared human identity” would
be destroyed if the technique were to go forward. Yet, as discussed
above in Section III.D.3., the idea of a “shared human identity” is
speculative. Some scientists, government officials, and members of the
public have called for moratoria on the clinical use of gene editing;
moratoria on research related to human gene editing; limiting the use of
gene editing to certain situations; international frameworks; and/or
combinations of some of the aforementioned options.302 Some
individuals oppose germline gene editing for various reasons, including
that they do not want the technology to exist due to its possible use for
human enhancements like improving intelligence beyond naturally
occurring capacities, increasing height, or even changing a child’s eye
color or muscle composition.303 Others believe that further deliberation
is required and that halting research and public deliberation would be
“unwise.”304
Ultimately, treating germline gene editing in the same manner as
traditional ART means placing the majority of regulation under state
rather than federal control. Some would argue that the possibility that
germline gene editing could affect the gene pool renders it a “classic area
for federal regulation”; however, natural reproduction has the same
effect and is not subject to federal regulation.305 Others note that at least
easier-for-gay-and-infertile-couples-to-start-families/2017/06/03/845c90d4-3c9911e7-8854-21f359183e8c_story.html.
302 See generally Baltimore et al., supra note 43, at 37; Bosley et al., supra note 41, at
484–86 (providing the perspectives of various legal scholars and scientists ethicists and
scientists on the practical effects of a moratorium on gene editing and the likelihood of
success); Russell A. Spivak et al., Moratoria and Innovation in the Reproductive Sciences:
Of Pretext, Permanence, Transparency, and Time-Limits, 14 J. HEALTH & BIOMEDICAL L. 5,
6–7 (2018); see also Lander et al., supra note 89, at 165. When scientists use the term
“moratorium,” their use of the term sometimes refers to a pause on research or clinical
use as opposed to a “ban,” which is the usual meaning of the germ. See also Editorial,
Germline Gene-Editing Research Needs Rules, NATURE (Mar. 13, 2019),
https://www.nature.com/articles/d41586-019-00788-5; Wolinetz & Collins, supra
note 89.
303 See Lander, supra note 284, at 166.
304 See, e.g., Daley et al., supra note 49, at 897. See generally Bosley et al., supra note
41, at 483–84.
305 See, e.g., Jack M. Balkin, Commerce, 109 MICH. L. REV. 1, 6 (2010); Brian Galle & Mark
Seidenfeld, Administrative Law’s Federalism: Preemption, Delegation, and Agencies at the
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the federal government has a clear structure for the testing of products;
however, other aspects of medicine flourish without the FDA’s
oversight.306 Surgical techniques, for example, are, as a part of the
practice of medicine, unregulated by the FDA, and many surgical
innovations have surfaced (and become widespread) over the years,
such as heart surgery and organ transplantation.307 Further, ART,
namely IVF, has flourished around the world and was the basis for the
2010 Nobel Prize in Physiology or Medicine.308 Siting authority in states
instead of the federal government could minimize the role of public
deliberation, which was not a part of the human clinical use of IVF in the
United States.309
IV. APPLYING TRADITIONAL ASSISTED REPRODUCTIVE TECHNOLOGY
REGULATION TO EMERGING GERMLINE GENE EDITING TECHNOLOGIES
As outlined supra in Part III, there are many reasons why
individuals are opposed to germline gene editing. That opposition,
however, should not prevent the use of germline gene editing in the
United States. While scholars and practitioners have acknowledged that
the current FDA regime can regulate gene therapy (and little debate has
ensued over that jurisdictional assertion), some think that germline
gene editing requires a new regulatory regime. This Article argues that
it does not because the tools to regulate gene editing in the United States
already exist, although the emphasis on federal regulation is
misplaced.310 Instead, past examples of FDA action related to medical

Edge of Federal Power, 57 DUKE L.J. 1933, 1987 (2008) (noting, regarding spillovers: “Lax
regulations in one state—be they on handguns, fireworks, or abortions—can make
restrictions in nearby states largely fruitless”) (citations omitted); Heather K. Gerken &
Ari Holtzblatt, The Political Safeguards of Horizontal Federalism, 113 MICH. L. REV. 57,
69–73, 101 (2014) (discussing spillover effects and federalism); Richard F. Storrow, The
Bioethics of Prospective Parenthood: In Pursuit of the Proper Standard for Gatekeeping in
Infertility Clinics, 28 CARDOZO L. REV. 2283, 2299 (2007).
306 See supra Section II.B.
307 Id.
308 Press Release, The Nobel Prize in Physiology or Medicine 2010, Nobel Prize (Oct.
4, 2010), https://www.nobelprize.org/prizes/medicine/2010/press-release
[https://perma.cc/CK2M-NNJE].
309 NAT’L ACADS. SCIS., ENG’G & MED., HUMAN GENOME EDITING: SCI., ETHICS, AND GOVERNANCE,
supra note 50, at 193–95 (recommending societal deliberation related to genome
editing).
310 See, e.g., NAT’L ACADS. SCIS., ENG’G & MED., HUMAN GENOME EDITING: SCI., ETHICS, AND
GOVERNANCE, supra note 50, at 110 (“RECOMMENDATION 4-1. Existing regulatory
infrastructure and processes for reviewing and evaluating somatic gene therapy to treat
or prevent disease and disability should be used to evaluate somatic gene therapy that
uses genome editing.”); Bosley et al., supra note 41, at 478, 483, 486; Kane, supra note 38,
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techniques involving genetic modification or assisted reproduction
indicates that federal involvement will likely stymie innovation in this
area.311 Thus, this Article argues for a regulatory treatment of germline
gene editing similar to that of traditional ART.
A. The Similarities Between Germline Gene Editing and
Drugs/Biologics
While this Article does not advocate for the federal regulatory
treatment of gene editing, the FDA has simultaneously declared
jurisdiction over gene editing and implied that it is distinct from other
“products” as has the NIH in funding decisions, which merits an
argument as to why gene editing is not exceptional.312 This
at 319 (2017) (arguing that germline gene editing has a “more complex regulatory
profile” than mitochondrial transfer or human reproductive cloning). .
311 See, e.g., supra note 8 and accompanying text; see also Carbone, supra note 135, at
354 (noting the impact of federal policy on the funding of embryo research). Id. (“Given
the lack of consensus on a basis for substantive regulation and the interaction of safety
requirements with deep-seated religious opposition to assisted reproduction,
substantive regulation is likely to shut down promising innovations rather than provide
a safer way to test their impact. The industry lobbying that subverts safety regulation
(but also overcomes obstructionist regulation) depends on powerful advocates for the
procedures at issue, something that does not exist for techniques still on the drawing
board.”).
312 See, e.g., Information About Self-Administration of Gene Therapy, U.S. FOOD & DRUG
ADMIN. (Nov. 21, 2017), https://www.fda.gov/vaccines-blood-biologics/cellular-genetherapy-products/information-about-self-administration-gene-therapy; Statement on
NIH Funding of Research Using Gene-Editing Technologies in Human Embryos, NAT’L INSTS.
OF HEALTH (Apr. 28, 2015), https://www.nih.gov/about-nih/who-we-are/nih-director/
statements/statement-nih-funding-research-using-gene-editing-technologies-humanembryos (“NIH will not fund any use of gene editing technologies in human embryos.”);
Therapeutic Cloning and Genome Modification, U.S. FOOD & DRUG ADMIN. (Mar. 16, 2018),
https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/
therapeutic-cloning-and-genome-modification (stating that “FDA has regulatory
authority over genetically manipulated cells” and therefore, investigational new drug
applications must be submitted before researchers use them); see Robert M. Califf & Ritu
Nalubola, FDA’s Science-Based Approach to Genome Edited Products, FDA VOICE (Jan. 18,
2017), http://blogs.fda.gov/fdavoice/index.php/2017/01/fdas-science-basedapproach-to-genome-edited-products [https://perma.cc/X936-U9JJ] (“[FDA oversight]
is one aspect of broader governance necessary for safe and responsible research and
development of genome editing applications. Moreover, the expansive scope of [gene
editing] has triggered debate on fundamental ethical and social issues . . . . Even as FDA
implements necessary steps for effective regulation to ensure the safety of products, the
role of broader, inclusive public discussion involving multiple constituencies . . . to
address the larger societal considerations should not be overlooked.”); Id. (“Human
medical products that apply gene editing to exert their therapeutic effect are regulated
under our existing framework for biological products, which include gene therapy
products. ‘Gene editing’ here refers to non-heritable situations somatic cell gene
therapy only, and not to heritable conditions (germ line gene therapy). The FY16
[Congressional] appropriations bill restricted use of federal funds ‘in research in which
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exceptionality should be analyzed because, while the FDA purports to fit
germline gene editing into its framework for biologics and drugs, the
FDA’s categorization of certain techniques into that framework has led
to the FDA essentially treating those reproductive techniques
differently than its other approved products.313 Further, due to the
budget rider that has been renewed every year since 2015, the FDA
cannot even consider approving gene editing techniques that would
lead to heritable changes.314 This also serves to stymie progress under
a federally-focused regime.
While the FDA is known for its regulatory baseline of “safety and
efficacy,” which must be achieved before a product obtains marketing
approval, this standard also exists within science and the practice of
medicine generally.315 For example, after the birth of Louise Brown
a human embryo is intentionally created or modified to include a heritable genetic
modification.’”); see also Francis S. Collins, NIH Supports International Moratorium on
Clinical Application of Germline Editing, NAT’L INSTS. OF HEALTH (Mar. 13, 2019),
https://www.nih.gov/about-nih/who-we-are/nih-director/statements/nih-supportsinternational-moratorium-clinical-application-germline-editing (“Research on the
potential to alter the very biological essence of humanity raises profound safety, ethical,
and philosophical issues . . . . Until nations can commit to international guiding
principles to help determine whether and under what conditions such research should
ever proceed, NIH strongly agrees that an international moratorium [on clinical
application of germline editing] should be put into effect immediately.”); Francis S.
Collins, M.D., Ph.D., Director, Statement on Claim of First Gene-Edited Babies by Chinese
Researcher, NAT’L INSTS. OF HEALTH (Nov. 28, 2018) https://www.nih.gov/about-nih/
who-we-are/nih-director/statements/statement-claim-first-gene-edited-babieschinese-researcher (“NIH does not support the use of gene-editing technologies in
human embryos.”); Gene Therapy for Rare Disorders, MOLECULAR MED. TRI-CON.,
https://www.triconference.com/transcripts/peter-marks-transcript (last visited July
28, 2020) (providing the statement of Peter Marks, the Director of the FDA’s Center for
Biologics Evaluation and Research, characterizing the area of “heritable genetic
modifications” as “a tremendously controversial area”).
313 See supra Part II; see also NAT’L ACADS. SCIS., ENG’G & MED., HUMAN GENOME EDITING:
SCIENCE, ETHICS, AND GOVERNANCE, supra note 50, at 136 (discussing the Congressional
budget rider that would apply to germline gene editing). While the actions of the FDA
and Congress are separate, the combined history of the FDA’s regulatory treatment of
techniques involving genetic modification and Congress’ budget rider, indicate that the
regulatory system is treating germline genetic modification differently than similar
techniques.
314 See NAT’L ACADS. SCIS., ENG’G & MED., HUMAN GENOME EDITING: SCI., ETHICS, AND
GOVERNANCE supra note 50, at 136.
315 For more on the phases of testing required to obtain marketing approval in the
United States for a drug or biologic, see Abigail All. for Better Access to Developmental
Drugs v. von Eschenbach, 495 F.3d 695, 698 (D.C. Cir. 2007) (citing 21 C.F.R. § 312.21);
see also Investigational New Drug (IND) or Device Exemption (IDE) Process (CBER), U.S.
FOOD & DRUG ADMIN. (May 14, 2019), https://www.fda.gov/vaccines-blood-biologics/
development-approval-process-cber/investigational-new-drug-ind-or-deviceexemption-ide-process-cber (explaining the investigational new drug applications
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resulting from IVF in the U.K. (but before the first American birth due to
IVF), a report from the precursor to the U.S. Department of Health and
Human Services’ Ethics Advisory Board noted that research related to
IVF in the U.S. would be ethically acceptable as long as “the studies were
designed to ‘establish the safety and efficacy of [IVF,] and to obtain
important scientific information toward that end not reasonably
obtainable by other means.’”316 That same report also “recommended
that only ‘married couples’ should be eligible for IVF procedures,”
illustrating the moral views that can impact federal regulation and
research in general.317
By emphasizing the unknown long-term effects of germline gene
editing as a reason not to permit the use of the technique, those who
wish to prohibit germline gene editing neglect the current treatment of
the unknown long-term effects of many approved pharmaceuticals.318
There is significant literature in the health law context, and specifically
in the food and drug law and tort law areas, surrounding risk, “side
effects” or “adverse drug reactions,”319 and the response of the
pharmaceutical law and tort law regimes to the side effects of
pharmaceuticals.320 While the Food, Drug, and Cosmetic Act leads to the
characterization that the FDA regulates products for “safety and
effectiveness,” pharmaceutical commercials and adverse event reports
remind the public that FDA-approved products are not completely
apply to drugs and biologics). But see Timothy Brewer & Graham A. Colditz,
Postmarketing Surveillance and Adverse Drug Reactions: Current Perspectives and Future
Needs, 281 J. AM. MED. ASSOC. 824, 824 (1999) (noting that premarket clinical trials,
“frequently do not have sufficient power to reliably detect important [adverse drug
reactions (ADRs),] . . . lack the follow-up necessary to detect [adverse drug reactions]
widely separated in time from the original use of the drug or delayed consequences
associated with long-term drug administration[,] . . . [and] often do not include special
populations such as pregnant women or children who may be at risk for unique ADRs
or for an increased frequency of ADRs compared with the general population”). For
more on “safety and efficacy” in the context of germline gene editing, see NAT’L ACADS.
SCIS., HERITABLE HUMAN GENOME EDITING, supra note 52, at 31 (“Many scientific and medical
questions about the procedures remain to be answered, and determining the safety and
efficacy of germline genome editing will be necessary but not sufficient conditions for
future clinical usage.”).
316 MARSH & RONNER, supra note 17, at 63–64.
317 Id. at 64.
318 See supra Section III.A.
319 See Brewer & Colditz, supra note 315, at 824.
320 See Brief of New England Journal of Medicine Editors and Authors as Amici Curiae
in Support of Respondent, Wyeth v. Levine, 555 U.S. 555 (2008) (No. 06-1249), 2008 WL
3851616, at *11–30. For more information on harmful products that were approved by
the FDA, see also Sue McGrath, Only A Matter of Time: Lessons Unlearned at the Food and
Drug Administration Keep Americans at Risk, 60 FOOD & DRUG L.J. 603 (2005).
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“safe.”321 Instead, the FDA’s regulatory regime emphasizes disclosure of
risk and balancing of benefits and harms as opposed to complete
safety.322 The same inability to guarantee safety that exists with
pharmaceuticals, whether prescription or over-the-counter, also exists
with gene editing and other medical techniques.323 Further, as noted
above, approved drugs, such as diethylstilbestrol, and environmental
harms that can be exacerbated by humans, like air pollution and
radiation, can have deleterious effects on fetuses, including germline
effects and increased incidences of cancer.324
Science and medicine have been moving toward more tailored
medical treatments, as emphasized by various initiatives related to
precision medicine, gene editing, and even gene therapy. In this way,
these treatments have moved closer to the state-regulated practice of
medicine.325 Gene therapy offers individualized treatments.326 For
example, a New York Times article on the recently approved gene
therapy, Kymriah (then referred to as “CTL019” or tisagenlecleucel),
321 See 21 U.S.C. § 355(b); Brewer & Colditz, supra note 315, at 824 (“Safety is not an
absolute concept.”).
322 Id. (“For example, the toxic effects of many available chemotherapeutic agents
would be unacceptable in drugs marketed for uncomplicated urinary tract infections.”);
see also Stephen F. Amato, Regulatory Strategies for Biomaterials and Medical Devices in
the USA: Classification, Design, and Risk Analysis, in REGULATORY AFFAIRS FOR BIOMATERIALS
AND MEDICAL DEVICES 31–33 (Stephen F. Amato & Robert M. Ezzell, Jr. eds., 2015).
323 See, e.g., Pontin, supra note 16 (“There are always unknowns. No innovative
therapy, whether it is a drug for a disease or something so bold and disruptive as germ
line intervention, can ever remove all possible risk. Fear of the unknown and
unquantifiable risks shouldn’t absolutely prohibit us from making interventions that
could have great benefits. The risks of a genetic, inherited disease are quantifiable,
known, and in many cases devastating. So we go forward, accepting the risks.” (quoting
George Q. Daley, Dean of Harvard Medical School)); DES History, CTRS. FOR DISEASE
CONTROL & PREVENTION, https://www.cdc.gov/des/consumers/about/history.html
(providing the history of diethylsibestrol, a drug that was prescribed to pregnant
women until the FDA warned against prescribing it to them due to its deleterious effects
on children exposed to DES in the womb); About DES, CTRS. FOR DISEASE CONTROL &
PREVENTION, https://www.cdc.gov/des/consumers/about/index.html. For more on the
“unknowns” that might exist with germline gene-editing technologies, see NAT’L ACADS.
SCIS., HERITABLE HUMAN GENOME EDITING, supra note 52, at 92–93.
324 See Vulimiri & Olivero, supra note 98, at 392–93.
325 See, e.g., Robertson, supra note 34, at 440 (referring to pharmacogenomics which
“may enable physicians to prescribe drugs tailored to a patient’s genotype”). For more
on precision medicine and pharmacogenomics, see All of Us Research Program Overview,
NAT’L INSTS. OF HEALTH, https://allofus.nih.gov/about/all-us-research-programoverview; What Is Precision Medicine? MEDLINEPLUS, https://ghr.nlm.nih.gov/primer/
precisionmedicine/definition (last updated Sept. 22, 2020).
326 See, e.g., Denise Grady, F.D.A. Panel Recommends Approval for Gene-Altering
Leukemia Treatment, N.Y. TIMES (July 12, 2017), https://www.nytimes.com/2017/07/
12/health/fda-novartis-leukemia-gene-medicine.html.
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emphasized a number of adverse reactions that resulted from the use of
the drug.327 The patient highlighted in the article successfully
completed the treatment, which was accompanied by “severe side
effects” that nearly killed her, but that ultimately led to her remission
for leukemia.328 While the patient highlighted in the New York Times
article did not die, several other patients died during pre-market clinical
trials.329 Nevertheless, these deaths were not sufficient to prevent FDA
approval of the pharmaceutical.330
Many FDA-approved drugs have known side effects that could
parallel the possible side effects of germline gene editing.331 Similarly,
many of the concerns related to gene therapy are similar to those related
to germline gene editing, including that germline gene editing may have
deleterious effects on patients later in life, which may also occur with
gene therapy patients.332 For instance, in the FDA-created Briefing
Document for the Oncologic Drugs Advisory Committee Meeting
discussing Kymriah, the FDA noted that “careful attention should be
given to antibody selection to minimize possible risks from nonspecific
or off-target effects.”333 Off-target effects are an often-cited objection
(and safety concern) that accompany germline gene editing and gene
therapy.334
FDA advisory committee documents provide useful insights into
the approval process, as they are one of the few sources of public
information available related to the FDA’s notoriously obscure approval
process.335 Yescarta, another gene therapy product that was approved
327 Id.; see also U.S. FOOD & DRUG ADMIN., FDA BRIEFING DOCUMENT: ONCOLOGIC DRUGS
ADVISORY COMM. MEETING, BLA 125646, TISAGENLECLEUCEL, NOVARTIS PHARM. CORP. (2017),
https://www.fda.gov/media/106081/download [hereinafter FDA BRIEFING DOCUMENT];
Press Release, Novartis, Novartis Receives First Ever FDA Approval for a CAR-T Cell
Therapy, Kymriah (TM) (tisagenlecleucel, CTL019), for Children and Young Adults with
B-cell ALL that is Refractory or has Relapsed at Least Twice (Aug. 30, 2017),
https://www.novartis.com/news/media-releases/novartis-receives-first-ever-fdaapproval-car-t-cell-therapy-kymriahtm-ctl019.
328 Grady, supra note 326.
329 Id.
330 Id.; Novartis, supra note 327.
331 See supra notes 59–61; infra note 333 (discussing the harms of FDA-approved
gene therapy products).
332 See Bosley et al., supra note 41, at 480; see also infra notes 350–51.
333 FDA BRIEFING DOCUMENT, supra note 327, at 16. In many regulatory documents
such as this, Kymriah is referred to as “tisagenlecleucel” as opposed to its commercial
name.
334 See supra notes 59–61, 333.
335 See, e.g., Patti Zettler, FDA Advisory Committees and Industry-Funded Patient
Advocacy, STAN. L. SCH.: STAN. L. & BIOSCIENCES BLOG (June 23, 2017),
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after Kymriah, was not subject to an FDA advisory committee meeting
“because Y[escarta] is not the first biologic in its class, and there were
no critical review issues that required input from an Advisory
Committee.”336
The advisory committee that was consulted on the approval of
Kymriah expressed concerns about the possibility of secondary cancers
and other long-term side effects that could not be known at the time of
treatment.337 Despite these concerns, the FDA still approved the
therapy.338 While off-target effects exist with gene therapies such as
Kymriah, those off-target effects were not enough to prevent FDA
approval of Kymriah. A recent article in Science magazine covered the
possibility that the viral vectors used in approved gene therapy
products may pose cancer risks, a concern that has persisted for “nearly
20 years.”339
Serious adverse effects can result from the use of Kymriah and
other approved gene therapies like Yescarta.340 Kymriah and Yescarta

https://law.stanford.edu/2017/06/23/fda-advisory-committees-and-industryfunded-patient-advocacy (citing Matthew Herper, The FDA Ignores Its Advisors A Quarter
of The Time, FORBES (Oct. 12, 2010), https://www.forbes.com/sites/matthewherper/
2010/10/12/the-fda-ignores-its-advisors-a-quarter-of-the-time/#474ed23c3b97)
(“Partly because advisory committee meetings may be the first public airing of the
agency’s questions about an unapproved drug and partly because the agency follows
advisory committee recommendations roughly 75% of the time, . . . these meetings and
recommendations frequently are closely watched.”).
336 Michael Havert, Summary Basis for Regulatory Action, U.S. FOOD & DRUG ADMIN. 17
(Oct. 18, 2017), https://www.fda.gov/media/108788/download.
337 Grady, supra note 326.
338 Press Release, U.S. Food & Drug Admin., FDA Approval Brings First Gene Therapy
to the United States (Aug. 30, 2017), https://www.fda.gov/news-events/pressannouncements/fda-approval-brings-first-gene-therapy-united-states.
339 Jocelyn Kaiser, Virus Used in Gene Therapies May Pose Cancer Risk, Dog Study Hints,
SCI. (Jan. 6, 2020), https://www.sciencemag.org/news/2020/01/virus-used-genetherapies-may-pose-cancer-risk-dog-study-hints.
340 For the documents providing the approvals of various gene therapy products, see
BLA Approval Letter from Wilson W. Bryan, M.D., Dir., Ctr. for Biologics Evaluation &
Research, U.S. Food & Drug Admin., to Dr. Manisha Patel, PharmD, Novartis Pharm. Corp.
(Aug. 30, 2017), http://www.fda.gov/media/106989/download [https://perma.cc/
Q9GS-BLVD] (granting BLA approval for Kymriah); BLA Approval Letter from Mary A.
Malarkey & Wilson W. Bryan, M.D., Dirs., Ctr. for Biologics Evaluation & Research, U.S.
Food & Drug Admin., to Rizwana F. Sproule, Ph.D., Vice President, Kite Pharma, Inc. (Oct.
18, 2017), http://www.fda.gov/media/108458/download [https://perma.cc/7V6PCZJP] (granting BLA approval for Yescarta); BLA Approval Letter from Mary A. Malarkey
& Wilson W. Bryan, M.D., Dirs., Ctr. for Biologics Evaluation & Research, U.S. Food & Drug
Admin., to Jim Wang, Ph.D., MBA, Spark Therapeutics, Inc. (Dec. 19, 2017),
http://www.fda.gov/media/109487/download [https://perma.cc/4SH4-ABJM]
(granting BLA approval for Luxturna); see also Cytokine Release Syndrome, NCI
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can both cause Cytokine Release Syndrome, which is an adverse event
that is closely monitored by physicians.341 While some patients recover
from “[l]ife-threatening Cytokine Release Syndrome” and subsequently
are in remission from the underlying disease, others do not.342 During
Kymriah’s clinical trial, several subjects developed infections after
infusion that included encephalitis, clostridium difficile, and fungal
sepsis, some of which were fatal.343 Other potential risks (which did not
preclude approval) include “secondary malignancy, new/exacerbated
neurological event, new/exacerbated autoimmune disorder, new
hematological disorder, [and] vector virus replication.”344
Further, at least three deaths out of 123 patients were “suspected”
to be related to the infusion of Kymriah.345 Similarly, “four deaths were
attributed to [Yescarta] as per FDA analysis. . . . Fatal cases of CRS and
neurologic toxicity have occurred after receiving Y[escarta].”346
Additionally, during the Kymriah advisory committee meeting, an FDA
employee expressed concern about the “possibility of long term
mutagenesis,” in which the DNA of the patient could be affected and
even lead to leukemia.347
Dictionary of Cancer Terms, NAT’L CANCER INST., https://www.cancer.gov/publications/
dictionaries/cancer-terms/def/cytokine-release-syndrome.
341 FDA BRIEFING DOCUMENT, supra note 327, at 47, 55; Havert, supra note 336, at 3, 13,
18.
342 FDA BRIEFING DOCUMENT, supra note 327, at 47, 55; see also NOVARTIS, ONCOLOGIC
DRUGS ADVISORY COMM. BRIEFING DOCUMENT, TISAGENLECLEUCEL (CTL019) FOR THE TREATMENT
OF PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE
LYMPHOBLASTIC LEUKEMIA 18–19 (2017) [hereinafter NOVARTIS BRIEFING DOCUMENT],
https://www.fda.gov/media/106093/download (noting that Cytokine Release
Syndrome is classified as an “expected on-target toxicity,” and explaining and identifying
deaths due to disease progression after the infusion of Tisagenlecleucel).
343 FDA BRIEFING DOCUMENT, supra note 327, at 48–51.
344 Id. at 52.
345 NOVARTIS BRIEFING DOCUMENT, supra note 342, at 76 (showing Table 6-10 “Deaths
attributed to adverse events—Studies B2202 and B2205J); id. at 66 (stating 123 as the
number of “patients enrolled in Studies B2202 and B2205J.”); id. at 83 (“Three patients
developed infections that proved to be fatal (Table 6-10).”); id. at 84.
346 Havert, supra note 336, at 15.
347 U.S. Food & Drug Admin., Summary Minutes of the Oncologic Drugs Advisory
Committee, Ctr. for Drug Evaluation and Research (July 12, 2017), at 5 (transcript
available at https://www.fda.gov/media/107129/download) [hereinafter Summary
Minutes of the Oncologic Drugs Advisory Committee]; see also Mutagen, NCI Dictionary of
Cancer Terms, NAT’L CANCER INST., https://www.cancer.gov/publications/dictionaries/
cancer-terms/def/mutagen; Transcript, U.S. Food & Drug Admin., Ctr. for Drug
Evaluation and Research Oncologic Drugs Advisory Comm., Morning Session,
Wednesday, July 12, 2017, 7:59 am to 11:00 am, at 67–68 (transcript available at
https://www.fda.gov/media/107138/download) [hereinafter Transcript, CDER
Morning Session].
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Other uncertainties related to Kymriah, including those related to
manufacturing consistency, the safety and efficacy of the product
outside of the clinical trial context, and secondary malignancy, also
merited the expression of concern but not the prevention of approval.348
Similarly, the possibility of secondary malignancy due to insertional
mutagenesis did not prohibit the approval of Yescarta.349 Further,
Novartis, the sponsor of Kymriah’s BLA, plans to monitor clinical trial
patients “for 15 years per the FDA guidance.”350 Kite Pharma
Incorporated, the sponsor of Yescarta, will also follow members of a
safety study for 15 years; the post-marketing study would thus be
completed in December 2037, with a final report submitted in 2038.351
The current federal regulatory framework, in which side effects are
discovered both before and after approval for pharmaceuticals, is
another similarity between gene editing technologies and products
currently regulated by the FDA.352 For example, many have noted that
“present technology cannot assure us that unintended modifications
created through an editing procedure would not result in a devastating
long-term outcome such as cancer or adverse developmental effects if
one were to modify a zygote.”353 Yet this same concern that
accompanies germline gene editing also exists with approved gene
therapy products.354

348 Transcript, CDER Morning Session, supra note 347, at 18–21 (providing “FDA
Introductory Remarks” by Wilson Bryan, M.D.); see also id. at 61 (“Unlike traditional
pharmaceutical drugs, tisagenlecleucel is a dynamic living biologic.”).
349 Havert, supra note 336, at 5.
350 Transcript, CDER Morning Session, supra note 347, at 93.
351 Havert, supra note 336, 16–17.
352 See, e.g., 21 C.F.R. §§ 201.80(e)–(g) (2020); 21 U.S.C. § 355(k) (2020); 21 C.F.R. §
314.98 (2020); 21 C.F.R. § 314.80 (2020); 21 C.F.R. § 201.57(a)(11) (2020); Evans, supra
note 149, at 446, 457 n.253 (2010); FDA BRIEFING DOCUMENT, supra note 327, at 25 (“In
2006, FDA published recommendations for the long-term follow-up monitoring of gene
therapy recipients for delayed adverse events (FDA Guidance for Industry: Gene Therapy
Clinical Trials—Observing Subjects for Delayed Adverse Events, 2006).”); Summary
Minutes of the Oncologic Drugs Advisory Committee, supra note 347, at 6 (“A committee
member stated concern over unknown late toxicities, but that long term survival
outweighs that potential risk.”).
353 Kohn et al., supra note 23, at 2554; see also Bosley et al., supra note 41, at 480
(providing the statement of Dr. Jennifer Doudna on the possible “unintended long-term
consequences of germline editing.”); id. at 482 (providing the statement of Martin Pera
where he referred to the “risk[] . . . [of] unanticipated consequences of genetic
intervention (variant alleles may have important advantages in some situations that we
cannot anticipate)”).
354 See supra Section III.B.
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Currently, state and federal regimes address the adverse effects of
pharmaceuticals post-approval.355 Within that literature, there is a
larger debate regarding which of the regimes is more helpful or which
polity should take the lead on regulating pharmaceuticals.356 The FDA
has expressed its views regarding its primacy as “the expert Federal
agency responsible for evaluating and regulating drugs.”357
Nonetheless, many well-publicized stories of drugs that were
withdrawn from the market after FDA approval emphasize the
limitations of this regime.358 The FDA has spent decades regulating
innovative therapies similar to more traditional areas of regulated
products, such as drugs and biologics.359 This Article argues that the
consequences of the use of germline gene editing, as examined from a
regulatory perspective, are not substantially different from the
consequences of using gene therapy. Accordingly, germline gene editing
should be minimally regulated, like traditional ART, which involves the
use of IVF (without genetic modification).360
There are of course limitations to this analogy. Some would draw
distinctions and note that pharmaceutical products can be removed
from the market. While this is a rarely exercised regulatory tool that
would not be available to the FDA if gene editing is regulated like IVF,
most pharmaceuticals that are withdrawn from the market are
withdrawn by the manufacturers and not the FDA.361 Further, there are
355 See Wyeth v. Levine, 555 U.S. 555 (2009). But see Mutual Pharm. Co. v. Bartlett,
570 U.S. 472 (2013).
356 Lars Noah, State Affronts to Federal Primacy in the Licensure of Pharmaceutical
Products, 2016 MICH. ST. L. REV. 1, 1–27 (2016); Patricia J. Zettler, Pharmaceutical
Federalism, 92 IND. L.J. 845, 845 (2017).
357 Requirements on Content and Format of Labeling for Human Prescription Drug
and Biological Products, 71 Fed. Reg. 3922, 3935 (Jan. 24, 2006) (to be codified at 21
C.F.R. § 201.56(d)).
358 See Brief of New England Journal of Medicine Editors and Authors as Amicus
Curiae in Support of Respondent, Wyeth v. Levine, 555 U.S. 555 (2008) (No. 06-1249),
2008 WL 3851616, at *11–30. For more information on harmful products that were
approved by the FDA, see Sue McGrath, Only A Matter of Time: Lessons Unlearned at the
Food and Drug Administration Keep Americans at Risk, 60 FOOD & DRUG L.J. 603 (2005).
359 See Lewis, Halted Innovation, supra note 122, at 1100–01.
360 See supra note 82 and accompanying text (describing ART as “minimally
regulated”). Traditional ART, which does not involve genetic modification, is minimally
regulated, whereas forms of ART involving genetic modification are highly regulated.
See supra Part III.
361 See 21 C.F.R § 7.3 (2012); 21 C.F.R. § 216.24 (2018); see also Cassie Frank et al.,
Era of Faster FDA Drug Approval Has Also Seen Increased Black-Box Warnings and Market
Withdrawals, 33 HEALTH AFF. 1453, 1455 (2014) (stating there is “no comprehensive
source of information on black-box warnings or withdrawals available to clinicians,
researchers, or the public”); Aaron S. Kesselheim et al., Pharmaceutical Policy in the
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medical procedures that do not work as intended; physicians stop
providing these techniques (if they are wholly ineffective) or accept the
failure (such as surgeries in which the patient dies or where a surgical
intervention failed). The same could be done for harmful forms of gene
editing, depending on the degree of failure.362 Notably, somatic cell gene
editing is currently viewed as “much closer to being shown safe and
effective” than germline gene editing.363
B. Regulating Gene Editing Like Assisted Reproductive Technology
Many of the scientific and ethical concerns related to ART, such as
those related to the ability of children to consent, the hubris of humans,
and the long-term medical effects of these techniques are the same as

United States in 2019: An Overview of the Landscape and Avenues for Improvement, 30
STAN. L. & POL’Y REV. 421, 452 (2019); Pierre La Rochelle, et al., Analysis of the Drugs
Withdrawn from the U.S. Market from 1976 to 2010 for Safety Reasons, 30 PHARM. MED.
277, 278, 286 (2016) (explaining “the FDA website does not contain . . . a consolidated
list [of withdrawals]” and that “[t]he first limitation of [the] study [was] the inability to
completely access the evidence justifying withdrawals ordered by the FDA or
voluntarily undertaken by drug companies”); W. Nicholson Price II, Drug Approval in a
Learning Health System, 102 MINN. L. REV. 2413, 2428–29 (2018). The FDA maintains
information on recalls and withdrawals on its website (subject to limitations noted by
commentators). See, e.g., FDA’s Role in Drug Recalls, U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/drugs/drug-recalls/fdas-role-drug-recalls (last updated July 3,
2018); Recalls, U.S. FOOD & DRUG ADMIN., https://datadashboard.fda.gov/ora/cd/
recalls.htm (last visited May 28, 2020); Recalls, Market Withdrawals, & Safety Alerts, U.S.
FOOD & DRUG ADMIN., https://www.fda.gov/safety/recalls-market-withdrawals-safetyalerts (last updated May 28, 2020). Many of these recalls are voluntarily made by the
drug manufacturer. For a list of such recalls, see Drug Recalls, U.S. FOOD & DRUG ADMIN.
(June 29, 2020), https://www.fda.gov/drugs/drug-safety-and-availability/drug-recalls
(“A drug recall is the most effective way to protect the public from a defective or
potentially harmful product. A recall is a voluntary action taken by a company at any
time to remove a defective drug product from the market.”).
362 But see David Epstein, When Evidence Says No, But Doctors Say Yes, ATLANTIC (Feb.
22, 2017), https://www.propublica.org/article/when-evidence-says-no-but-doctorssay-yes (noting that some physicians still continue to prescribe approved drugs and use
them in spite of a lack of clinical effectiveness); Frank Pasquale, The Hidden Costs of
Health Care Cost-Cutting: Toward a Post-Neoliberal Health-Reform Agenda, 77 L. &
CONTEMP. PROBS. 171, 173–74 (2014).
363 Greely, supra note 227, at 253, 258–60 (discussing the “moral status” of the
embryo); see also Emily Mullin, Gene Editing Study in Human Embryos Points Toward
Clinical Trials, MIT TECH. REV. (Aug. 2, 2017), https://www.technologyreview.com/
2017/08/02/242242/gene-editing-study-in-human-embryos-points-toward-clinicaltrials; Antonio Regalado, US Scientist Who Edited Human Embryos With CRISPR Responds
to Critics, MIT TECH. REV. (Aug. 8, 2018), https://www.technologyreview.com/2018/08/
08/141119/us-scientist-who-edited-human-embryos-with-crispr-responds-to-critics.
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those that accompany germline gene editing.364 Further, they are the
same as those that accompany natural reproduction, as genes are
inheritable (without consent), as evidenced by the rules of reproduction
and also recent coverage of the impact of donating a sample to a genetic
database.365 These concerns were analyzed in Part III. The FDA’s
assertion of jurisdiction over gene editing and forms of ART involving
genetic modification does not mean that the FDA is the best regulator of
these innovative therapies. Scholars like Jane Bambauer have asked,
“what would happen if medical AI were regulated like their closest
substitutes—doctors—instead of like devices?”366 This Article argues
for leaving the regulation of ART to the physician-patient
relationship.367 State medical boards and tort law regulate doctors; this
regulatory system treats other techniques like surgery and IVF.368
While some characterize the field of ART as unregulated, there is a
robust literature on regulation within the medical field.369 At the same
time, some argue that doctors are incapable of self-policing.370
364 For more on the safety concerns that accompany germline gene editing and ART
see Sections II.A.3.–4. For more on the ethical concerns that accompany ART and
germline gene editing, see Sections III.A.–C.
365 See Natalie Ram, DNA by the Entirety, 115 COLUM. L. REV. 873, 873–78, 898–900
(2015).
366 Bambauer, supra note 14, at 391.
367 For a discussion of the physician-patient relationship, see Ezekiel J. Emanuel &
Linda L. Emanuel, Four Models of the Physician-Patient Relationship, 267 JAMA 2221,
2221–26 (1992); Mark A. Hall, The Legal and Historical Foundations of Patients as
Medical Consumers, 96 GEO. L.J. 583, 593–94 (2008); Code of Medical Ethics Opinion
1.1.1, AMA, https://www.ama-assn.org/delivering-care/ethics/patient-physicianrelationships.
368 But see George J. Annas, Human Cloning: A Choice or an Echo?, 23 U. DAYTON L. REV.
247, 263–66 (1998) (“Professional-organization ethics committees composed primarily
of practitioners are simply too narrow to be anything but self-serving in their outlook
and actions. A similar observation can be made concerning IRBs and state licensing
boards.”).
369 See Sandra Johnson, Structure of Governmental Oversight of Quality in Healthcare,
in THE OXFORD HANDBOOK OF U.S. HEALTH LAW 490–510 (I. Glenn Cohen, Allison K. Hoffman
& William M. Sage eds., 2017); Kristen Madison & Mark Hall, Quality Regulation in the
Information Age: Challenges for Medical Professionalism, in MEDICAL PROFESSIONALISM IN
THE NEW INFORMATION AGE 23–24 (David J. Rothman & David Blumenthal eds. 2010);
Robert I. Field, Regulation of Health Care in the United States: Complexity, Confrontation
and Compromise, 16 AN INST HIG MED TROP, S61, S61–S62, S65 (2017); Robert I. Field, Why
is Health Care Regulation so Complex?, 33 HEALTH CARE & L. 607, 607–08 (2008); Lars
Noah, Ambivalent Commitments to Federalism in Controlling the Practice of Medicine,
53 U. KAN. L. REV. 149, 164 (2004); William M. Sage, Relational Duties, Regulatory Duties,
and the Widening Gap Between Individual Health Law and Collective Health Policy, 96 GEO.
L.J. 497, 497–501 (2008);
370 See, e.g., Annas, supra note 368, at 263–66 (criticizing professional societies in
reproductive medicine); Goodwin, supra note 20, at 1079 (noting “compelling evidence
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Malpractice regimes and physician discipline also exist. Furthermore,
the field of ART is populated by a number of professional, though
voluntary, societies, including the American Society for Reproductive
Medicine, American College of Obstetricians Gynecologists (which is
broader than the field of ART), and the Society for Assisted Reproductive
Technology. These organizations provide specific guidance for
physicians in the field on a number of topics, including medical practice
and nondiscrimination.371 While these professional societies are
criticized by some commentators because their guidelines are
voluntary, they are nonetheless a source of useful guidelines and
professional norms.372
Instead of treating germline gene editing as a medical product,
treating it as a medical procedure, like ART, could maximize innovation
and parental autonomy.373 In other words, the FDA should withdraw
previous assertions of jurisdiction over germline gene editing and
instead employ the same hands-off approach to germline gene editing
that it has applied to ART that does not involve genetic modification.
This hands-off approach includes, for example, the application of
laboratory safety standards to prevent cross-contamination and the
applicability of regulations related to disease transmission that apply to
laboratories and fertility treatment centers that conduct IVF.374 It would
not, however, require pre-market approval by the federal government.
that the [fertility] industry self-regulates quite poorly (doctors are not reprimanded or
censured for implanting embryos in women over sixty years old or for implanting too
many embryos in women in their thirties)”); Yaniv Heled, The Regulation of Genetic
Aspects of Donated Reproductive Tissue—The Need for Federal Regulation, 11 COLUM. SCI.
& TECH. L. REV. 243, 276–77 (2010) (discussing the insufficiency of self-regulation in the
ART field); Maxwell J. Mehlman, Professional Power and the Standard of Care in Medicine,
44 ARIZ. ST. L.J. 1165, 1229 (2012) (“Numerous critics complain, for example, about the
profession’s unwillingness to sanction incompetent colleagues.”) (citation omitted).
371 Moses, supra note 26, at 542–45 (2005); Richard F. Storrow, Medical Conscience
and the Policing of Parenthood, 16 WM. & MARY J. WOMEN & L. 369, 390–91 (2010).
372 Code of Medical Ethics: Genetics & Reproductive Medicine, AMA, at 4 (2016),
https://www.ama-assn.org/sites/ama-assn.org/files/corp/media-browser/code-ofmedical-ethics-chapter-4.pdf; Anne Drapkin Lyerly, Marking the Fine Line: Ethics and the
Regulations of Innovative Technologies in Human Reproduction, 11 MINN. J.L. SCI. & TECH.
685, 702–10 (2010); Brenda Reddix-Smalls, Assessing the Market for Human
Reproductive Tissue Alienability: Why Can We Sell Our Eggs But Not Our Livers?, 10 VAND.
J. ENT. & TECH. L. 643, 676, 685–86 (2008); Jennifer L. Rosato, The Children of ART: Should
the Law Protect Them from Harm?, 2014 UTAH L. REV. 57, 66–71 (2014).
373 NAT’L ACADS. SCIS., ENG’G & MED., HUMAN GENOME EDITING: SCI., ETHICS, AND GOVERNANCE,
supra note 50, at 120 (“The possible benefits of heritable genome editing accrue most
immediately to individuals: the prospective parents who want to have an unaffected
genetically related child (and that child) but fear passing along a disease.”).
374 See supra note 83 (providing federal regulations applicable to laboratories that
provide ART services).
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The FDA requires that “sponsors” (also referred to as “sponsorinvestigators”) have an active IND application to continue their human
clinical investigations.375 This Article disagrees with the application of
the federal IND requirements to a technique that should be the subject
of state jurisdiction.376
Beyond the jurisdictional debate, the FDA’s IND requirements have
been critiqued from a number of perspectives, including their operation
as an obstacle to innovation and unsuitability for non-traditional
medical products.377 Many researchers find the FDA’s IND requirement
burdensome when applied to “everyday uses” of foods and routine
medical treatments. For example, probiotics research in the United
States requires an IND application, the approval of which many view as
the cause of research delays.378 Similarly, the IND requirements, as
noted through Untitled Letters to physician-researchers, had a “chilling
effect” on innovation, and have stymied the use of ART techniques that
involve genetic modification.379 Additional critiques have focused on
the structural limitations of the FDA’s regime.380
It is unclear why the FDA, which continues to maintain that it does
not regulate the practice of medicine, would treat germline gene editing,
a medical technique similar to IVF or heart surgery, as a product. In fact,
375 See Drug Approval Process, U.S. FOOD AND DRUG ADMIN., https://www.fda.gov/
media/82381/download; Information for Sponsor-Investigators Submitting
Investigational New Drug Applications (INDs), U.S. FOOD AND DRUG ADMIN. (June 27, 2017),
https://www.fda.gov/drugs/investigational-new-drug-ind-application/informationsponsor-investigators-submitting-investigational-new-drug-applications-inds.
376 See supra Section II.B. and accompanying text (discussing the practice-products
divide).
377 See, e.g., Lewis, Halted Innovation, supra note 122, at 1110 (criticizing the
application of investigational new drug application requirements to innovative medical
therapies); Richard A. Merrill, Human Tissues and Reproductive Cloning: New
Technologies Challenge FDA, 3 HOUS. J. HEALTH L. & POL’Y 1, 53–56 (2002) (explaining how
the FDA’s use of investigational new drug requirements led to a “theoretical legal
moratorium” on cloning in the late 1990s); Merrill & Rose, supra note 123, at 102 (noting
that the lack of clarity and “casual” nature of the FDA’s regulation of cloning research
put researchers at legal risk if they “failed to seek and secure agency approval”); Pilar N.
Ossorio & Yao Zhou, FMT and Microbial Medical Products: Generating High-Quality
Evidence Through Good Governance, 47 J.L., MED., & ETHICS 505, 511–13 (2019)
(providing commentators’ arguments that the FDA should not regulate stool and stoolderived products as drugs, which require investigational new drug applications).
378 See, e.g., Mary Ellen Sanders et al., Advancing Probiotic Research in Humans in the
United States: Challenges and Strategies, 7 GUT MICROBES 97, 97–98 (2016) (positing that
the reason for the small number of probiotics research trials conducted in the United
States as compared to other countries is the FDA’s treatment of probiotics as “drugs”
requiring investigational new drug application approval).
379 Lewis, How Subterranean, supra note 8, at 1256.
380 Id. at 1241; Sanders et al., supra note 378 at 97–98.
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the now-disgraced Dr. Jiankui routinely referred to his use of CRISPR
technology in embryos as “gene surgery.”381 Academics examining the
obligations of parents to address genetic disparities have employed the
same analogy.382 Using that analogy, one could see that gene surgery or
gene editing, in which defective genes are replaced or corrected, could
be similar to the forms of surgery in which defective organs are replaced
or corrected.
The regulation of ART has been criticized by many, including those
who would prefer (or advocate for) additional governmental regulation.
Nevertheless, in the absence of a strict regulatory regime, a number of
norms of self-regulation have developed in ART, in addition to the
requirements imposed by state and federal statistical reporting
requirements.383 These norms are in addition to the fact that providers
of ART are physicians who are licensed by the state, as are the facilities
where ART would take place.384 Germline gene editing allows parents a
chance to improve their children’s health, a normative goal that is
supported by laws related to child welfare and the practice of
medicine.385 The Nuffield Council on Bioethics has recommended that
germline genome editing only be used for purposes intended to “secure
the welfare . . . of a person who may be born as a consequence of” the
genome editing treatment, a recommendation that this Article
supports.386

381

Greely, supra note 6, at 134 (2019) (“In short: germline editing creates changes
that a person’s descendants can inherit, as opposed to changes that could not be passed
on to future generations.”).
382 See, e.g., Rakowski, supra note 11, at 1384 (“[S]uppose that a surgeon modifies a
fetus’s genes in utero so that it is born and later lives a self-conscious individual with
normal sensory capacities. Further suppose that had the surgeon done nothing, the
person would have been born and remained deaf, dumb, and blind.”).
383 See, e.g., Code of Medical Ethics Overview, AMA, https://www.ama-assn.org/
delivering-care/ethics/code-medical-ethics-overview (Chapter 4 is entitled “Ethics of
Genetics & Reproductive Medicine”); Oversight of Assisted Reproductive Technology, AM.
SOC. REPROD. MED. 1, 7–11 (2010), https://www.asrm.org/about-us/media-and-publicaffairs/public-affairs/oversight-of-assisted-reproductive-technology; supra note 91
(discussing the Fertility Clinic Success Rate Act).
384 See David Adamson, Regulation of Assisted Reproductive Technologies in the United
States, 78 FERTILITY & STERILITY 932, 932–33 (2002).
385 See, e.g., Vermette, supra note 158, at 32.
386 NUFFIELD COUNCIL ON BIOETHICS, GENOME EDITING AND HUMAN REPRODUCTION: SOCIAL AND
ETHICAL ISSUES, supra note 26, at xvii, 77, 96.
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Thus, while there are limits on parental autonomy, those limits on
parental autonomy tend to focus on prohibiting harms to children, like
those associated with child cruelty.387 Following through on the lack of
regulation of traditional ART and the tendency of family law to treat the
children of ART in a manner that parallels that of children conceived
through natural reproduction, the less germline gene editing is
regulated by the federal government, the more it (and the children
conceived with its assistance) will be treated in the same way as natural
reproduction.
Somatic and germline gene editing technologies are not different in
a legally significant manner from existing technologies in other areas.
For example, other technologies, such as nuclear energy and radiation
(which can accompany nuclear energy and medical treatment), can
impact existing and future humans in negative ways, yet they remain
legal.388 This legality (and associated availability) continues, although
the field of epigenetics focuses on the impacts of the environment on the
epigenome and genetic expression; thus, even though many
environmental factors, including radiation, can affect genetic
expression, those environmental factors continue to exist and
sometimes negatively impact reproduction.389 In this regard, germline
387 Id. at 96; Coleman, Dodge & Campbell, supra note 158, at 120; see also NAT’L ACADS.
SCIS., ENG’G & MED., HUMAN GENOME EDITING: SCI., ETHICS, AND GOVERNANCE, supra note 50, at
121.
388 See Ashley Hardy & Dontan Hart, Policy Meltdown: How Climate Change Is Driving
Excessive Nuclear Energy Investment, 24 BUFF. ENVTL. L.J. 137, 190 (2016–18); cf. Sandra
E. Black et al., This is Only a Test? Long-Run and Intergenerational Impacts of Prenatal
Exposure to Radioactive Fallout, 101 REV. ECON. & STAT. 531, 543–44 (2019). For more on
nuclear medicine, see Nuclear Medicine, HOPKINS MED., https://www.hopkins
medicine.org/health/treatment-tests-and-therapies/nuclear-medicine (last visited
Nov. 1, 2020) and NUFFIELD COUNCIL ON BIOETHICS, GENOME EDITING AND HUMAN
REPRODUCTION: SOCIAL AND ETHICAL ISSUES, supra note 26, at 89.
389 What is Epigenetics?, NAT’L INSTS. HEALTH, https://ghr.nlm.nih.gov/primer/
howgeneswork/epigenome (last updated Sept. 21, 2020) (“Environmental influences,
such as a person’s diet and exposure to pollutants, can also impact the epigenome.
Epigenetic changes can help determine whether genes are turned on or off and can
influence the production of proteins in certain cells, ensuring that only necessary
proteins are produced.”); see also Black et al., supra note 388, at 543–44; Savulescu,
supra note 173, at 38 (noting that “the environment only acts to affect our biology. If we
accept environmental manipulations, by force of consistency, we must accept genetic or
other biological manipulations that are safe and have the same effects”); Andrew Curry,
Parents’ Emotional Trauma May Change Their Children’s Biology. Studies in Mice Show
How, SCI. (July 18, 2019, 2:05 PM), https://www.sciencemag.org/news/2019/07/
parents-emotional-trauma-may-change-their-children-s-biology-studies-mice-showhow (exploring the hypothesis that emotional trauma can lead to inheritable changes in
DNA); Birth Defects Research, MARCH OF DIMES, https://www.marchofdimes.org/
research/birth-defects-research.aspx (last visited Oct. 19, 2020).
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gene editing is not necessarily as exceptional as commentators note
because it is one of many technologies or factors that impact genetic
expression.
C. Lessons from Assisted Reproductive Technology
Germline gene editing implicates multiple areas of controversy,
including controversy related to the use of embryos in research and
clinical use, heritable changes, and ART in general.390 The fact that
germline gene editing involves reproduction, unlike somatic cell gene
editing, warrants particular scrutiny of federal involvement in light of
the particularly complicated nature of reproduction in the American
legal and political sphere. The regulation of ART provides an option for
the regulation of gene editing. Traditional ART does not come without
risks, including risks related to the drugs used in ART (which are
regulated by the FDA). There are also risks related to maternal-fetal
outcomes and the connections between ART and certain adverse birth
outcomes, such as “low birth weight[] and congenital malformations,
even among singleton pregnancies.”391 Even with its continued use and
acceptance, the long-term effects of ART on offspring and the women
involved in the creation of those offspring remain unknown.392
These long-term effects have not hindered the legality of non-gene
modifying or traditional ART in the United States. The idea of regulating
gene editing more like other products or techniques instead of federallyregulated products has arisen before. Jennifer Doudna, one of the
American developers of CRISPR-Cas9, has described it as “analogous to
software that is easily reprogrammable for a wide variety of
experiments and functions across a broad range of plant and animal
systems.”393 Further, gene editing, at least for embryos, still has to be

390

See supra Parts II and III.
Maria Velez et al., Care Plans for Women Pregnant Using Assisted Reproductive
Technologies: A Systematic Review, 16 REPROD. HEALTH at 1, 2 (2019),
https://reproductive-health-journal.biomedcentral.com/articles/10.1186/s12978019-0667-z. See also id. at 10; Goodwin, supra note 20, at 1058–60 (2010); King, supra
note 70, at 304–05, 308; Good Clinical Treatment in Assisted Reproduction—An ESHRE
Position Paper, EUR. SOC’Y HUM. REPROD. & EMBRYOLOGY at 1, 4 (June 2008),
https://www.eshre.eu/-/media/sitecore-files/Guidelines/Guidelines/PositionPapers/GCT-in-ART.pdf.
392 See, e.g., Baruch, supra note 70, at 249.
393 The Science and Ethics of Genetically Engineered Human DNA, supra note 22, at 20
(providing the Prepared Statement of Dr. Jennifer Doudna).
391
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combined with “medical procedures to successfully deliver modified
gametes or embryos into the human reproductive cycle.”394
Some would argue that the current lack of regulation of traditional
IVF is due to path dependence, not a reasoned inquiry.395 While
attempts to federally regulate IVF and ART occurred, they never
succeeded.396 In the realm of gene editing, human germline gene editing
has so far been the subject of regulation via federal research funding
restrictions and the ban on the FDA’s consideration of any such
applications.397
ART has addressed many of the issues that germline gene editing
will need to address as it moves toward human clinical use. As noted in
Section II.B., in the late 1990s and early 2000s, the FDA targeted
cytoplasmic transfer, a form of ART involving genetic modification, for
regulation.398 During an advisory committee meeting after the FDA’s
issuance of letters to those providing cytoplasmic transfer, physicians
noted the difficulty of long-term studies in the context of ART.399 Often,
parents have no interest in including their children in follow-up studies
following the excitement of a presumably healthy birth. It is also
difficult for physicians to keep track of patients in light of the transience
of patients in general.400 Those same difficulties could likely arise in the
from gene editing context. As patients grow older, move, and change
physicians, it is likely harder to keep track of them and the long-term
effects of certain medical treatments.401 Further, parents may not wish
to subject their children to a physician’s intrusive tests by virtue of their
conception using new technologies. Additionally, those conceived using
ART might object to continued long-term studies. But various bodies,
including the National Academies of Sciences, have emphasized the

394 See also Bosley et al., supra note 41, at 485 (providing the statement of Martin
Pera, Department of Anatomy and Neuroscience at the University of Melbourne).
395 Volokh, supra note 251, at 1035–36 (discussing path dependence in the context
of slippery slope arguments).
396 MARSH & RONNER, supra note 17, at 108.
397 See supra Section II.B.
398 See Lewis, How Subterranean, supra note 8, at 1250, 1254–61.
399 See, e.g., Transcript, Center for Biologics Evaluation and Research, Food and Drug
Administration, Biological Response Modifiers Advisory Committee Open Session,
Meeting #32, 375 (May 9, 2002, 8:00 AM), https://www.fda.gov/OHRMS/DOCKETS/
ac/02/transcripts/3855t1-01.pdf [https://wayback.archive-it.org/7993/2017040408
2240/https://www.fda.gov/OHRMS/DOCKETS/ac/02/transcripts/3855t1.htm].
400 Id. at 123–24.
401 Id.
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need for follow-up studies in the realm of germline gene editing.402 The
National Academies of Sciences has also emphasized the usefulness of
developing ethical norms and the existing regulatory regimes that
accompany “human clinical research, gene transfer research, and
existing somatic cell therapy” with heritable genome editing.403 This
Article argues that the norms of ART and its accompanying regulatory
framework would be better than treating germline genome editing like
a medical product.
Federal regulation adds an additional hurdle to access because it
tends to lengthen the time between access and innovation. It also
arguably increases prices for consumers, as regulatory compliance
increases costs for developers who must pay for the approval process,
and who eventually pass those costs on to consumers. Federal
regulation can contribute to reproductive or medical tourism, which
increases barriers to access. Minimizing regulation would reduce
barriers to access because, at the very least, those with financial means
would be able to access germline gene editing in the United States,
similar to other medical techniques, as opposed to having to face
burdensome federal regulation or hurdles that hinder even research.404
Instead of regulating germline gene editing as an exceptional
technology or product, regulating it like IVF, a traditional form of ART,
could have many benefits. It would help to prevent the stigmatization
of those who are produced as a result of gene editing by not treating
them differently than children who are conceived through sex or
traditional ART.405 Many of the bioethical concerns explored in Part III
indicate a concern by the public or bioethicists that those who are
402 NAT’L ACADS. SCIS., HERITABLE HUMAN GENOME EDITING, supra note 52, at 84–85; NAT’L
ACADS. SCIS., ENG’G & AND MED, HUMAN GENOME EDITING: SCI., ETHICS, AND GOVERNANCE supra
note 50, at 104, 135.
403 Id. at 6.
404 For examples of scholars asking for more regulation of ART, see NAOMI R. CAHN,
TEST TUBE FAMILIES: WHY THE FERTILITY MARKET NEEDS LEGAL REGULATION (2009); see also
Steve P. Calandrillo & Chryssa V. Deliganis, In Vitro Fertilization and the Law: How Legal
and Regulatory Neglect Compromised a Medical Breakthrough, 57 ARIZ. L. REV. 311,
336–41 (2015). This Article is particularly America-centric and focuses on how
germline gene editing fits within the American legal system. Other countries, notably
the UK, have a robust governmental framework for using ART that imposes
governmental limitations on ART access. See, e.g., Judith Daar, Federalizing Embryo
Transfers: Taming the Wild West of Reproductive Medicine?, 23 COLUM. J. GENDER & L. 257,
297 (2012); Alicia Ouellette et al., Lessons Across the Pond: Assisted Reproductive
Technology in the United Kingdom and the United States, 31 AM. J.L. & MED. 419, 419–21
(2005).
405 Courtney Megan Cahill, Reproduction Reconceived, 101 MINN. L. REV. 617, 671
(2016) (discussing the separate legal treatment of sexual and alternate reproduction).
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“created” with the use of gene editing will be different from the general
population. Reducing regulation, with an emphasis on reducing the
federal government’s involvement in their lives, reduces the likelihood
that they will be deemed different from the “naturally occurring”
population.
V. CONCLUSION
Gene editing presents a number of unique opportunities.
Scientifically, improving gene editing will correspond with an increase
in scientific knowledge, as scientists will gain an increased
understanding of a number of issues, including the role of genetics in
disease and human development. Medically, gene editing offers the
possibility of eradicating a number of diseases.406
ART, which has existed since at least 1978, is accompanied by
safety concerns—as are germline gene editing, gene therapy, and most
medical treatments. Treating germline gene editing like ART, namely
IVF, a technology that must be used in any gene editing of the embryo
that would result in the birth of the child, not only serves to reduce
stigmatization of those who might be born as a result of the technique
but also removes the federal government from the regulation of
reproductive rights. Treating germline gene editing like IVF also
minimizes the federal government’s ability to introduce social and
political concerns into the regulatory process, to the advantage of
innovation that would allow parents to give birth to children that are
not affected by their family members’ genetic conditions. Additionally,
estimates indicate that somatic and reproductive gene editing might be
ready for widespread human clinical use in the next five years. As such,
germline gene editing (at least in the United States) is one of the few
opportunities for the law to develop at the same time as scientific
innovation, or to precede scientific application instead of lagging behind
science, as it often does.

406 The Science and Ethics of Genetically Engineered Human DNA, supra note 22, at 23
(providing the testimony of Dr. Elizabeth McNally).

